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Surgery Alone in Adenocarcinoma of the
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Calgary, Calgary, Alta.

sophagogastrectomy, particu
larly for an obstructing adeno
carcinoma of the esophagus, has
been the “ gold standard” of treat
ment for cure and for palliation. A
report on this procedure by Smith
and Kwan in this issue (pages 97 to
100) is timely because esophageal
adenocarcinoma may be increasing
in frequency.1 Two other large re
trospective studies23 have recently

E

The Canadian Journal of S urgery
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been published on surgical resec
tion and bypass for adenocarcinoma
of the esophagus, and the results
parallel those of Smith and Kwan.
However, the literature in general
documents much more grief with
this approach than the 4% death
rate and the average 3-week hospi
talization these studies report.
These good results are, I am sure,
due mainly to the technical skill of
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the surgeons but may also be relat
ed to the referral pattern and the
preselection of patients. In Smith
and Kwan’s report we learn only
about those who the authors ulti
mately treated, who do not repre
sent the true picture of this disease
in that hospital or community. For
example, preselection in this article
is evidenced by the fact that only 2
of the 21 patients had lost weight
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before surgery. This group of pa
tients tolerates major surgery rela
tively well.
What worries me, however, is the
danger of considering surgery as
having only palliative value when
the disease in at least 15% of such
patients may be curable. By consid
ering only a palliative surgical ap
proach to this disease when it is
only locally extensive, we may limit
our therapeutic interventions to in
complete resections and, even
worse, we may not look beyond our
discipline for help. In the report of
Smith and Kwan, the proximal eso
phageal margins were involved in
24% of cases. There is no discus
sion of whether some of these pa
tients were presumed incurable by
virtue of only extensive local dis
ease. I suspect that unrecognized
esophageal extensions may play a
part in the relatively high local
recurrence rate, despite resection,
reaching up to 35% in the litera
ture. In 30% of patients with local
recurrence, it may be the first and,
less commonly, the only site identi
fied before death.
This problem of local recurrence
challenges us to rethink our ap
proach and to identify an effective
local adjuvant therapy. The dramat
ic results locally of adjuvant preop
erative treatment with radiation or
chemotherapy, or both, in squa
mous cell carcinoma of the esopha
gus, which has similar biologic fea
tures, are not well documented in
adenocarcinoma of the esophagus.
The latter has traditionally been
considered both radioresistant and
relatively chemo-insensitive. These
observations, I suspect, reflect the
fact that the tumour is rarely com
pletely sterilized or shrinks rapidly,
rather than that adjuvant therapy
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has a negligible effect. If radiation
therapy could sterilize the periphery
of the tumour, the lymphatics and
minimally involved nodes, preopera
tive therapy might improve local
control. In similar diseases, such as
in fixed and unresectable rectal ade
nocarcinoma, which is another rela
tively radioresistant disease, preop
erative therapeutic radiation works
extremely well when combined with
surgery for local control and, in
many patients, results in cure.4
To support further this therapeu
tic concept in adenocarcinoma of
the esophagus, MacFarlane and as
sociates,5 in a recent preliminary
report of experience with preopera
tive chemotherapy and radiothera
py, obtained sterilization of adeno
carcinoma prior to resection in 23%
of cases, a dramatic increase in the
incidence of stage I and stage II
lesions (from 3% to 38% compared
with historical controls) and a total
absence of local recurrence in their
21-month follow-up. Although
there was no increase in operative
mortality in these patients, in my
experience they are more prone to
complications. We have used preop
erative therapeutic radiation in
three patients with adenocarcinoma
of the esophagus and have been
encouraged by the impressive
shrinkage (more than 50%), lack of
involved nodes or subsequent re
sectability at surgery. A preopera
tive approach, whether it be radio
therapy alone or radiotherapy and
chemotherapy, has the advantage
also of providing a biological win
dow to assess the progress of re
gional and systemic disease so that
surgery, which is both expensive
and morbid, may be limited to those
who have the most chance of bene
fit. Furthermore, some of the pa

tients considered only for palliation
may subsequently be considered to
have curative disease by virtue of
local regression. In the experience
of MacFarlane and colleagues5 ap
proximately 20% of patients with
the preoperative treatment did not
undergo surgery, a group that is
comparable to the patients who
underwent surgery and had short
term survival reported by Smith and
Kwan.
In conclusion, Smith and Kwan
are to be congratulated on an excel
lent technical experience. I agree
with their conclusion that a surgical
bypass alone, by surgeons skilled in
this operation, is indicated for se
lected patients if palliation is the
only goal. However, in the future
treatment of this disease we must
explore preoperative adjuvant ther
apy for its value in increasing re
sectability and local control for both
palliation and cure.
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Biliary Colic
Nis Schmidt, MD, FRCSC
Member. Editorial Board. Canadian Journal o f Surgery. Clinical Professor, Department o f
Surgery. University o f British Columbia. St. Paul's Hospital, Vancouver. BC

C

olic (as in biliary tract disease)
has occurred on occasion
amongst those who care for the
patients, through debate and pos
turing over which doctor should be
doing what for whom.
Historically, it is just over 100
years since Langenbuch first per
formed cholecystectomy (1882) and
Kummel explored the common bile
duct (1884). During that time there
has been little choice other than a
standard cholecystectomy to treat
symptomatic biliary stone disease,
and general surgeons have handled
the procedure. There were, of
course, variations, and many modi
fications have been reported to the
techniques of cholecystostomy, cho
lecystectomy, indications for com
mon-bile-duct x-ray and explora
tion, as have ideas for retrieving
common-bile-duct and intrahepatic
stones, and indications and recom
mendations for duodenostomy,
sphincterotomy or sphincteroplasty.
In the February 1990 issue of the
Journal (pages 13 and 14) Bickel
and colleagues from the Nahariya
Government Hospital in Nahariya,
Israel, described their technique for
managing high-risk patients who
require cholecystectomy. They pre
sented a series of eight patients in
whom they carried out a modified
subtotal cholecystectomy. The tech
nique they used is similar to that
recommended by Thorek (1946)
and is familiar to most experienced
general surgeons doing frequent ab
dominal operations. The authors

advise this technique in difficult
cases of cholecystitis, acute or
chronic, in patients with liver dis
ease, portal hypertension and possi
bly gallbladder perforation. Their
advice is well taken, but the opera
tion itself in the presence of in
creased risk factors, in sick pa
tients, may be a thing of the past.
Since the mid-1960s the modali
ties available for the management of
biliary tract problems have mush
roomed. Retained common-bile-duct
stones after cholecystectomy meant
certain repeat surgery until Burhenne (1973) perfected his steerable
catheter to facilitate the percutane
ous removal of stones through the
T-tube tract. This obviated a gener
al surgical procedure on the biliary
tract, reducing the risk and morbid
ity of difficult reoperations. Endo
scopic retrograde cholangiopan
creatography (ERCP) also was per
fected and, by 1975, a number of
centres around the world were ad
vocating this procedure as the pri
mary one for common-bile-duct
stones with or without cholecystec
tomy in chronic and acute situa
tions. Percutaneous transhepatic
techniques advanced to the point at
which radiologists also could drain
the common bile duct, dissolve or
crush ductal stones and provide
drainage in cases of ascending cho
langitis. Once again the general
abdominal surgeon was relieved of
emergency cholecystectomy and
common-bile-duct exploration in pa
tients who were often critically ill.

Technologic advances, however,
did not stop there. From Munich,
Germany, in 1980 came a report of
extracorporeal shock-wave lithotrip
sy for renal stone therapy which,
within 3 years, reduced the surgery
for urolithiasis from 30% to 1% of
urologic procedures. General sur
geons did not feel threatened by
this advance until it became avail
able for clinical use in biliary tract
procedures in Munich (1985) and
Vancouver (1987). The prospect of
gallstone lithotripsy, ERCP papil
lotomy and percutaneous cholecys
tostomy for biliary sludge extrac
tion and gallbladder sclerosis as the
future basic treatment for choleli
thiasis sent shock waves also
through the general surgical com
munity. Now, in addition to this, for
selected patients with uncomplicat
ed chronic cholelithiasis and chole
cystitis, is the choice of day-care
percutaneous or laparoscopic chole
cystectomy with or without opera
tive cholangiography, minus the ab
dominal incision. Standard chole
cystectomy appears to be going the
way of the dodo.
A major characteristic of modern
health care is the proliferation of
single disease and single treatment
specialists. This is good and neces
sary, because advancement usually
arises from determined individuals
with a focused interest. It becomes
totally impossible, however, if the
treatment of biliary tract disease is
a cafeteria approach where a patient
passes through a lineup of menus
CJS, VOL. 33. NO. 2, A P R IL 1990
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and offerings all advocating ways
and means of treatment. Someone
must take charge of the decision
making. Endoscopists, radiologists,
medical gastroenterologists all have
an important part to play in this
process. However, there are not
enough facilities, resources or “superlaparoscopists” available for all
centres to offer all possible treat
ments to all biliary tract sufferers,
unless some order prevails. The
general surgeon should therefore
play a central role in communica
tions with the family physician,
with the patient and with other
specialists, in making the diagnosis,

and in evaluating and recommend
ing, on the basis of illness or
health, simplicity or complexity,
available resources and technolo
gies, the best possible and least
difficult approach to treatment.
Standard uncomplicated chole
cystectomy for chronic cholelithia
sis is still the basic and best, lowrisk, inexpensive, expedient, perma
nent cure available for symptomatic
gallbladder disease in all communi
ties. All other modern techniques
available and accessible are impor
tant advances and additions when
more than a simple standard ap
proach is needed, but they are not a

substitute for basic treatment. The
supervision of overall care should
be assumed by clinically involved
surgeons who are capable of man
aging the patient’s response to
treatment, since complications can
and do arise; overall care should not
be handled by clinical diagnosti
cians and technicians who do not
have access to hospital beds or
patient follow-up.
A general-surgeon-directed ap
proach should help to cure biliary
colic with the least morbidity and
mortality and reduce the personal
colic that has arisen among those
who deliver the care.B

emphasis on associated cardiovascular
and diabetic problems in the elderly.
I have some minor criticisms. The
chapters on amputation level and selec
tion by noninvasive methods are too
long and may confuse the reader. Al
though immediate postoperative fitting
is recommended, many centres do not
possess the available facilities. My pref
erence is for prosthetic fitting within 7
to 10 days of the amputation. The three
pages on upper-extremity amputations
are irrelevant in a text specifically re
stricted to lower-extremity amputation.
The chapters on lower-limb prosthetics
do not contain sufficient basic princi
ples to allow the reader to prescribe a
suitable prosthesis. Prosthetic rehabili
tation has become of international con
cern, and I would have preferred more
references from outside the United
States.
It is estimated that approximately
50 000 lower-extremity amputations
are performed each year in the United
States alone, and the incidence of major
lower-limb amputation in high-risk, dia
betic patients ranges from 6% to 12%
per year.
This monograph provides state-ofthe-art information on all aspects of

lower-extremity amputation. It is essen
tial reading for those concerned with
the care of the amputee and should be
available in every hospital library in
order to provide physicians with suit
able reference material for postgraduate
specialty examinations.

1

BOOK REVIEWS

LOWER EXTREMITY AMPUTA
TION. Edited by Wesley S. Moore and
James M. Malone. 354 pp. Illust. W.B.
Saunders Company Canada Limited,
T o ro n to , 1989. $93.75. ISBN
0-7216-6485-7.
This monograph advances the art and
science of prosthetics and amputation
of the lower limb. It is the hope of the
editors that this information will meet
the needs of the surgeon caring for
patients who require amputation and
will ensure the health and optimal reha
bilitation of those who possess the
maximal length of residual extremity.
Throughout the text, the authors
emphasize the importance of a multidis
ciplinary team approach in which the
patient is the principal member.
The chapters on surgical technique
at various levels are clearly presented
and stress the need for a senior surgeon
to perform or closely supervise the
surgery and the patient’s subsequent
rehabilitation.
The success rates of lower-extremity
arterial reconstruction in the 1980s are
accurately recorded. The early and late
postoperative complications of lowerlimb amputation are described, with
88
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TEXTBOOK OF MICROSURGERY.
Edited by G. Brunelli. 1038 pp. Illust.
Masson, Milano, 1988. Price not stat
ed.
All the leading experts in reconstructive
microsurgery from around the world
have contributed to this impressive
work. Although microsurgery involves
all of the surgical specialties, from
ophthalmology to neurosurgery, this

continued on page 134
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HOW I DO IT

Improved Technique for Insertion of a
Dual Chamber Port-A-Cath
C. Del Campo, MD, FRCSC
he Port-A-Cath totally implant
able drug-delivery system has
become a popular therapeutic meth
od. The system is used most com
monly for bolus injections and con
tinuous infusions of chemothera
peutic agents. It can also be used
for blood sampling, transfusions
and administration of parenteral nu
trition. These systems greatly facili
tate therapy, minimize patient dis
comfort and increase compliance.
Recently, a dual chamber system
(Figs. 1 and 2) has been introduced
by Pharmacia Canada Inc., Dorval,
PQ, for patients in whom two ve
nous routes are required. The sys
tem is composed of two independ
ent chambers in a single device,
joined to a double-lumen catheter
with a double-barrel shotgun-type
configuration at the distal end. It is
recommended that this catheter be
installed through a no. 13F peelback cannula by way of the subcla
vian vein.
I present an improved technique
for implantation and use of this
device, using an independent cathe
ter for each chamber instead of the
conventional double-lumen cathe
ter.

T

shoulder and pectoralis area are
selected for insertion under local
anesthesia. The technique for inser
tion of a single-lumen Port-A-Cath
has been described previously.1 A
similar technique is used with the
following modifications. Once the
vessel dilator and sheath have been
inserted in the subclavian vein, the
dilator is removed. A regular single
lumen silicone rubber catheter is
precut to the desired length. It is
then threaded over the wire and
guided fluoroscopically to the area
where the superior vena cava joins
the right atrium (Fig. 3). The J
guide wire is then removed and
reinserted through the same cannu
la (Fig. 4). The peel-back sheath is
then removed (Fig. 5) and a second
dilator and cannula are introduced
into the subclavian vein parallel to
the first silicone catheter so that
the catheter stays outside the new
cannula (Fig. 6). The second sili
cone catheter is then introduced

FIG. 2. Dual chamber Port-A-Cath ins
erted with its conventional double
lumen catheter. Notice proximity of
both lumina at exit site.

FIG. 3. Silicone rubber catheter is
inside cannula. Catheter has been
threaded over J wire. Note that peelback cannula appears larger than its
real size for clarity.

Technique
Under sterile conditions in the
operating room, the nondominant

FIG. 1. Single and dual
Port-A-Cath systems.
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chamber

FIG. 4. J guide wire has been removed
from silicone catheter and reinserted
through lumen of same peel-back can
nula.
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over the J wire, as before, and
positioned at the opposite end of
the superior vena cava. The intro
ducer is then completely removed
(Fig. 7). Both catheters are tunnel
led subcutaneously and connected
to the dual chamber. The more
proximal catheter (second) is always
connected to the lateral chamber so
it can be easily identified as a
dedicated total parenteral nutrition
(TPN) line if so desired. The final
steps of this procedure remain un
changed.

Discussion
This system has been marketed
as a dual lumen Port-A-Cath, which
has led to misinterpretation by a
number of physicians and nurses
who believed that the device had a
single chamber and a second back
up catheter to be used in case the
first one clotted. This assumption
could lead to errors in flushing
techniques and it would prevent the
dual system from being used to its
full potential (i.e., simultaneous ad
ministration of incompatible drugs).
For this reason I like to refer to it
as a dual chamber or dual system
Port-A-Cath.
The intravenous dual chamber
Port-A-Cath has a number of advan
tages over the single chamber ver
sion: (a) simultaneous administra-

FIG. 5. Peel-back cannula has been
removed. Catheter and J wire remain
in place inside subclavian vein and
superior vena cava.
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tion of incompatible drugs, (b) ad
ministration of drugs through one
chamber, dedicating the second one
to TPN and (c) use of the system
without surgical revision when one
catheter becomes occluded.
The standard technique for in
serting this catheter calls for the
use of a no. 13F introducer for its
insertion. The outside diameter of
the double-lumen catheter is 3.9
mm and fits well through the 4.33
mm internal diameter of 13F intro
ducer. Smaller introducers do not
allow this maneuver when the
added space occupied by blood (vis
cosity) between the two is consid
ered. When I first used this cathe
ter, I found it very difficult in
muscular patients to thread the
double-lumen catheter because of
compression of the cannula by the
pectoralis muscle and fascias. A

FIG. 6. Second dilator and cannula
have been inserted over J guide wire.

FIG. 7. Second silicone rubber catheter
has been positioned under fluoroscopic
control much more proximally than
first catheter. Both are now connected
to dual chamber Port-A-Cath.

diameter reduction or deformity of
0. 4 mm is all that is needed to
prevent this step. The catheter can
not be directed by the J wire be
cause of the small inside lumina, so
I modified the technique as de
scribed. The silicone catheter of a
regular intravenous Port-A-Cath
was used. This catheter is long
enough to be cut and used for both
portals.
This technique has become my
procedure of choice for this system
because it minimizes blood loss and
may decrease the possibility of air
embolism by using smaller intro
ducers. Thus, larger introducers,
which may otherwise have no pur
pose, do not have to be kept in
stock. It also allows positioning of
the second catheter much more
proximally than the first, so it can
be used as a dedicated TPN line
(remember, it is always connected
to the lateral catheter for universal
identification). Since blood flows
away from the exit orifice of the
second catheter and toward the
first, contamination is much less
likely. When two incompatible
drugs are used simultaneously, they
are more likely to mix with blood
before coming in contact with each
other.
It is conceivable that in the fu
ture this dual chamber catheter
might have one catheter dedicated
to intravenous use and the second
for regional intra-arterial chemo
therapy. However, in this situation
the margin for error is high, and
the wrong route of administration
could be used inadvertently. In this
case it would be safer to use two
separate systems in different ana
tomical locations for easy identifica
tion.
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K ock to Urethra: Continent Functional
Bladder Replacement
William L. Orovan, MD, FRCSC, FACS; Ian R. Davis, MD, FRCSC
Since 1950 when Bricker first described the construction of the ileal conduit, this
procedure has become a standard method of urinary diversion after pelvic
exenteration. Recently, increasing interest in continent diversions has resulted in
the development of several new procedures, using both small bowel and large bowel
to produce an internal urinary reservoir. Such reservoirs still maintain a urinary
stoma which requires periodic catheterization for emptying. With the development
of the Kock low-pressure urinary reservoir, it has now become possible to
re-establish the continuity of the urinary system by anastomosing this internal
reservoir to the posterior urethra. This procedure utilizes the distal urethral
sphincter as a continence mechanism and allows functional bladder emptying
without a stoma. An antireflux valve is constructed to protect the kidneys. The
authors report their experience with 20 such diversions, describing the operative
technique, detailing the perioperative complications and providing urodynamic
evidence of restored bladder function.

Depuis la premiere description de la construction d’un conduit ileal par Bricker, en
1950, cette intervention est devenue la methode standard de derivation urinaire
apres une exenteration pelvienne. L’interet qui s’est developpe recemment pour les
derivations continentes a entraine la mise au point de plusieurs nouvelles
techniques faisant appel aussi bien a l’intestin grele qu’au gros intestin pour la
construction d’un reservoir urinaire interne. De tels reservoirs conservent un stoma
urinaire necessitant un catheterisme periodique pour assurer la vidange. Avec la
mise au point du reservoir urinaire a faible pression de Kock, il est maintenant
possible de restaurer la continuite du systeme urinaire par anastomose de ce
reservoir interne a l’uretre posterieure. Cette intervention utilise le sphinctere
externe distal de l’uretre comme mecanisme de continence et permet la vidange
fonctionnelle de la vessie sans recourir a un stoma. Une valvule antireflux est
introduite afin de proteger les reins.
Les auteurs commentent les resultats obtenus avec 20 diversions de ce type; ils
decrivent la technique operatoire, signalent les complications peroperatoires et
fournissent les preuves urodynamiques du retablissement de la fonction vesicale.

I

n 1950 Bricker1 documented the
ease of construction and the low
complication rate of the ileal con
duit urinary diversion. Since then,

this procedure has become the stan
dard for urinary diversion after pel
vic exenteration. This simple con
duit, which utilizes a 20-cm seg
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ment of distal ileum, drains continu
ously and uses an external collect
ing device for storing urine. Al
though the ileal conduit is an effec
tive low-pressure urinary diversion,
many patients suffer slow but pro
gressive renal deterioration second
ary to chronic pyelonephritis, which
results from the reflux of urine
from the conduit.
The concept of replacing the
bladder with a longer segment of
bowel to create a continent, nonre
fluxing, urinary reservoir was first
proposed by Gilchrist and col
leagues2 in 1950. This concept was
not widely accepted because of its
complexity and high rate of compli
cations. It was not until 1982,
when Kock and associates3 reported
the construction of a continent,
nonrefluxing urinary reservoir
using distal ileum alone, that atten
tion returned to the concept of
continence with respect to urinary
diversion.
A continent urinary reservoir may
be defined as one which duplicates
the storage function of the bladder
internally and permits passive emp
tying at convenient intervals, usual
ly by intermittent self-catheteriza
tion. In most cases, these reservoirs
do not duplicate the bladder’s emp
tying function. An ideal urinary
diversion would be both continent
and nonrefluxing, provide active
emptying and avoid creation of a
separate urinary stoma by re-estab
lishing normal continuity of the
urinary tract. Camay and LeDuc,4 in
1979, first demonstrated the feasi
bility of such a functional bladder
replacement. The Camay procedure
C JS, VO L. 33, N O . 2, A P R I L 1990
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includes an intact segment of distal
ileum in the form of a large U, the
distal portion of which is anas
tomosed to the proximal membra
nous urethra. Unfortunately, in
traluminal pressures within this in
tact, tubular segment of ileum
occur as a result of ongoing peri
stalsis and often lead to inconti
nence, especially at night when res
ervoir pressures exceed the resting
tone of the urinary sphincter. It
remained for Weinberg and col
leagues5 to define a method of
combining the low-pressure, detubularized, Kock reservoir with anas

tomosis to the proximal membra
nous urethra to produce a truly
functional, nonrefluxing, continent
urinary diversion without any uri
nary stoma. We report here our
initial experience with 20 patients,
all of whom underwent radical cys
tectomy for high-grade bladder can
cer and had urinary diversion using
the Kock to urethra continent func
tional urinary reservoir.

Patients and Methods
Between Jan. 1 and Dec. 31,

FIG. 1. Portion of distal ileum used for reservoir (63 cm).

FIG. 3. Mucosa approximated with double layer of 3-0 Vicryl.
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1988, 20 men underwent radical
cystectomy and pelvic lymphadenectomy for high-grade invasive blad
der cancer. The patients ranged in
age from 54 to 80 years (mean 65
years). All patients had full preoper
ative work-up which included chest
roentgenography, computed tomog
raphy of the abdomen and pelvis
and bone scanning. The alternatives
for urinary diversion, including a
standard ileal conduit and a conti
nent reservoir involving an abdomi
nal stoma, were discussed at length
and informed consent was obtained
from all patients. Preoperative renal

FIG. 2. Two 22-cm segments are anastomosed side to side
with 3-0 Vicryl and then opened longitudinally 5 mm from
suture line.

FIG. 4. Mesenteric “window” is formed by denuding 8 cm of
small-bowel mesentery.

CONTINENT BLADDER REPLACEMENT

function was assessed by measure
ment of the serum creatinine and
blood urea nitrogen levels; no pa
tient had a pre-treatment serum
creatinine level exceeding 120
mmol/L.

Surgical Technique
The technique is similar to that
previously described for the stan
dard Kock to skin continent diver
sion,6 but the efferent limb and its

FIG. 5. Three rows of 4.8-mm staples
are placed using TA-55 stapler.

accompanying second intususscepting nipple valve are unnecessary.
The basic steps are outlined in
Figs. 1 to 7 as follows.
• A three-segment portion of
distal ileum is isolated (Fig. 1),
beginning proximal to the ileocecal
valve at the mesenteric avascular
plane of Treves. The segment is
marked off in 22-, 22- and 19-cm
lengths.
• The body of the pouch is
formed by anastomosing the two
22-cm segments side to side (Fig.
2), with first a serosal suture and
then, after longitudinally opening
the bowel (Fig. 3), with a two-layer
mucosal closure with absorbable su
ture.
• An intususscepted antireflux
ing nipple valve is constructed at
the afferent-limb (19 cm) segment
by stripping the mesentery over 8
cm of bowel, creating a “window”
(Fig. 4) and intususscepting the
bowel onto itself. A 2.5-cm serosal
collar of Vicryl mesh soaked in a
5% tetracycline solution encircles
the bowel. Additional nipple stabili
zation is achieved using three rows
of AMS 4.8-mm staples applied with
the TA-55 Auto-Suture (Auto Su
ture Co., Division of U.S. Surgical
Corp., Norwalk, Conn.) device (Fig.
5).

FIG. 6. Pouch is dosed transversely with 3-0 Vicryl, leaving
2-cm opening at one corner.

• The body of the pouch which
was opened in a longitudinal direc
tion is now closed transversely.
This produces disordered peristalsis
and maintains intraluminal pres
sures below 20 cm H20. A lateral
corner of the transverse closure is
left open to a diameter of 2 cm for
anastomosis to the proximal ureth
ral stump (Fig. 6).
• Ureters are implanted into the
afferent limb of the pouch.
• The pouch is anastomosed to
the posterior urethra (Fig. 7).

Results
Operative time ranged from 4 to
6.5 hours (mean 5.3 hours). The
hospital stay ranged from 21 to 39
days (mean 31 days). There were no
perioperative deaths. Complications
included deep venous thrombosis,
requiring anticoagulant therapy, in
seven patients and a superficial
wound abscess in one. One patient
had a urethral cutaneous fistula
which was closed without difficulty
and another had a fistula from the
Kock pouch to the rectum. This
was repaired through a posterior
transanal approach, and the patient
is now fully continent of both urine
and stool.

FIG. 7. Pouch is anastomosed to posterior urethra using 2-0
Vicryl.
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Our longest follow-up is 16
months and results have been excel
lent. Two patients died of progres
sive malignant disease and 1 re
mains alive, with disease, on chemo
therapy. Of the 18 survivors, 10
have complete continence both day
and night; 6 have partial continence
with some night-time dribbling or
stress-type incontinence; 2 patients
suffer from incontinence which is
sufficiently severe that they must
wear anti-incontinence garments
and pads or condom catheter drain
age devices. We have found that up
to 3 months may be required for the
patient to recover continence, and
some show improvement even be
yond that time. Urodynamic assess
ment was carried out on 15 patients
after a minimum postoperative fol
low-up of 4 months (Table I). Good
reservoir volumes were noted and
filling pressures were less than 20
cm H20 in every case. Voiding was
done by Valsalva's maneuver, which
generated adequate flow rates in
most cases. The sensation of blad
der fullness was noted as abdominal
cramping, making volitional voiding
possible. Voiding times were occa
sionally prolonged, but reservoir
emptying was good in every case.
Initially, because of the heavy pro
T a b le 1. U ro d y n a m ic A s s e s s m e n t in 15
P a tie n ts M o re T h a n 4 M o n th s A fte r S u rg e ry
P o u c h v o lu m e , m l
In fu s io n p re s s u re , cm H 20
V o id in g p re s s u re s , cm H 20
P ea k flo w , m l/ s
M e a n flo w , m l/ s
V o id in g tim e , s
P o s t-v o id re s id u u m , m l

250 - 1000
< 20
2 0 -4 0
1 3 .8 -1 9 .2
4.1 - 5 . 5
45 - 247
< 50

duction of mucus by the reservoir,
patients are encouraged to selfcatheterize and irrigate with 50 to
100 ml of normal saline twice daily.
As mucous production decreases,
the frequency of catheterization is
also decreased and is usually not
necessary after 4 months. The
avoidance of an abdominal wall sto
ma, even a continent stoma, as in
the Kock to skin diversion, has
been a very positive factor for all
patients, who have been extremely
satisfied with the results of the
procedure.

mal voiding without any urinary
stoma and without the need for
regular self-catheterization has
been well received by patients. It
may be that some will require an
artificial bulbous urethral sphincter
to overcome persistent inconti
nence, but our experience suggests
that this will be 10% or less of the
total. We believe this technique rep
resents an important addition to our
armamentarium of urinary diver
sions and seems to provide an im
proved quality of life for patients
who must undergo radical pelvic
exenteration.

Discussion

1

< V

1
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Pyloromyotomy of Ramstedt: Experience
of a Nonspecialized Centre
S. Dube, MD, FACS, FRCSC;* P. Dube, MD;* J.F. Hardy, MD, FRCPC;t
R.E. Rosenfeld, MD, FRCPCJ
In a general hospital over a period of 6 years 57 infants with congenital
hypertrophic stenosis underwent a Ramstedt pylorotomy. In most cases a surgical
resident-in-training performed the operation under the direct supervision of a
general surgeon. There were no complications of anesthesia, no deaths and no
substantial morbidity. The majority of infants left the hospital within 48 hours. The
results in this series compared favourably with those reported from more specialized
centres.

Au cours des 6 dernieres annees, 57 enfants souffrant d’une stenose hypertrophique
congenitale du pylore ont ete operes dans l’hopital general. La majorite des patients
ont ete operes par un resident en chirurgie, sous la supervision directe d’un
chirurgien general. II n’y a eu aucun probleme anesthesique ni aucune morbidity
significative. La majorite des enfants ont quitte l’hopital en dedans de 48 heures.
Cette serie se compare favorablement avec les resultats obtenus dans les centres
specialises. La pyloromyotomie de Ramstedt a pu etre completee de facon securitaire
dans l’Hopital Maisonneuve-Rosemont de Montreal et les auteurs croient que malgre
qu’ils soient un centre de chirurgie generate, qu’ils peuvent continuer a proceder a
cette intervention.

he general surgeon’s field of
activity has narrowed dramati
cally in recent years. Moreover,
standards for certain types of opera
tion have increased because of
overspecialization. It is necessary,
therefore, that nonspecialist sur
geons prove their competence. Con
genital hypertrophic pyloric steno
sis used to be treated by general
surgeons, but today it is more likely
to be managed by a pediatric sur
geon. Because this operation is
never performed as an emergency,
it is perhaps safer to transfer the
baby to a specialized centre.
McDonald1 has reported that in
some district hospitals in England
the rates of wound infection and

T

dehiscence for the Ramstedt proce
dure are 6% and 4%, respectively.
These rates are much higher than
those reported by specialized cen
tres (0.5% and 0.2%).2 Despite that,
district hospitals still continue to do
this operation. Anesthesia can also
present a problem for physicians
unaccustomed to administering an
esthesia to infants.
The aim of this study was to
review the complication rate of an
esthesia and surgery, the outcome
of the Ramstedt procedure with
respect to refeeding and length of
stay in our general hospital, and to
compare these results with those
from specialized centres, to deter
mine if we should continue to per
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form this procedure at our institu
tion.

Patients and Methods
A retrospective study was under
taken of 57 consecutive patients
(46 boys, 11 girls) with congenital
hypertrophic stenosis seen at the
Hopital Maisonneuve-Rosemont be
tween 1978 and 1986. The opera
tions were performed by second- to
fourth-year residents under the di
rect supervision of several general
surgeons. All operations were per
formed under general anesthesia,
administered by residents-in-training, also under the immediate su
pervision of an anesthesiologist, or
by the anesthetist himself. Thirteen
infants were intubated awake, and
44 were intubated after rapidsequence intravenous induction of
anesthesia and cricoid pressure. All
infants were extubated awake. All
the abdominal incisions were trans
verse rectus skin incisions, and the
muscle was split vertically. The
wounds were closed with absorb
able interrupted sutures. A standard
longitudinal Ramstedt pyloromyotomy was carried out as described
previously.3 Any perforation of the
duodenal mucosa that was noted
was sutured with Dexon or Vicryl.
The infants were treated before and
after surgery by pediatricians and
surgeons, and an early feeding pro
tocol was implemented. No antibiot
ics were used.
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The clinical manifestations of
congenital hypertrophic stenosis
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were typical; in the majority of
cases they were mild or moderate.
Only 50% of infants presented with
metabolic alkalosis. A palpable py
loric tumour was present in half the
cases. In the majority a barium
meal radiologic examination or ab
dominal ultrasonography were done
to confirm the diagnosis. The mean
duration of anesthesia and surgery
was 40 minutes. There was only
one difficult intubation and no aspi
ration occurred. There were seven
duodenal perforations; all were re
paired by simple suture. No further
leak or complication occurred.
There were no deaths, wound
infection, dehiscence, hernia or
need for reoperation.
These results are compared with
those from other series in Table I.
For the majority, refeeding was
started 8 hours postoperatively and
a standardized protocol was imple
mented. Those in whom the duode
nal mucosa was repaired were not
fed orally for 24 hours. The postop
erative hospital stay was 48 hours
except in children who required
duodenal repair whose stay was 72
hours.

Discussion
The majority of infants in this
study of Ramstedt’s procedure in a
general hospital did not present
with severe dehydration and were
well prepared by pediatricians preoperatively. They had mild to mod

T a b le

S e r ie s

1.

erate symptoms according to Ben
son’s classification.3 The fact that
only 50% had a palpable tumour
compared with 90% reported by
others4 suggests that physicians
now are more inclined to rely on
tests than on a physical examina
tion or that the cases are diagnosed
earlier. Barium meal radiologic ex
amination has an accuracy of 95%,
but abdominal ultrasonography is
now the test of choice for confirm
ing the diagnosis.5 In our study all
anesthetics were uncomplicated. In
particular, no gastroesophageal re
flux with subsequent aspiration of
gastric contents was noted. Adher
ence to well-accepted guidelines for
the practice of anesthesia in these
cases (induction sequence for the
patient with a “full stomach”) and
ultrasonography rather than barium
meal examination to confirm the
diagnosis help to explain these re
sults. Furthermore, extubation of
the trachea when the infant is
awake ensures that no marked aspi
ration occurs during emergence
from anesthesia. Seven duodenal
perforations were noted, a rate
higher than that reported by spe
cialized centres.6'8 In order to re
duce this complication, the surgeon
must stop the original incision just
short of the white line that demar
cates the true junction of the stom
ach and duodenum. This must be
taught to residents with greater
emphasis. Our wound infection and
dehiscence rates were similar to
those of specialized centres and our

results were superior to those re
ported by English district hospi
tals.19
We agree with Condon,10 when
he questioned the safety of pyloromyotomy in certain district general
hospitals. If a nonspecialist team
cannot attain the current standards
of care, it should not be doing this
procedure.
Our study has demonstrated that
Ramstedt’s pyloromyotomy can be
performed safely in our general hos
pital. Regular appraisal of our re
sults is, however, mandatory in
order to compete with specialized
centres.
We thank Mrs. Claire Lemyre for her
technical assistance.
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Palliative Surgery for Adenocarcinoma of
the Gastroesophageal Junction
Ian F. Smith, MD, FRCSC; Alan Kwan, MD, FRCSC
Adenocarcinomas of the gastroesophageal junction are usually incurable at the time
the patient is first seen. The charts of 21 consecutive patients with this condition
were reviewed. All had histologically documented transmural extension of tumour
and lymph-node or distant metastases. A variety of surgical techniques were used to
restore the ability to swallow. From the charts of these 21 cases, the authors
analysed the success in restoring swallowing, the length of hospital stay, the
surgical death rate, complications, survival and the ability to swallow normally at
the time of death.
Restoration of normal or near-normal swallowing appears to be a realistic goal.
Selection of an appropriate surgical option, with resection of the primary tumour
when technically feasible, allows this to be done with negligible mortality and
acceptable morbidity.
Les adenocarcinomes de la jonction oeso-gastrique sont habituellement deja
incurables lorsque les patients sont vus pour la premiere fois. On a etudie les
dossiers de 21 patients consecutifs souffrant de cette affection. Tous montraient
des preuves histologiques d’extension transmurale de la tumeur et de metastases
ganglionnaires ou a distance. Diverses techniques chirurgicales ont ete utilisees
pour restaurer la capacite de deglutition. Les auteurs ont analyse, a partir de ces 21
dossiers, le succes de l’intervention destinee a retablir le mecanisme de deglutition,
la duree d’hospitalisation, la mortalite operatoire, les complications, la survie et la
capacite d’avoir une deglutition normale au moment du deces.
La restauration d’une deglutition normale ou quasi normale paratt etre un objectif
realisable. Le choix d’une approche chirurgicale appropriee comprenant la resection
de la tumeur primitive, lorsque cela s’avere techniquement possible, permet
d’atteindre cet objectif avec un taux de mortalite negligeable et une morbidity
acceptable.

it with squamous cell carcinomas
and adenocarcinomas of the esopha
gus or with carcinomas o f the stom
ach. The few reports dealing specifi
cally with adenocarcinoma o f the
gastroesophageal junction focus
primarily on curative resection.
However, most patients have incur
able disease at the time o f presenta
tion.2 We believe that the goal of
therapy in these patients should be
to restore normal or near-normal
swallowing and relieve pain through
the safest and easiest operation
available. To justify resection as the
treatment of choice, it must be
applicable to most patients with
incurable adenocarcinoma o f the
gastroesophageal junction, be ac
companied by low morbidity and
mortality, and be successful in re
storing the swallowing mechanism.
In the present report we focus on
these points.

Patients and Methods
denocarcinomas o f the stom
ach and in particular those of
the gastroesophageal junction have
a poor prognosis, as shown by
Webb and Busuttil.1 Treatment re
mains controversial, especially

A

when the lesion is found to be
incurable at the time o f presenta
tion. Unfortunately, most previous
reports in the literature address
adenocarcinoma o f the gastroeso
phageal junction either by grouping
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We reviewed records o f all the
patients we treated at the Health
Sciences Centre, Memorial Universi
ty o f Newfoundland between 1980
and 1987, who had a diagnosis of
adenocarcinoma o f the gastroeso
phageal junction. Patients who un
derwent potentially curative resec
tion were excluded from the study.
There were 21 patients (16 men, 5
women) available for study. All had
advanced tumours documented his
tologically by extension o f tumour
into adjacent structures, lymphCJS, VOL. 33, NO. 2, A P R I L 1990
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node metastases or distant metastases. No patient had clinically detect
able ascites preoperatively although
in several patients peritoneal seed
lings and small volumes of malig
nant ascites were found at opera
tion.
The patients ranged in age from
36 to 99 years (mean 67.8 years).
Most patients had dysphagia, dis
comfort, anorexia and weight loss
(Table I). All underwent endoscopy
preoperatively and had a biopsy
confirming adenocarcinoma of the
gastroesophageal junction, as well
as a preoperative barium swallow.
Seventeen patients underwent com
puted tomography of the chest and
upper abdomen preoperatively. All
had intravenous or enteral nutri
tional support preoperatively and
postoperatively until they were eat
ing normally; however, no opera
tion was delayed in an attempt to
improve a patient’s nutritional sta
tus.
All 21 patients in the study un
derwent a surgical procedure. No
patient was denied palliative surgi
cal treatment because of advanced
disease or other medical illness and
no patient with advanced adenocar
cinoma of the gastroesophageal
junction had an alternative form of
therapy. The surgical procedures
included 17 resections and 4 by
passes (Table II). No patient re
ceived adjuvant radiotherapy or
chemotherapy.
Transabdominal esophagogastrectomy was the most commonly
performed procedure. Using the
upper hand retractor and with re
section of a portion of diaphragm in
the region of the hiatus, where
necessary, 7 to 10 cm of distal
esophagus was resected and the
EEA stapler (Auto Suture Co., Divi
sion of U.S. Surgical Corp., Nor
walk, Conn.) was used to perform
an anastomosis between the end of
the esophagus and the anterior wall
of the gastric remnant. A pyloro98
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myotomy or pyloroplasty was done
to facilitate gastric drainage on all
patients who underwent a resection
or substernal gastric tube bypass.
A thoracoabdominal approach
was used for patients with gross
tumour extending up the esopha
gus for a distance that made ab
dominal resection and reconstruc
tion unsafe or impossible.
Bypasses were performed in
those patients who had local exten
sion to and invasion of adjacent
structures, particularly the aorta,
precluding resection. Our first
choice in this situation was a substernal esophagogastrostomy be
cause it avoids the need for a
thoracotomy. A tube of stomach
was created from the greater curva
ture using stapling devices and
avoiding gross tumour at the gas
troesophageal junction. An appro
priate length of stomach was
achieved by full mobilization of the
distal stomach and kocherization of
the duodenum. When the tube was
passed substernally into the neck,
the distal cervical esophagus was
transected using a TA-55 stapler
(Auto Suture Co.) and the proximal
cervical esophagus was anas
tomosed to the anterior wall of the
transposed greater curvature using
one layer of interrupted 3-0 Prolene
sutures.
If the size of the primary tumour
made development of a satisfactory
length of gastric tube impossible, a
Roux-en-Y loop of jejunum was
brought up via a separate hole
created in the left hemidiaphragm
and an esophagojejunal anastomo
sis was performed 3 to 5 cm above
the gross tumour. The distal esoph
agus above the tumour was stapled
and transected to facilitate this
anastomosis, if necessary.
We always inserted a feeding jejunostomy in patients who under
went surgery for carcinoma of the
gastroesophageal junction. Al
though hyperalimentation was used

both pre- and postoperatively, a
feeding jejunostomy allows early
enteral feeding if anastomotic or
other complications do arise.

Results
The resectability rate was 80.1%
(17 of 21 patients) as noted in Table
II. The 30-day operative death rate
was 4.8% (1 of 21 patients). The
one death occurred in a patient with
a documented seizure disorder who
underwent a thoracoabdominal esophagogastrectomy. The patient died
of massive aspiration following a
grand mal seizure. Three days be
fore the seizure a Gastrografin
swallow had shown that the anasto
mosis was intact and the patient
had been started on an oral intake.
All patients had roentgenography
after a Gastrografin or barium swal
low 6 to 9 days postoperatively.
Leaks were demonstrated radiologically in 19% (four patients). None of
the leaks was clinically serious and
on repeat examination after 1 week

.

Table 1 D om inant Preoperative S ym ptom s
Symptom

No. of patients

A bso lu te dysphagia
D ysphagia fo r liquids and
so lid s
D ysphagia fo r so lid s o nly
E pigastric o r retrosternal
pain
A norexia and w e ig h t loss

2
2
10
5
2

Table II. O perations Perform ed
Procedure
R esection
Transabdom inal
esophagogastrectom y
Thoracoabdom inal
esophagogastrectom y
Total esophagectom y
and proxim al
g a stre cto m y
B ypass
S ubsternal
e sophagogastrostom y
Thoracoabdom inal
esophagojejunal
bypass

No. of patients
17
13
3

1
4
2
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had healed spontaneously in three
of the four patients. In the fourth
the leak sealed spontaneously 3
weeks postoperatively. There were
no leaks in the 13 patients who
underwent transabdominal esophagogastrectomy.
The patient’s ability to swallow
was assessed both before discharge
and at outpatient follow-up and is
summarized for the 20 discharged
patients in Table III. Preoperatively
81% (17 patients) had some degree
of dysphagia, with dysphagia being
the dominant symptom in 66.7%
(14 patients). All patients who had
dysphagia preoperatively reported
marked improvement postoperative
ly, with 80% (16 of 20 patients)
having normal or near-normal swal
lowing. The six patients classified
as near normal noted minimal sub
jective differences in their ability to
swallow from their normal precan
Table III. P ostoperative A b ility to Swallow
Swallowing
ability

No. of patients
%

Norm al
Near norm al
Occasional dysphagia fo r
solids
In te rm itte nt dysphagia
requiring dilatation

1 0 (5 0 )
6 (3 0 )
3 (1 5 )
1

(5 )

Table IV. C om p licatio n s
Complication

No.

Pneum onia
Empyem a
C linically im p o rta n t atelectasis
Right low er lobe co llapse
Bile reflux

2
2
5
1
1

Table V. Length o f H ospital S tay According
to O peration
Procedure
Transabdom inal
e sophagogastrectom y
Thoracoabdom inal
esop h a g og a strecto m y
Total esophagectom y
Substernal bypass
Esophagojejunal bypass

Duration, d
(range)

cerous state; however, they had no
dysphagia. Those classified as nor
mal noted no differences whatsoev
er. Even the four patients who had
residual dysphagia were markedly
improved and were able to resume a
normal diet with only the occasional
need (once or twice a week on
average) to clear a bolus of solid
food with large volumes of liquid.
One patient required dilatations
every month postoperatively. She
complained of dysphagia almost as
soon as she resumed oral feeding. A
barium swallow showed no evidence
of a leak and only minimal anasto
motic narrowing. Despite her need
for dilatation, there was a marked
improvement over her preoperative
absolute dysphagia.
All patients had complete relief of
preoperative epigastric or retroster
nal pain. Dysphagia due to recur
rent tumour did not develop even
though 23.8% (five patients) had
positive esophageal resection mar
gins. No patient had a deterioration
in the ability to swallow during the
follow-up.
In addition to the one death and
the four leaks there were 11 other
complications (Table IV). Only one
case of atelectasis occurred in the
13 patients who underwent transab
dominal esophagogastrectomy. No
other complication was seen in this
subgroup.
Table V indicates length of hospi
tal stay for surviving patients.
Three of the 20 patients who
were discharged were alive and well
at 5, 8 and 50 months respectively
after operation; 17 patients died of
progressive disease and had a mean
survival of 6.6 months (range from
2 to 16 months). None of these 17
patients had dysphagia at the time
of death.

14.5 ( 1 0 - 2 7 )
21.3 ( 9 - 3 5 )
29.0
23.0 ( 1 6 - 3 0 )
20.5 ( 1 6 - 2 5 )

Discussion
Unlike previous reports in which

small numbers of patients who had
advanced adenocarcinoma of the
gastroesophageal junction were in
cluded in much larger series of
patients with esophageal or gastric
cancer, many of whom underwent
resection for cure, this study deals
only with those proven histological
ly to have incurable lesions. Despite
this, our resectability rate of 80.1%
stands up well against collected
series in which resectability rates
ranged from 32% to 67% and aver
aged 50%.3 Likewise, our operative
death rate of 4.8% for the whole
group and 0% for those who under
went transabdominal esophagogas
trectomy compares favourably with
that of other studies in which 7% to
30% of patients died in the immedi
ate postoperative period.1' 6
In other reports, the most fre
quent cause of death was anasto
motic leakage, with rates ranging
from 5% to 50%.3 We had no clini
cally serious leaks, and the rate of
radiologically detected leaks was
19% for the entire group and 0% for
those having a transabdominal eso
phagogastrectomy.
The fact that some anastomoses
leak is not surprising, considering
the dysphagia, marked weight loss,
general debility and immunocom
promised nature of these patients.
However, we consider that pre- and
postoperative hyperalimentation,
emphasis on careful surgical tech
nique and placement of the anasto
mosis in either the abdomen or the
neck are important in reducing the
number of leaks. Preoperative ra
diotherapy was not used because of
its proven association with pulmo
nary complications and anastomotic
leaks.7
In those with radiologically iden
tified leaks in our series the clinical
course did not differ from that of
the other patients except that the
hospital stay was longer. The leaks
healed spontaneously in all patients.
The objectives of treatment for
CJS, VOL. 33, NO. 2, APRIL 1990
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patients who have advanced carci
noma of the gastroesophageal junc
tion must be restoration of normal
or near-normal swallowing and re
lief of pain. The techniques of sur
gical treatment are not important as
long as these objectives are met,
although resection of a primary
tumour is generally associated with
longer survival than bypass proce
dures.8 Although computed tomog
raphy of the chest and upper abdo
men was done in 17 patients, its
value in preoperative planning of
surgical treatment for carcinoma of
the gastroesophageal junction is
limited.9 Surgical exploration has
proven to be the only accurate
method to determine tumour ex
tent.1011
Procedures requiring transgres
sion of the thoracic cavity were
associated with a significantly lon
ger hospital stay (Table V), even
though they were equal to trans
abdominal esophagogastrectomy in
terms of relieving pain and re
storing normal or near-normal swal
lowing.
In our study, all patients with
dysphagia preoperatively reported
marked improvement postoperatively. The operation relieved preopera
tive pain in all. None had a deterio
ration in the ability to swallow
during the follow-up period. Hence,
it seems safe to conclude that the
procedures employed were success
ful in meeting these objectives.
Series which include patients
with adenocarcinoma of the gastro
esophageal junction as part of a
larger study group usually quote
median survival rates of 10 to 20
months.3-412 Those dealing only
with adenocarcinoma of the gastro
esophageal junction have median
survivals in the range of 10
months.2 All these studies have in

100
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cluded patients with lesions resect
ed for cure as well as those treated
for palliation only. Perhaps the me
dian survival of 6.6 months in this
report more accurately reflects the
prognosis for patients who undergo
surgical treatment for palliation
only.
Some recent reports in the litera
ture suggest improved resectability
rates and decreased local recurrence
rates with combined preoperative
radiotherapy and chemotherapy.13
However, we do not consider this to
be of great benefit in those with
advanced carcinoma of the gastro
esophageal junction; 15% to 20%
of patients never undergo surgery if
started on a multimodality proto
col.13 Furthermore, combined radio
therapy and chemotherapy does not
immediately relieve the patient’s
symptoms or control distant recur
rence, which remains the major
cause of death.13

Conclusions
The data suggest that, despite
the dismal long-term prognosis, res
toration of normal or near-normal
swallowing and relief of pain are
realistic goals in patients with ad
vanced adenocarcinoma of the gas
troesophageal junction. Selection of
an appropriate surgical option al
lows this to be done with acceptable
morbidity and mortality. In our se
ries, transabdominal esophagogas
trectomy was the quickest, easiest
and safest way to achieve effective
palliation.
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Dietary Habits After Ileal Pouch-Anal
Anastomosis
C. Chartrand-Lefebvre, BSc; J. Heppell, MD, FRCSC; I. Davignon, BSc; S. Dube, MD, FRCSC, FACS;
A. Pomp, MD, FRCSC
Dietary habits of patients who had undergone ileal pouch-anal anastomosis were
assessed and correlated with bowel function. Twenty-four well-adapted patients (11
women, 13 men; mean age 32 years) voluntarily entered the study 30 ± 4 months
after closure of the diverting ileostomy. A standardized questionnaire on 108 food
items and a 3-day food journal were used in the assessment. Twenty-one patients
had no difficulty in selecting an appropriate diet. Caloric intake was adequate.
Specific symptoms associated with several foods were as follows: increased stool
frequency (beer, spirits, Chinese food), decreased stool consistency (beer, wine, fried
fish), perianal irritation (spicy foods), undigested particles (grapefruit, lettuce),
odours (eggs). Pasta and bananas were associated with increased stool consistency.
The authors believe that these observations may help in dietary counselling after
ileal pouch-anal anastomosis.

Les habitudes alimentaires apres anastomose ileo-anale et leur relation avec le
resultat fonctionnel ont ete evaluees. Vingt-quatre patients (11 femmes, 13 hommes;
age moyen 32 ans) ont participe a l’etude, apres 30 ± 4 mois d’adaptation. Un
questionnaire portant sur 108 aliments et un journal alimentaire ont ete utilises.
Vingt-et-un patients ont une diete convenable. L’apport energetique est adequat. Les
symptomes specifiques associes aux aliments sont: frequence des selles augmentee
(biere, spiritueux, mets chinois), consistance diminuee (biere, vin, poisson frit),
irritation peri-anale (mets epices), particules non digerees (pamplemousse, laitue),
odeurs (oeufs); pates et bananes ont ete associees a une consistance augmentee. Ces
observations aideront au conseil dietetique apres anastomose ileo-anale.

leal pouch-anal anastomosis is
an alternative to permanent ileos
tomy for well-selected patients with
ulcerative colitis and familial poly
posis. The reported long-term func
tional results are encouraging.12
However, optimal dietary manage
ment of patients after this proce

I

dure has not been clearly defined.
Often our patients empirically asso
ciate their pouch function with vari
ations in diet. This study was car
ried out to determine the eating
habits of patients after ileal pouchanal anastomosis and to correlate
diet with bowel function. We
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wished to identify factors that
would be of use in dietary counsel
ling and eventually to improve func
tional outcome.

Patients and Methods
Patients

Twenty-four patients (11 women,
13 men) who underwent an endo
rectal ileoanal anastomosis with
construction of an ileal reservoir
entered the study voluntarily; 20
were operated on for ulcerative coli
tis, 3 for familial polyposis coli and
1 for multiple colonic carcinomas.
During the primary surgery, pa
tients underwent total colectomy,
mucosal proctectomy and endorec
tal ileoanal anastomosis with con
struction of a “J”-type ileal reser
voir in each patient, using the tech
nique of Beart and colleagues.3 A
diverting loop ileostomy protected
the reservoir after the procedure; it
was closed an average of 3 months
after the initial operation. The di
verting ileostomy had been closed
for less than 1 year in 5 patients
and for longer than 1 year in 19
(mean interval ± SEM of 30 ± 4
months). The mean age of the pa
tients was 32 ± 3 years (range from
19 to 50 years).
Medications to modify intestinal
transit were used occasionally in
only five patients. Ten patients used
psyllium, 3.6 g daily, routinely.
Assessment o f Functional Outcome

The functional outcome after the
CJS, VOL. 33, NO. 2, A P R IL 1990
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operation was evaluated by two in
dependent observers (C.C.L. and
I.D.), using a standardized question
naire during a personal interview.
Patients were asked to assess their
well-being on a scale of 1 (poor) to
10 (excellent) during the disease
period, during the loop ileostomy
interval and at the time of inter
view. The functional parameters in
vestigated were: stool frequency
and consistency, perianal irritation,
continence during day and night,
evacuation of intestinal gas and
undigested particles, and the modi
fication of stool odours.
Assessment of Dietary Habits
Two methods were used to evalu
ate dietary habits. First, a food
journal was kept by the patients to
document their usual intake of solid
foods, liquids and medications over
a 3-day period. This journal includ
ed the mean consumption of food
for 2 days during the week and 1
day during the weekend. The data
was entered in a Microvax II com
puter (Digital Equipment of Canada,
St. Laurent, PQ) and was analysed
by a professional dietitian, using
software based on the Canadian
Nutrient File, Food Directorate.4
Second, a detailed standardized
questionnaire on 108 food items
was discussed with the patients dur
ing an interview. The patients were
asked whether they were eating
each food item and if a given symp
tom could be associated with a
specific item. Table I illustrates the
15 symptoms that were presented
to the patients.
Associations
An association between consump
tion of a given food item and a
specific symptom was considered if
at least 10 of the 24 patients had
consumed the food item since clo
sure of the diverting ileostomy and
102
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at least 20% of them had reported
the symptom.
Statistical Evaluation
Student’s t test was used to com
pare the means of data with normal
distribution. Body weight and sub
jective well-being were analysed
using analysis of variance for re
peated measures, the within-subject
factor having three levels. Whenev
er the overall variance ratio (F) was
significant, a multiple comparison
procedure (Tukey B technique5) was
used to identify where the differ
ences were. A Pearson linear corre
lation coefficient was used to estab
lished a correlation between food
intake and specific symptoms.

Function
All patients were able to evacuate
spontaneously. The mean number
of stools per 24 hours was 6.8 ±
0.5 (range from 2 to 11). Nineteen
patients woke at night to empty
their bowel (mean frequency 1.2 ±
0.2 stools). Eleven patients com
plained of occasional abdominal
cramping. The majority had no dis
comfort with passage of intestinal
gas. Perianal irritation was not a
major problem; however, 50% of
the patients occasionally used oint
ments to protect the skin. Anal
soiling occurred in 12 patients during day and night in 4 and
during the night only in 8. The type
of soilage was mucoid in seven
patients and stool in five.
Alimentary Habits

Results
Of the 24 patients, 20 were fully
employed and involved in sports
and social activities after the opera
tion. Their body weight was stable
or increased postoperatively. When
the patients were healthy, their re
ported mean body weight (± SEM)
was 62.1 ± 3.5 kg; during their
disease it was 53.2 ± 3.0 kg and
after the surgery it was 63.8 ± 3.5
kg. There was substantial variability
in these weights and no statistically
significant differences could be ob
tained by analysis of variance (p >
0.05).
Subjective Well-being
A score of subjective well-being
of 4.2 ± 0.6 was recorded for the
disease period, of 5.6 ± 0.5 for the
diverting ileostomy period and of
8.4 ± 0.4 postoperatively. By analy
sis of variance the last score was
significantly (p < 0.05) better than
either the first or second. There was
no bias between observers (Stu
dent’s t-test.

Twenty-one patients (88%) were
satisfied with the diet they chose.
Dinner was considered the largest
meal of the day and most patients
kept to the same schedule of daily
meals as before the operation.
Food Journal
Food journals were completed by
20 patients. According to standards
determined by Canada’s food
guide,6 17 patients had a deficiency
in consumption of dairy products,
11 in fruit and vegetables and 8
Table I. Symptoms Sought During Patient
Interview
Increased stool frequency
Decreased stool frequency
Increased stool consistency
Decreased stool consistency
Increased stool volume
Decreased stool volume
Perianal irritation
Incontinence
Gas
Undigested particles in the stool
Modification of stool odours
Abdominal cramps
Abdominal discomfort
Diarrhea

DIET AFTER ILEOANAL ANASTOMOSIS

patients in meat and meat substi
tutes. No deficiency in bread and
cereals was detected. The content of
fibres in the diet varied considera
bly; the mean total fibre content of
the diet was 10.8 ± 1 .4 g /d (range
from 2 to 20 g/d). Again, on a
daily basis, total energy intake was

8735 ± 822 kJ (2086 ± 196 kcal);
protein intake was 85.6 ± 6.5 g;
lipid intake was 89.2 ± 8.1 g;
carbohydrate intake was 250.3 ±
27.2 g, in which there was 66.5 ±
13.1 g of concentrated sugar; po
tassium intake was 2895.6 ± 252.7
mg; calcium intake was 887.9 ±

Ite m s
P o ta to e s
P a s try
Hot Dogs

Questionnaire

C o ffe e
M ilk + e g g s
P a s ta
R a w c a r ro ts
W in e + s p irits
C o rn
B eer
C abbage
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% o f p a tie n ts w ith s y m p to m s
Fig. 1. Sample of food items associated with symptoms.
T a b le II. A s s o c ia tio n o f S y m p to m s W ith S p e c ific F oods
S ym p tom

Food ite m

In cre a s e d s to o l fre q u e n c y

B eer
S p irits
C h in e se fo o d s
W h o le w h e a t ce re a ls
C o rn
A p p le
W in e
S p ic y fo o d s
F rie d fo o d s
S tra w b e rrie s
B eer
W in e
F rie d fis h
S tra w b e rrie s
C o rn
P o p c o rn
S p irits
M o la s s e s
C o le s la w
G ra p e fru it
T u rn ip s
R a s p b e rrie s
S p ic y fo o d s
R aw c a rro ts
G ra p e fru it
L e ttu c e
R aw to m a to e s
E gg s

D ecre a se d s to o l c o n s is te n c y

P erianal irrita tio n
U n d ig e s te d p a rtic le s in s to o l

S to o l o d o u rs

95.7 mg; phosphorus intake was
1434.0 ± 121.2 mg; iron intake
was 13.48 ± 1.04 mg; and sodium
intake (excluding added salt) was
3177.0 ± 282.7 mg.
During the period in which the
patients kept the journal, half of
them consumed alcohol. Assuming
beer as 13 g, a glass of wine as 18
g and liquor as 15 g of alcohol, the
mean daily alcohol consumption
was 12.8 ± 5.3 g (range from 0.0
to 90.9 g).

% of p a tie n ts
36
33
26
25
25
25
24
20
20
20
43
41
29
25
25
25
25
23
23
21
21
21
50
20
27
23
20
20

Figure 1 demonstrates that the
effect on bowel function varies be
tween food items. For example, cab
bage, beer and corn were associated
with symptoms by more than 75%
of patients. However, potatoes,
pastry, hot dogs and coffee were
troublesome in less than 21% of
patients. Overall, one food item out
of four (25%) was frequently associ
ated (i.e., by more than 50% of
patients) with symptoms.
Several food items were eliminat
ed from the diet after trial by more
than 20% of patients because of
associated problems. These includ
ed cabbage, corn, coleslaw, legumi
nous foods, turnips, boiled broccoli,
whole wheat cereals and spicy
foods.
Associations
Various foods were associated
with specific symptoms in more
than 20% of patients as shown in
Table II; 25% of the 108 foods
analysed were so associated.
Abdominal cramping and anal
soilage could not be correlated with
specific food items in this question
naire. Interestingly, pasta and ba
nanas increased the consistency of
stools. The total fibre content of the
diet correlated only with perianal
irritation (Pearson coefficient, p <
0.05).
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Discussion
The majority of our patients were
satisfied with their diet after ileal
pouch-anal anastomosis. However,
we observed that diet can influence
the functional outcome after this
procedure; 25% of the 108 food
items analysed were associated with
specific symptoms. Similar findings
have also been noted after ileorectal
anastomosis7 and after the con
struction of a permanent ileosto
my.89
Bingham and colleagues8 and
Thomson and associates9 have
shown that the ileostomates modify
their diet by avoiding foods that
they think produce an ileal effluent
which is excessive in amount, very
fluid, odoriferous or contains recog
nizable food particles. Wexner and
colleagues2 reported that 32% of
patients needed dietary adjustment
after the construction of an ileoanal
reservoir. Of our 24 patients, 21
(88%) had no difficulty in choosing
a diet. The sensitivity of patients for
specific items in the diet was vari
able. Although no single food ad
versely affected all patients inter
viewed, 25% of food items were
upsetting in more than 50% of the
patients. The most common of
these were cabbage, beer and corn.
The foods that caused problems
after ileal pouch-anal anastomosis
did not always cause upsets in pa
tients who underwent ileostomy or
ileorectal anastomosis. For exam
ple, in the latter group cabbage
seemed to be tolerated but onions
caused problems. Alcoholic bever
ages, especially beer, were reported
to decrease the consistency of the
output after ileostomy89 and ileo
rectal anastomosis.7 Although al
coholic beverages decreased stool
consistency and increased the fre
quency of evacuation they were not
usually avoided by our patients who
had undergone ileal pouch-anal
anastomosis. Patients with an ileos
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tomy eat more in the morning than
those without and less during the
evening, probably to minimize the
ileal flow at night when it may
disturb sleep.8 After ileoanal anasto
mosis, Wexner and associates2 re
ported, patients can avoid nocturnal
emptying by eating an early dinner.
In our study, patients did not
change their daily schedule of
meals, and dinner was the largest
meal of the day, which may explain
the high nocturnal stool rate.
Wexner and colleagues2 also re
ported that stool frequency is asso
ciated with alcohol, spicy foods,
chocolate and a large quantity of
fluids. However, Kramer,10 in a con
trolled study of patients who had an
ileostomy, failed to demonstrate
this. It is interesting that when
objective measurements are made,
many dietary substances generally
avoided by or forbidden to ileosto
mates do not notably increase the
amount of ileal excreta. Wexner
and colleagues, like us,2 noted that
starchy foods like pasta and rice
were related to decreased stool fre
quency.
The relation of fibre intake to
functional outcome is controversial
and deserves comment. In patients
who have a standard ileostomy,
Dalhamn and associates11 have
shown that the addition of bulk to
the diet resulted in a more viscous
ostomy effluent. It facilitated stoma
management and diminished peris
tomal skin problems. In our study,
the mean daily fibre intake was
relatively low (10.8 ± 1 . 4 g). Ray
mond and Becker12 recommended a
daily intake of 30 g of fibre to
obtain coarser stools and decrease
stool frequency. Spiller and col
leagues13 showed that the addition
of cellulose to the diet decreased
intestinal transit time and increased
the total fecal wet weight, but that
pectin had no such effects. This
implies that the effect of “dietary
fibre” cannot be generalized and

that individual fibre components
should be examined separately, as
demonstrated by Anderson14 with
hydrosoluble and insoluble fibre.
We found a positive correlation be
tween dietary fibre and anal irrita
tion, which may be attributed to the
adsorption of biliary acids by di
etary fibres. Bosaeus and col
leagues15 demonstrated that biliary
acid excretion is significantly in
creased by addition of pectin to the
diet. However, Raymond and associ
ates16 showed that loperamide 4 mg
and psyllium 30 g, each given twice
daily, reduced stool frequency but
had no apparent effect on stool
content, including biliary acids.
Newton and Baker7 reported that
after ileorectal anastomosis, body
weight remained steady or in
creased. This was also noted in our
patients. The mean daily intake of
energy calculated from our food
journal suggests that patients main
tain an adequate caloric intake after
ileal pouch-anal anastomosis.
Two methods were used to evalu
ate diet and its relation to function
al outcome - a questionnaire com
pleted at a personal interview and a
food journal. A standardized ques
tionnaire was used by McDonald
and Fazio17 to assess the diet of
patients with Crohn’s disease not
operated on, by Bingham and col
leagues8 and Thomson and associ
ates9 for patients with an ileostomy
and by Newton and Baker7 for
patients with an ileorectal anasto
mosis. The advantage of a question
naire is that it is easy to complete
and computerize; however, it relies
on a subjective report by the pa
tient. It may be difficult for a pa
tient to identify accurately the prop
er effect of a specific food, especial
ly when it is consumed with other
foods. A food journal is preferable
for identifying a relation between
food and pouch function, especially
for less overt food items such as
fibre.

DIET AFTER ILEOANAL ANASTOMOSIS

Patients who undergo ileal
pouch-anal anastomosis usually
complain about the effect of various
foods on functional outcome. Clini
cians lack pertinent data to give
dietary advice. This systematic eval
uation of the effect of more than
100 food items on functional out
come, based on several months ex
perience with the 24 subjects, can
be used to provide improved dietary
counselling. The number of patients
in our study who completed the
questionnaire and the food journal
constitute a group that is similar in
age, sex, lifestyle and functional
results to the group as a whole. It
would appear reasonable to assume
that their experience with the food
items is representative of that en
countered by all patients after ileal
pouch-anal anastomosis in our
country. Other controlled studies of
diet after ileal pouch-anal anasto
mosis are warranted to improve
dietary counselling, even if they
involve methodologic challenges.
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SESAP VI Question
Items 8 2 -8 4
82. Ulcer recurrence rate 10% to 20%

We thank Mrs. Linda Gagne for secre
tarial assistance.

83. Indicated for treatment of perforation in low-risk patients with
long-term history of peptic ulcer disease
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84. Indicated for high-risk patients with acute perforation of duodenal
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(A) Ulcer plication (Graham closure)
(B) Ulcer plication (Graham closure) plus proximal gastric vagoto
my
(C) Both
(D) Neither
For the numbered statements above choose the appropriate lettered
answer.
For the critique of Items 8 2 -8 4 see page 142.
(Reproduced by permission from SESAP VI Syllabus; Surgical Educa
tion and Self-Assessment Program No. 6. For enrolment in the Surgical
Education and Self-Assessment No. 6, please apply to the American
College of Surgeons, 55 East Erie St., Chicago, IL 60611.)
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to the fetus and/or the mother. Ceftriaxone has been detected in the umbilical cord blood, amniotic fluid and
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precipitate in the urine was observed in one patient dosed with ‘Rocephin’ (sterile ceftriaxone sodium) at 10 g/
day (2.5 times the maximum recommended dose). No other case of overdosage has been reported to date with
‘Rocephin’. No specific information on symptoms or treatment is available. Excessive serum concentration of
ceftriaxone cannot be reduced by hemodialysis or peritoneal dialysis. Treatment should be symptomatic.
DOSAGE AND ADMINISTRATION ‘Rocephin’ (sterile ceftriaxone sodium) may be administered intravenously
or intramuscularly after reconstitution. Dosage and route of administration should be determined by the severity
of infection, susceptibility of the causative organisms, and condition of the patient. The intravenous route is
preferable for patients with septicemia or other severe or life-threatening infections. With the exception of
gonorrhea, which is treated with a single dose, the administration of ‘Rocephin’ should be continued for a
minimum of 48 to 72 hours after the patient defervesces or after evidence of bacterial eradication has been
obtained, usually 4 to 14 days. In bone and joint infections the average duration of treatment during clinical trials

was 6 weeks, with a range of 1 to 13 weeks, depending on the severity of the infection. When treating infections
caused by beta-hemolytic Streptococcus, it is recommended that therapy be continued for at least 10 days. The
average duration of therapy for infections associated with beta-hemolytic Streptococcus during clinical trials
was 2 weeks, with a range of 1 to 5 weeks, depending on the site and severity of the infection. Prophylaxis
(Vaginal or Abdominal Hysterectomy) For preoperative use as prophylaxis before vaginal or abdominal
hysterectomy, a single dose of 1 g administered 1/2 to 2 hours before surgery is recommended. Impairment
of Renal and/or Hepatic Function In patients with mild to moderate renal impairment, changes in the dosage
regimen are not required, provided liver function is intact. In cases of preterminal renal failure (creatinine
clearance less than 10 mL/min), periodic monitoring of serum ceftriaxone concentrations is recommended. The
daily dosage should be limited to 2 g or less. In patients with liver damage, there is no need for the dosage to
be reduced provided renal function is intact. In cases of coexistent renal and clinically significant hepatic
insufficiency, close monitoring of serum ceftriaxone concentrations, at regular intervals, is recommended. If
there is evidence of accumulation, dosage should be decreased accordingly. ADMINISTRATION Intramus
cular: The reconstituted solution of ‘Rocephin’ should be administered by deep intragluteal injection. It is
recommended that not more than 1 g be injected at a single site. Pain on intramuscular injection is usually mild
and less frequent when ‘Rocephin’ is administered in sterile 1% Lidocaine solution. Intravenous (bolus)
Injection: The reconstituted solution should be administered over approximately 5 minutes. Short Intrave
nous Infusion: The further diluted intravenous solution should be given over a period of 10 to 15 minutes in
infants and children and 20 to 30 minutes in adults. NOTE: Rocephin’ solution should not be physically mixed
with aminoglycoside antibiotics nor administered at the same site because of possible chemical incompatibility.
PHARMACEUTICAL INFORMATION
Reconstitution
For Intramuscular Use
Reconstitute ‘Rocephin’ powder with the appropriate diluent:
• Sterile Water for Injection
• Bacteriostatic Water for Injection
• 0.9% Sodium Chloride Injection
• 1% Lidocaine Solution
• 5% Dextrose Injection
Reconstitute as follows:
Reconstitution Table (IM)
Approximate
available
volume mL

Volume to be
added to vial mL

Vial Size

Approximate
average
concentration g/mL

0.25g

0.9

1

0.5 g

1.8

2

0.25

1.0 g

3.6

4

0.25

2.0 g

7.2

8

0.25

0.25

Shake well until dissolved.
NOTE: SOLUTIONS PREPARED FOR INTRAMUSCULAR USE OR ANY SOLUTION CONTAINING
LIDOCAINE OR BACTERIOSTATIC WATER FOR INJECTION SHOULD NEVER BE ADMINISTERED
INTRAVENOUSLY.
For Intravenous Use
Reconstitute only with Sterile Water for Injection.
Reconstitute as follows:
Reconstitution Table (IV)
Approximate
available
volume
mL

Volume to be
added to vial
mL

Vial
Size

Approximate
average
concentration
g/mL

0.25 g

2.4

2.5

0.1

0.5 g

4.8

5.0

0.1

1.0 g

9.6

10.0

0.1

2.0 g

19.2

20.0

0.1

Shake well until dissolved. The prepared solution may be further diluted to the desired volume with any of the
“Solutions for IV Infusion" listed below.
Solutions for IV Infusion
0.9% Sodium Chloride Injection, 5% Dextrose Injection, Dextrose and Sodium Chloride Injection.
Pharmacy Bulk Package Reconstitution for Preparation of Intravenous Infusion Solutions
The closure of the pharmacy bulk vial shall be penetrated only one time after reconstitution, using a suitable
sterile transfer device or dispensing set which allows measured dispensing for the contents.
Reconstitution Table for Bulk Pharmacy Package

Vial
size

Volume to be
added to vial
mL

Approximate
available volume
mL

Approximate
average concentration
g/mL

10 g

95

100.0

0.1

Shake well until dissolved. Withdraw the required amount and dilute with one of the “Solutions for IV
Infusion". Any unused solution remaining within a period of 8 hours should be discarded.
Stability of Solutions - Storage
For complete stability and storage information, consult the Product Monograph.
Incompatibility:
‘Rocephin’ should not be physically mixed with other antimicrobial agents.
‘Rocephin’ should not be added to blood products, protein hydrolysates or amino acids.
‘Rocephin’ should not be added to solutions containing calcium.
DOSAGE FORM
Availability: ‘Rocephin’ is available in vials containing dry substance equivalent to 0.25 g, 0.5 g, 1 g or 2 g of
ceftriaxone and as a pharmacy bulk vial containing the equivalent of 10 g ceftriaxone (not for direct
administration). The availability of the Pharmacy bulk vial is restricted to hospitals with a recognized intravenous
admixture program.
Storage: Rocephin’ sterile powder should be stored at a controlled room temperature (between 15° and 30°C)
and protected from light.
References: 1. Hell K: Chemotherapy 1989;35:228-235. 2. ‘Rocephin’ Product Monograph.
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Recurrent Acute Pancreatitis — Rarely
Idiopathic: 1989 Du Pont Lecture
L.C. Carey, MD, FACS*
The majority (about 75%) of patients who suffer from acute pancreatitis do so as a
consequence of gallstones or alcohol abuse. The other 25% of patients often present
difficult diagnostic problems. Over several years the author has accumulated a series
of patients with remedial causes of pancreatitis. They include a group of congenital
conditions such as pancreas divisum, choledochal cysts and congenital abnormalities
of the pancreatic ductal system.
Patients who have had pancreatitis and who have an intact gallbladder often have
stones that are difficult to identify. Repeated attacks of pancreatitis in the absence of
any other apparent cause justifies cholecystectomy, which will often identify the
cause so that recurrence can be prevented.
A group of nonanatomic causes are also known. They include hyperlipidemia,
drugs and toxins, certain systemic illnesses such as systemic lupus erythematosus,
pregnancy, hypercalcemia, hereditary causes and occasionally cancer.
In his lecture the author reviews the various etiologies of acute pancreatitis and
describes an algorithm that can be used when the diagnosis is difficult.

La majorite (environ 75%) des cas de pancreatite aigue est la consequence de calculs
biliaires ou de l’alcoolisme. L’autre 25% des patients pose souvent des problemes
diagnostiques. Sur une periode de plusieurs annees, l’auteur a identifie une serie de
patients dont les causes de pancreatite pouvaient etre gueries. On compte parmi
celles-ci, des problemes congenitaux tels que division du pancreas, kystes choledociens et anomalies congenitales des canaux pancreatiques.
Les patients qui ont eu une pancreatite et dont la vesicule biliaire est intacte, ont
souvent des calculs difficiles a identifier. Des attaques repetees de pancreatite en
l’absence de toute autre cause apparente justifient une cholecystectomie qui, bien
souvent, permettra d’identifier la cause et de prevenir la recidive.
Un nombre de causes extra-anatomiques sont aussi connues. On compte parmi
celles-ci, l’hyperlipidemie, des medicaments et des toxines, certaines maladies
generalises telles que le lupus erythemateux dissemine, la grossesse, l’hypercalcemie, des causes hereditaires et, occasionnellement, un cancer.
Dans cette communication, l’auteur passe en revue les diverses etiologies de la
pancreatite aigue et il decrit un algorithme qui peut etre utilise lorsque le diagnostic
est difficile.
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practitioners are well
M ost
aware of the relation of acute
pancreatitis to gallstones and alco
hol abuse. Of unselected patients
with pancreatitis about 75% will
have one of the two as an etiologic
factor; the remaining 25% often
present difficult diagnostic prob
lems. Thompson and associates,1 in
an epidemiologic study in northeast
Scotland found that alcohol and
gallstones accounted for about 60%
of all cases of pancreatitis. The next
most common cause was “ idiopath
ic” (19% in men, 22% in women).
Most patients with “idiopathic”
pancreatitis can be helped if the
practitioner is aware of all the con
ditions with which pancreatitis is
associated. When an exhaustive
search is made by a knowledgeable
clinician, few patients are found to
have true idiopathic pancreatitis.
This lecture is intended to outline
a number of factors known to be
related to the development of acute
pancreatitis and to describe a sys
tematic approach to identifying the
cause.
Very little is known about the
cause of pancreatitis. However, the
literature describing conditions
which seem to produce pancreatitis
is extensive even though the mech
anism by which they do so remains
obscure. In an attempt to organize
this literature I will categorize the
causative factors into anatomic and
non-anatomic, but I will not address
treatment of the various conditions
or the related pancreatitis. My pur
pose is to emphasize that the diag
nosis of conditions causing pan
creatitis is difficult, time-consuming
CJS, VOL. 33, NO. 2, APRIL 1990
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and tedious. But the benefit to the
patient makes this effort worth
while.
Anatomic Factors
Congenital

Pancreas division. In 1978 Heiss
and Shea2 reported four patients
with recurrent pancreatitis who had
abnormal ductal anatomy, a condi
tion now known as pancreas divisum.
Pancreas divisum, present in 7%
to 10% of the population, appears
to result from improper fusion of
the pancreatic ducts of the dorsal
and ventral primordia of the gland.
The consequence is a ductal system
with two totally separate compo
nents — a small duct joins the
common bile duct as it enters the
duodenum and vents the uncinate
process. The second duct provides
drainage for the cephalad portion of
the head of the pancreas and the
entire body and tail of the gland.
This duct enters the duodenum 1.5
to 2 cm proximal to the papilla of
Vater.
Most patients with pancreas divi
sum have no symptoms. A few have
recurrent attacks of pancreatitis
with no other identifiable cause.
Another group has recurrent ab
dominal pain without elevation of
serum enzyme levels.
Several factors are noteworthy.
Although the condition is present at
birth, pancreatitis does not become
apparent until the third to fifth
decade of life in most cases, and
although the variant seems to be
equally distributed by sex, pan
creatitis occurs more frequently in
women. In two series, totalling 80
patients, there were 56 women and
14 men.34
Finally, although there have been
vigorous efforts to demonstrate an
impediment to ductal emptying,
none has withstood the test of
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These usually occur at the termi
nus of the pancreatic duct. We
treated a patient with one such
abnormality, involving the uncinate
process, by resection of the abnor
mal duct and the uncinate (Fig. 1).
This procedure was curative. Four
others had recurrent attacks of pan-

creatitis; three were under 20 years
of age with one child having had
attacks from 9 months of age until
treatment at 5 years of age. These
three children underwent pancreaticojejunostomy which provided
relief. The fourth patient was ma
naged by pancreaticoduodenectomy.
None had evidence of either endo
crine or exocrine pancreatic insuffi
ciency and all were followed up for
more than 2 years. We are presently
managing a young woman with a
duplicate pancreatic ductal system
who has recurrent pancreatitis (Fig.
2 ).
Choledochal cysts. Another
group of five patients had choledo
chal cysts. Initially in this group,
communication of the cyst with the
pancreatic ductal system was not
divided and recurrent pancreatitis
persisted. Reoperation with resec
tion of the intrapancreatic portion
of the cyst with division of the
pancreatic ductal communication
was curative.
A cyst-pancreatic duct communi
cation is not demonstrable in all
patients with choledochal cyst. It
was present, however, in all those
who had recurrent pancreatitis.
When a choledochal cyst is discov
ered in a patient with recurrent
pancreatitis, the ductal communica
tion must be identified, the in
trapancreatic portion of the cyst
removed and the direct communica
tion divided. Choledochal cyst has
rarely been associated with pan-

FIG. 1. Patient with congenital abnor
mality of pancreatic duct involving
uncinate process. Resection of unci
nate process was curative.

FIG. 2. Duplicate pancreatic ductal
system in young woman causing recur
rent pancreatitis.

prospective analysis, comparing pa
tients with the variant who have
pancreatitis with those who do not.
It has been suggested that there is
a measurable dysfunction of the
papilla at the duct of Santorini, but
the data are inadequate to draw
conclusions.5
Physicians with an interest in the
disease believe that there is an
acquired stenosis at the terminus of
the duct. Their prejudice is support
ed by relief of symptoms provided
by enlarging the ductal opening,
but persuasive preoperative proof of
ductal stenosis has been elusive.
Some patients with pancreas divi
sum clearly suffer recurrent pan
creatitis as a result of the anatomic
variant. Continued efforts will no
doubt lead to more precise ways to
identify these patients preoperatively-

Pancreas divisum and small gall
stones explain the majority of ob
scure cases of pancreatitis, but
there are a number of less common
anatomic problems which must be
considered.
Other Congenital Abnormalities
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creatitis,6 since in most cases the
pancreatitis has been related to
choledochocele, a variant of chole
dochal cyst.
Aberrant gastroduodenal artery.
One other patient was treated by
resection of an aberrant branch of
the gastroduodenal artery, which
resulted in ductal obstruction at the
junction of the neck and head of
the pancreas. In this patient pancre
atic ductal occlusion was demon
strated on endoscopic retrograde
cholangiopancreatography. Resec
tion of the aberrant vessel was
curative.
Pancreas sequestrum. A series of
patients who begin to suffer attacks
of pancreatitis months to years after
pancreatic trauma has been report
ed.7 They had what we have called
pancreas sequestrum. Resection of
the sequestered segment of pancre
as was curative in all but one who
was managed by pancreaticojejunostomy.
Duct entry through the Oddi
sphincter. In another group of pre
viously reported cases,8 the pancre
atic duct was found to enter the
duodenum through the fibres of the
sphincter of Oddi with no common
channel; these patients were ma
naged by sphincteroplasty of the
common bile and pancreatic ducts.
The majority had undergone chole
cystectomy previously and none had
common-duct stones. The average
patient had been hospitalized re
peatedly with acute pancreatitis.
The diagnosis remains one of exclu
sion and is only entertained after an
in-depth search for other causes
and after several well-documented
attacks. The operation of double
sphincteroplasty provided relief
from further attacks in more than
80%.
Diverticula. In an occasional pa
tient, a duodenal diverticulum has
resulted in acute pancreatitis. The
phenomenon may be the result of a
diverticulum with a narrow orifice

which becomes filled with inspissat
ed material and produces pancreatic
ductal occlusion. The treatment is
careful removal of the diverticulum,
avoiding injury to the pancreatic
duct. Others have reported pan
creatitis with intraluminal diver
ticula.9 Kune’s group10 pointed out
the increase in frequency of both
gallstones and pancreatitis with du
odenal diverticula.
An alternative arrangement may
be a diverticulum into which the
common and pancreatic ducts enter
the duodenum at the apex of the
diverticulum (choledochocele). In
this condition, resection of the di
verticulum with reimplantation of
the bile-pancreatic duct complex
into the duodenum is curative. This
is a difficult operation requiring
considerable care to avoid damage
to the terminal pancreatic duct.
Gallstones
When gallstones are found in
patients who have acute pancreati
tis, cholecystectomy and removal of
common-duct stones, if present, will
cure the pancreatitis in more than
90%.n It is well known that small
gallstones are more likely to result
in pancreatitis than large ones.12
Logic suggests that biliary lithotrip
sy then may result in an increase in
gallstone pancreatitis — a question
as yet unanswered.
How should we best manage a
patient who has recurrent attacks
of pancreatitis but in whom an
exhaustive search for gallstones
and other causes has been fruitless.
Inevitably, gallbladder ultrasonogra
phy will be carried out, and, if
normal, oral cholecystography will
be done. Aspiration of duodenal
contents may help in identifying
microstones or cholesterol crys
tals.13
What should be done if all tests
are negative? The answer is to re
move the gallbladder. If a truly

diligent search has been made for
alternative causes, gallstones will
nearly always be found.14 The
stones will be tiny, explaining the
difficulty in diagnosis. It is unac
ceptable to watch helplessly while a
patient has multiple attacks of pan
creatitis and assume that the dis
ease is idiopathic.

Non-anatomic Factors
Alcohol
There is certainly a well-estab
lished relationship between alcohol
consumption and pancreatitis. Al
though the causative mechanism
remains obscure, there is some evi
dence of a metabolic disorder.
Sarles15 has studied a protein in
pancreatic juice (pancreatic stone
protein). His studies suggested that
in chronic pancreatitis this protein
is deficient and its deficiency leads
to calcium precipitation resulting in
stone formation. Others have noted
an increase in serum triglyceride
levels after alcohol consumption,
suggesting an alternative mecha
nism of pancreatitis.16
Other possible mechanisms have
been considered but were either not
confirmed or rejected because of
lack of information.
Of interest is the fact that most
heavy drinkers suffer from neither
pancreatitis nor cirrhosis. Of those
who suffer from cirrhosis, only a
few get pancreatitis and of those
who suffer from pancreatitis, only a
few also have cirrhosis. These find
ings suggest that pancreatitis oc
curs in alcoholics who have a pecu
liar reaction to alcohol; this reac
tion may be a metabolic variant
resulting in a pancreas-specific tox
in.
Two errors are commonly made
by physicians in establishing a diag
nosis of alcoholic pancreatitis. First
is a lack of vigour in obtaining a
history of alcohol addiction. Many
CJS, VOL. 33, NO. 2, APRIL 1990
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“closet alcoholics” are quite deft at
concealing their addiction, and con
siderable effort may be required to
obtain a proper history. Second, a
casual drinking history is incrimi
nating as the cause of pancreatitis
and other possibilities are ignored.
The amount of alcohol necessary
to induce pancreatitis is quite vari
able but generally 150 to 200 g /d
of pure alcohol are required.
In most reported experience, 25%
to 50% of patients with pancreatitis
are heavy alcohol drinkers. That
fact should focus attention on the
critical importance of an accurate
drinking history in all patients with
pancreatitis.

lipidemia and acute pancreatitis
have Fredrickson type V hyperlipo
proteinemia but patients with types
I and IV have also been reported.
Confounding the issue is the ob
servation that in some patients pan
creatitis may produce hyper
lipidemia. Whether or not this phe
nomenon is associated with under
lying lipoprotein abnormality is un
clear. Care must be taken in mak
ing the diagnosis since the hyper
lipidemia may mask an elevation of
the serum amylase level.20
All patients with unexplained re
current pancreatitis should have
serum lipid measurement as well as
lipoprotein electrophoresis.

Hyperlipidemia

Drug- and Toxin-Induced Factors

As early as 192917 a relationship
between serum lipids and acute pan
creatitis was recognized. Since then
a great deal has been learned, but
much remains unknown.
As with most factors related to
pancreatitis, the mechanism re
mains obscure. However, a clever
experiment by Saharia and col
leagues18 has cast some light on
this issue. Isolated dog pancreases
were perfused with free fatty acid
(oleic) and with triglycerides. In
both groups of animals, pancreatic
edema and hemorrhage occurred. In
the venous effluent of the glands
perfused with triglycerides, the con
centration of free fatty acids in
creased, suggesting that neutral fat
may be converted to free fatty acids
in the intact pancreas leading to
inflammation in a mechanism such
as that proposed in 1969 by Ha
vel.19
In the clinical setting several fac
tors are known to produce hyper
lipidemia and to be associated with
pancreatitis. They include estrogen
ingestion, oral contraceptives, preg
nancy, lipid infusion, lipoprotein
C-II deficiency, alcohol and beta
blockers. Most patients with hyper

It is clear that certain drugs are
associated with acute pancreatitis
and the list continues to grow.21
Table I describes those agents that
have resulted in acute pancreatitis
and upon rechallenge have pro
duced the disease again.
Some of these agents may induce
secondary conditions, for example
estrogen resulting in hyperlipidemia
and vitamin D causing hypercal
cemia. Others appear to produce a
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direct effect on the pancreas. Other
agents (Table II) have been incrimi
nated as causing acute pancreatitis,
but the relationship has not been
proven. Organophosphates22 which
are anticholinesterase agents have
been noted to induce severe and
often fatal acute pancreatitis. Both
ingestion and transcutaneous ab
sorption have been toxic. Other
industrial compounds such as pentachlorophenol have been implicat
ed in causing pancreatitis.23
A species of scorpion, Tityus trinitatis,24 is known to cause pan
creatitis in 80% of those stung.
Pseudocyst formation as evidence
of the severity of pancreatitis may
occur. No other species of scorpion
has been responsible for acute pan
creatitis.
Infections
Both coxsackievirus and mumps
virus have been reported to cause
acute pancreatitis. In mumps infec
tion, there has often been evidence
that the hyperamylasemia may be
from parotid inflammation without
pancreatic disease. There are cases
of true pancreatitis in patients with
mumps.25

Table 1. Drugs Associated With Acute Pancreatitis. Causal Relationship Established
Azathioprine
Calcium
Corticosteroid (dexamethasone)
Cytosine arabinoside (ARA-C)
Estrogen
Furosemide
6-mercaptopurine
Methyldopa

Nitrofurantoin
Pentamidine
Procainamide
Sulfonamide
Tetracycline
Thiazide diuretics
Vitamin D

Table II. Drugs Associated With Acute Pancreatitis. Causal Relationship Not Established
Acetaminophen
Amphetamines
Anticoagulants
Asparaginase
Chlorthalidone
Cholestyramine
Cimetidine
Clonidine
Corticosteroids
Cyproheptadine
Diazoxide
Enalapril

Ethacrynic acid
Histamine
Indomethacin
Isoniazid
Meprobamate
Methanol
Opiates
Phenformin
Propoxyphene
Propylthiouracil
Rifampin
Salicylates
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Coxsackievirus has been shown
to be injurious to the pancreas in
experimental animals. Further, ele
vated antibody titers have been
noted in patients with acute pan
creatitis. Imirie and colleagues26
studied prospectively 116 patients
with acute pancreatitis and found
rising viral titers in 5 (4%). Howev
er, two patients also had gallstones.
These studies suggest a possible
relation between acute viral infec
tions and pancreatitis.
Systemic Illness

Systemic lupus erythematosus
(SLE) has been found to be associ
ated with acute pancreatitis. Reyn
olds and associates27 reported 20
cases and reviewed the world litera
ture. The issue is complicated by
the use of corticosteroids to treat
pancreatitis. Gastrointestinal in
volvement is found in more than
33% of patients with SLE, 20%
have abdominal pain and in 10%
abdominal pain is the initial com
plaint. It is quite clear that pan
creatitis develops in patients with
SLE who are not and in some cases
have never been on steroid medica
tion. To further complicate the mat
ter, SLE may cause hyperlipidemia.

for some pancreatic enzymes. It is
also clear that hypercalcemia is as
sociated with acute pancreatitis.
The hypercalcemia may be secondaiy io Hyperparathyroidism, viuuniii
D ingestion, metastatic cancer or
excess calcium. In searching for
causative factors in acute pancreati
tis serum calcium levels, total and
ionized, should be measured. It
must be remembered that acute
pancreatitis lowers the serum calci
um level. We have demonstrated
the effect to last as long as 5 days
(unpublished data). Several calcium
levels should be measured, but this
should be done well after the acute
attack has subsided.
Cancer

Cancer of the pancreas may re
sult in acute pancreatitis.30 This is
an unusual event. Logic suggests
that ductal obstruction may be a
factor, and, indeed, at operation
most pancreatic cancers occlude the
duct and result in an indurated
abnormal gland. However, acute
pancreatitis is less common. In
three of our own cases and one in
the literature, no ductal involve
ment was demonstrable with cancer
of the pancreas associated with
acute pancreatitis.

Pregnancy
Heredity

Acute pancreatitis in young
women who are pregnant is uncom
mon but well described.28 Both gall
stones and hyperlipidemia are also
known to be increased in frequency
in pregnant women. The majority of
cases occur late in pregnancy and
recurrence early post partum is
common. Most have gallstones. A
family history of hyperlipidemia
should alert one to the need for
lipoprotein electrophoresis.29
Hypercalcemia

Calcium is known to be a catalyst

Hereditary pancreatitis generally
has two forms — one related to a
primary hereditary disease as de
scribed with hyperlipidemia and the
other idiopathic. There are several
hundred patients now recognized to
have idiopathic hereditary pan
creatitis.31 This condition starts at
an early age; other causative condi
tions such as gallstones, alcoholism
and hyperlipidemia are absent and
pancreatic calcification is common.
In the initial phase of the disease
repeated attacks of pancreatitis are
the rule. A careful family history

often leads to the proper diagnosis.
Afferent Loop

When gastric resection and gas
trojejunostomy have been per
formed the afferent loop of bowel is
the conduit for pancreatitis secre
tion. Obstruction of the loop may
impair pancreatic drainage, result
ing in acute pancreatitis.
In addition, chronic or acute af
ferent-loop obstruction may result
in abdominal pain and an elevated
serum amylase level closely mimick
ing acute pancreatitis.32 In one pa
tient with chronic obstruction and
symptoms suggesting pancreatitis,
the initial computed tomogram was
thought to show a pancreatic pseu
docyst. An awareness of the possi
bility will often lend to the proper
diagnosis.

Comment
In three of four patients with
recurrent bouts of acute pancreati
tis, the underlying cause will be
easily identified. The other 25% will
test the diagnostic skills of the
most astute clinician. Paramount in
this effort is an awareness of the
possibilities. The algorithm in Fig.
3 is an effort to assist in establish
ing a sequence of diagnostic proce
dures. In modern medicine, we are
indeed blessed with a wonderful
menu of diagnostic tools. The trick
is to know which one to use in what
sequence and how to interpret the
result.
With knowledge of where to look
and the tools available to allow us
to look we can reduce the incidence
of true idiopathic pancreatitis to a
very few cases.
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Early Metabolic and Neurologic
Predictors of Long-Term Quality of Life
After Closed Head Injury
Michael Stambrook, BA(Hons), MA, PhD, CPsych;* Allan D. Moore, BA(Hons), MA;t Shauna Kowalchuk;J Diamond A. Kassum, MA, MB, BChir, FRCS, FRCSC, FRCS:§ Lois C. Peters, BSc, MA;H
Blake M. McClarty, MD, FRCPC;|| Garry A. Hawryluk, BA(Hons), MA, PhD, CPsych**
Research has begun to identify early markers that predict survival after traumatic
brain injury. In this study, trauma and biochemical indicators of severity were used
to predict quality of life in 61 adults with traumatic brain injury and no damage to
other organ systems. Severity markers available within 24 hours of injury were
predictive of later psychosocial, behavioural and social role functioning. Multiple
regression analyses demonstrated that the Glasgow Coma Scale, plasma glucose
levels, leukocyte cell count and serum potassium concentration accounted for 12% to
66% of variance in certain measures of later quality of life. The importance of
health-care resource allocation and psychosocial and behavioural intervention to the
outcome after moderate traumatic brain injury is discussed.
On a amorce la recherche visant a identifier les marqueurs precoces servant a
predire la survie apres un traumatisme cranien. Dans cette etude, on a utilise des
marqueurs de gravite traumatique et biochimique afin de predire la qualite de vie de
61 adultes victimes d’un traumatisme cranien mais n’ayant aucune atteinte d’autres
organes. Des marqueurs de gravite, accessibles moins de 24 heures apres la
blessure, avaient une valeur predictive quant au fonctionnement psychosocial et
comportemental, de meme qu’a l’integration au role social. Par analyses de
regression multiple, on a demontre que l’Echelle du coma de Glasgow, la glycemie,
la numeration leucocytaire et les taux de potassium plasmatique comptaient pour de
12% a 66% de la variance de certaines mesures de la qualite de vie future. On
commente l’importance des ressources affectees aux soins de sante et des interven
tions psychosociales et comportementales sur Tissue des patients ayant subi un
traumatisme cranien modere.
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he annual incidence of head
injuries has increased to be
tween 2.2 and 4 per 1000 popula
tion,1-2 the majority of these being
due to motor-vehicle accidents and
falls.3 Although many injuries are
still fatal, improved medical care
has decreased the death rate subs
tantially,4 so the health-care system
is faced with an increasing number
of patients who suffer residual psy
chosocial, physical and cognitive
im pairm ent.5 Therefore, rapid
screening techniques are needed so
that physicians can predict long
term outcome for patients with
traumatic brain injury (TBI) and
allocate resources appropriately.
The purpose of this study was to
determine if a set of regularly ob
tained admission variables can serve
as accurate predictors of later defi
cits. Kassum and associates6 recent
ly reported that biochemical data
collected within 6 hours of admis
sion can be used to predict survival
in TBI patients. Glasgow Coma
Scale (GCS) score, plasma glucose
and serum potassium levels and the
leukocyte count were found to be
related to outcome in terms of
survival versus death. Such early
predictors are important for triage,
in determining the level of care
required and in allocating re
sources. Although children differ
from adults in their response to
TBI,7 both were included in Kassum’s study,6 as were patients with
multisystem injury, a factor that
may obscure the effects of the TBI
itself. In the current study, the
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same biochemical variables were
evaluated within 24 hours of admis
sion and only adults with TBI with
out other system trauma were in
cluded. Outcome was examined in
patients 1 to 7 years after injury
and was assessed in terms of quality
of life as reported by both the
patient and a close relative.
Assessment of quality of life en
compassed psychosocial, emotional,
role functioning and interpersonal
domains in a manner similar to
“operationalizations” reported by
McSweeny and colleagues.8

Patients and Methods
Sixty-one patients with TBI and
no other initial injury admitted to
St. Boniface General Hospital or the
Health Sciences Centre in Winnipeg
between 1981 and 1987 were the
subjects of the study. Medical re
cords were reviewed and the follow
ing information was obtained: GCS
score on admission, duration of
coma and of post-traumatic amnesia
(PTA), plasma glucose and serum
potassium levels and leukocyte
count. The patient and a close
relative completed a series of ques
tionnaires including the Profile of
Mood States (POMS9), Sickness Im
pact Profile (SIP10) and the Katz
Adjustment Scale — Relatives
Form (KAS-R).11 Patients were cate
T a b le 1 P a tie n t D ata
V a ria b le

No.

S u b je c ts
S ex
M ale
F e m a le
S e v e rity g ro u p
M ild
M o d e ra te
S eve re
C ause o f in ju ry
M o to r v e h ic le
Fall
A s s a u lt
C a r/p e d e s tria n
O th e r

61

116

gorized into three groups according
to the severity of their initial injury:
severe — when the GCS score on
admission was equal to or less than
8; moderate — when the GCS score
on admission was greater than 8
and less than 13, or greater than 13
with neurologic damage evident on
computed tomography or when
neurosurgical intervention was re
quired; mild — when GCS was
greater than 13, the computed to
mograms appeared normal and no
neurosurgical intervention was re
quired. These criteria are consistent
with those used by other research
ers examining psychosocial out
comes after TBI.512 Patients who
died were excluded from the study.
Comparisons of the groups were
made using univariate two-tailed ttests. Multiple regression analysis
was used to assess early predictors
of quality of life.

Results
Of the 61 patients, males out
numbered females (Table I), as re
ported by others, and the main
causes of injury were motor- vehicle
accidents or falls.13 Most patients
were in the moderate or severe
groups. Metabolic and neurologic
findings are shown in Table II.
When the moderate and severe
groups were compared using
univariate two-tailed f-tests (Table
III), it was noted that demographic
variables (age, months after injury)

were not significantly different. Sig
nificant differences were document
ed, however, with patients in the
severe group having, by definition,
a lower GCS score, and a higher
leukocyte count, longer coma and
PTA. There were insufficient data
for similar analyses with the mild
group.
Quality o f Life
Significant differences also exist
ed between the moderate and severe
groups with respect to quality of
life (Table III). The severe group
reported significantly (p < 0.008)
higher depression/dejection as
measured by the POMS, more resid
ual problems (p < 0.05) and greater
difficulty with work-related activi
ties (p < 0.002) as measured by the
SIP, and relatives reported higher
general psychopathologic problems
(p < 0.003) and less social activity
(p < 0.05) as measured by the
KAS-R.
Early Predictors o f Quality o f Life
In the sequential stepwise multi
ple regression analysis the early
predictor variables (age, GCS score,
leukocyte count and glucose and
potassium levels) were used as the
independent variables and the quali
ty of life outcome measures in
dividually, as dependent measures.
Months after injury did not enter
the equation and this variable was
not considered further. The results

%
100

56
5

9 1 .8
8 .2

9
27
25

14 .8
4 4 .2
4 1 .0

28
23
1
2
7

4 5 .9
3 7 .7
1.6
3 .3
11 .4
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T a b le II. M e ta b o lic , N e u ro lo g ic and D e m o g ra p h ic D ata on 61 P a tie n ts

V aria b le

M ean

S ta n d a rd
d e v ia tio n

A ge, yr
M o n th s a fte r in ju ry
G la sg o w C o m a S cale s c o re on a d m is s io n
L e u ko cy te co u n t, X 109/ L
P o ta s siu m le ve l, m m o l/L
G lu co se le ve l, m m o l/L
D u ra tio n o f c o m a (GCS s c o re < 8 ), d
D u ra tio n o f p o s t-tra u m a tic a m n e s ia (GCS < 1 5 ), d

42.71
4 3 .6 7
10.61
16 .13
3 .6 7
9 .0 8
1.5 3
8 .9 8

1 7 .4 5
2 0 .3 7
3 .9 4
7 .1 3
0 .4 7
3 .3 2
3.81
1 6 .0 5

B io ch e m ic a l p re d ic to rs w e re s a m p le d w ith in 2 4 h o f in ju ry.

Range
20
4
3
4 .7
2 .3
5 .0
0
0

- 85
- 8 9
- 1 5
- 3 6 .3
- 4 .4
- 1 7 .0
- 3 1
- > 90

EARLY OUTCOME PREDICTORS AFTER CHI

are summarized in Table IV. The
set of early predictor variables was
significantly related to many of the
measures of quality of life outcome
on the KAS-R, POMS and SIP.
Early trauma severity variables pre
dicted, for example, later belliger
ence, verbal expansiveness, negativ
ism, general psychopathology, help
lessness and amount of free-time
activity and work. Biochemical
markers added substantially to the
outcome predictability. Multiple
correlation coefficients ranged from
0.35 predicting POMS vigour/activity to 0.81 predicting KAS-R
general psychopathologic problems.
Thus, 12% to 66% of the variability
in psychosocial outcome was pre
dictable from demographic, neuro
logic and biochemical data within

Table III. Comparison of Moderate and Severe Groups
Moderate
(n = 27)
Variable
Descriptive variables
Age, yr
Months after injury
GCS score on admission
Leukocyte count, x 109/L
Potassium level, mmol/L
Glucose level, mmol/L
Duration of coma (GCS
score < 8), d
Duration of PTA (GCS
score < 15), d
Quality of life variables
POMS depression/dejection
Residual problems
SIP work
SIP physical
SIP psychosocial
KAS-R general
psychopathology
KAS-R amount of social
activity

Severe (ni = 25)

Mean

SD

Mean

SD

df

t

p value

43.59
41.78
13.56
14.54
3.65
8.94

20.96
21.23
2.04
6.35
0.49
3.46

40.64
42.60
6.52
18.70
3.65
9.65

13.29
18.59
1.50
7.00
0.45
3.21

50
50
50
43
44
41

0.63
- 0.15
14.21
- 2.09
0.00
- 0.69

NS
NS
< 0.001
< 0 .0 5
NS
NS

0.45

0.58

4.40

5.64

44

- 3.48

< 0.002

2.25

4.98

20.89

22.12

41

- 3.42

< 0.003

21.29
33.07
15.84
4.39
11.73

7.64
5.58
28.21
6.39
10.83

28.96
37.54
45.30
7.20
16.71

10.95
8.61
33.05
8.20
12.91

48
49
46
48
48

-

2.82
2.17
3.31
1.29
1.46

< 0.008
< 0.05
< 0.002
NS
NS

35.00

8.13

47.67

14.28

38

- 3.35

< 0.003

38.90

4.93

34.61

7.09

38

2.18

< 0.05

Table IV. Prediction of Outcome After Injury Using Predictors Available 24 Hours After Injury
Amount of variance accounted for by predictor, %
Scale description
Katz adjustment scale
Belligerence
Verbal expansiveness
Negativism
Helplessness
Suspiciousness
Withdrawal and retardation
General psychopathologic
problems
Nervousness
Hyperactivity
Amount of social activity
Expected social activity
Amount of free-time activity
Expected free-time activity
Profile of mood states
Anger/hostility
Vigour/activity
Confusion/bewilderment
Sickness impact profile
Sleep and rest
Emotional behaviour
Home management
Mobility
Social interaction
Alertness behaviour
Work
Recreation and pastimes
Physical dimension

Mult R

R2

0.66
0.59
0.65
0.80
0.36
0.38

0.43
0.35
0.42
0.64
0.13
0.14

<
<
<
<
<
<

0.005
0.006
0.002
0.0002
0.07
0.06

0.81
0.49
0.62
0.41
0.35
0.73
0.40

0.66
0.24
0.38
0.16
0.13
0.53
0.16

<
<
<
<
<
<

0.0001
0.01
0.01
0.04
0.07
0.0002
0.04

0.45
0.35
0.50

0.20
0.12
0.25

0.02
< 0.08
< 0.04

0.38
0.41
0.37
0.38
0.38
0.44
0.75
0.44
0.49

0.14
0.17
0.14
0.14
0.14
0.20
0.57
0.20
0.24

<
<
<
<
<
<
<
<
<

p value

0.06
0.04
0.07
0.06
0.06
0.03
0.001
0.03
0.04

Glucose
level

Leukocyte
count

1 4 (1 )[-]
1 4 (2 )[-]
3 2 (1 )[-]
31 (1 )1 -1

12(2) [+ ]
21 (1 )[+ ]

1 7 (3 )[-]

1 9 (2 )[-]
2 4 (1 )[-]
1 4 ( 3 ) [- 1
1 6 (1 )[+ ]

35 (1 )[+ ]

GCS

Age

15(2) [+]
1 3 (1 )1 + ]
1 4 (1 )[+ ]

1 0 (2 )[-]
9 (4 )[-]

Potassium
level

9 (3) [+ ]

1 2 (3 )[-]

1 4 (1 )1 + ]

11 (2)1+1

1 3 (1 )[+ ]
31 (1 )1 -1

21 ( 2 )1 - 1
1 6 (1 )[+ ]
2 0 (1 )[-]
1 2 (1 )[-]
1 3 (2 )[-]

11 (1 )1 -1
1 4 (1 )1 + ]
1 7 (1 )1 -1
1 4 (1 )1 + ]
1 4 (1 )1 + ]
1 4 (1 )1 -1
20 (1 )[+ ]
9 (4) [+ ]
20 (1) [+ ]

2 8 (1 )[-]
1 2 (2 )[-]

1 0 (2 )[-]

9 (3) [+ ]

1 2 ( 1 ) [+ ]

( ) following the variance accounted for by each predictor, variable contains the step number at which that variable entered the equation. [1 indicates the
relation of the variable to a higher score on that scale, e.g., for the Katz belligerence scale, the lower [ - ] the GCS score, the higher the glucose level
[+ ], and the lower the WBC [ - ], the higher the belligerence score.
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24 hours of injury. The Glasgow
Coma Scale score and biochemical
indicators are powerful predictors
of long-term outcome with lower
GCS scores, higher plasma glucose
and serum potassium levels and
lower leukocyte count being related
to poorer psychosocial prognosis.

Discussion
These results demonstrate that
there are early markers of injury
severity after TBI that can predict
psychosocial and behavioural out
come. This study expands on that
of Kassum and associates6 by using
traumatic brain injured patients
with no other system damage, and
by focusing on quality of life in
survival. Predicting outcome after
TBI is important not only in deter
mining patient management, but
also in allowing the family to pre
pare for changes in the patient’s
psychosocial, physical and cognitive
functioning. However, biochemical
predictors can only provide a rough
estimate of outcome since it is not
only the injury itself, but the pa
tient’s response to that injury, as
well as pre- and postmorbid social
factors which affect later function
ing.512
Glasgow Coma Scale score still
appears to be the one variable most
highly predictive of outcome with
higher admission scores being relat
ed to better prognosis. In terms of
the other measures of severity, due
to the physical stress associated
with any type of injury, plasma
glucose levels tend to rise. There
fore, it follows that the more severe
the TBI, the higher will be the
plasma glucose, which is correlated
with poorer outcome. In univariate
analyses, a higher leukocyte count
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was found to be associated with
more severe injury in our series.
However, in multiple regression
analyses, worse outcome was asso
ciated with a lower leukocyte count.
This finding may be an artifact of
the multiple regression procedure
when leukocyte count enters the
equation later than GCS score and
plasma glucose level. Potassium
was a weak predictor of outcome
with higher serum levels often
being associated with poor out
come. This agrees with the older
literature, in which hyperkalemia is
stated to occur after injury due to a
release of cellular potassium, but
not with recent literature1415 which
suggests an adrenergic mechanism
producing a lower serum potassium
level in the severely stressed pa
tient.
With biochemical data available
to physicians within 6 to 24 hours
of injury, outcome predictability is
enhanced compared with that using
the GCS score alone. With this
approach, and by developing and
cross-validating regression equa
tions predictive of outcome, it may
be possible to identify those pa
tients who can benefit from cogni
tive and psychosocial rehabilitation
programs leading to more effective
long-term management. Further re
search will need to examine these
issues and to identify whether long
term outcome can be modified by
such programs.

References
1. O ’S hauchnessy EJ, F owler R S jr , R eid

V: Sequelae of mild closed head injuries.
JFam Pract 1984; 18: 391-394

Williams & Wilkins, Baltimore, 1987:
1-19
4. E isenberc HM, Weiner RL, T abaddor
K: Emergency care and initial evalua
tion. In Ibid: 20-33
5. K lonoff PS, S now WG, C osta LD:
Quality of life in patients 2 to 4 years
after closed head injury. Neurosurgery
1986; 19: 735-743
6. K assum DA, T homas EJ, Wong CJ: Early
determinants of outcome in blunt injury.
Can J Surg 1984; 27: 64-69
7. A lberico AM, Ward JD, Choi SC, et al:
Outcome after severe head injury. Rela
tionship to mass lesions, diffuse injury,
and ICP course in pediatric and adult
patients. J Neurosurg 1987; 67: 648656
8. McS weeny AJ, Grant I, Heaton RK, et
al: Life quality of patients with chronic
obstructive pulmonary disease. Arch In
tern Med 1982; 142: 473-478
9. McN air DM, L orr M, Droppleman LF:
EDITS Manual for Profile o f Mood
States, Educational and Industrial Test
ing Service, San Diego, 1971
10. B ercner M, B obbitt RA, P ollard WE,
et al: The sickness impact profile: valida
tion of a health status measure. Med
Care 1976; 14: 57-67
11. Hocarty GE, K atz MM: Norms of ad
justment and social behavior. Arch Cen
Psychiatry 1971; 25: 470-480
12. S tambrook M, P eters LC, Moore AD,
et al: Psychological and social burden
following moderate and severe traumatic
brain injury. Can J Rehabil 1988; 1 (4
suppl): 74
13. B ond MR: Neurobehavioral sequelae of
closed head injury. In Grant I, Adams
KM (eds): Neuropsychological Assess
ment o f Neuropsychiatric Disorders, Ox
ford U Pr, New York, 1986: 347-373
14. S mith JS jr : Hypokalemia in resuscita
tion from multiple trauma. Surg Gyne
col Obstet 1978; 147: 18-20

2. P arkinson D, S tephensen S , P hillips S:

Head injuries: a prospective, computer
ized study. Can J Surg 1985; 28: 79-83
3. K raus JF: Epidemiology of head injury.
In Cooper PR (ed): Head Injury, 2nd ed,

15. B rown MJ, B rown DC, Murphy MB:
Hypokalemia from beta2-receptor stimu
lation by circulating epinephrine. N
Engl J Med 1983; 309: 1414-1419

ORIGINAL ARTICLES

Prosthetic Replacement of the Arthritic
Knee After Patellectomy
H.U. Cameron, MB, ChB, FRCSC;* Y.B. Jung, MDt
The results of total knee replacement with a semiconstrained prosthesis after
patellectomy are poor because the stabilizing effect of the patella is lost. A series of
bicompartmental unicompartmental knee replacements (five patients) carried out for
this condition was compared with a series of Insall-Burstein posterior stabilized
knee prostheses (six patients). If both cruciate ligaments are present the results are
not notably different, but those with an Insall-Burstein prosthesis generally fared
better at stair-climbing using the replaced side as the lead leg. Since the InsallBurstein knee is technically easier to implant there seems little to recommend the
bicompartmental unicompartmental prosthesis in this condition.

Les resultats des arthroplasties totales du genou a l’aide de protheses semi-contraintes sont mauvais, a cause de la perte de l’effet stabilisateur de la rotule. Cinq
patients qui avaient subi une arthroplastie bicompartimentale-unicompartimentale
apres patellectomie ont ete compares a six autres qui avaient re?u une prothese
Insall-Burstein avec stabilisation posterieure du genou. En presence des deux
ligaments croises, les resultats n’etaient pas tellement differents mais ceux qui ont
refu une prothese Insall-Burstein etaient generalement avantages pour monter les
escaliers, alors qu’ils pouvaient utiliser la jambe operee pour amorcer leur escalade.
Comme la prothese Insall-Burstein est techniquement plus facile a implanter, il y a
done peu de raisons de recommander une prothese bicompartimentale-unicompartimentale.

fore, we inserted bicompartmental
unicompartmental knees in patients
who had severe osteoarthritis of the
knee and had previously undergone
patellectomy. The objectives were
to determine if retention of both
cruciate ligaments provided an
teroposterior stability and if the
incidence of patellar pain was less
ened by allowing the patellar ten
don to articulate with the natural
articular cartilage covering the
trochlear groove.
Since completion of that study,
we have also tried the Insall-Bur
stein posterior stabilized knee pros
thesis and the results achieved with
each type of prosthesis have been
compared.

Patients and Methods
he patella acts as an an
teroposterior stabilizer in total
knee replacement.1' 3 In a previous
study,4 it was shown that the re
sults of total knee replacement after
patellectomy with excision of the
cruciate ligaments were not particu
larly good, and when revision was

T

needed in these cases, far superior
results were obtained with a stabi
lized knee.4 Some of these patients,
however, continued to have patellofemoral pain because the patellar
tendon rubbed on the anterior metal
flange.
In a small series of cases, there

From the Department o f Surgery, The Orthopaedic and A rth ritic Hospital, University o f
Toronto, Toronto, Ont.
*Assistant Professor, Department o f Surgery, Department o f Pathology and Department o f
Engineering, University o f Toronto. S taff orthopedic surgeon, the Orthopaedic and A rth ritic
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f Associate Professor, Chung-Ang University, Seoul. S. Korea
Accepted fo r publication May 5, 1989
Reprint requests to: Dr. H.U. Cameron, Ste. 318. 43 Wellesley St. E, Toronto, Ont. M4 Y 1H1

Eleven patients who had previ
ously undergone patellectomy had
replacement by either a bicompart
mental unicompartmental knee
prosthesis (5) or an Insall-Burstein
knee prosthesis (Johnson and John
son, New Brunswick, NJ). The pro
cedures were carried out by the
senior author and the patients re
viewed prospectively at 6-month in
tervals using the Hospital for Spe
cial Surgery rating system5 and
3-foot standing films and lateral
x-ray films.
The unicompartmental knee was
the Tricon P (Richards Manufactur
ing Co., Memphis, Tenn.). It con
sists of a cemented femoral compo
nent and an uncemented plastic
CJS, VOL. 33, NO. 2, A P R IL 1990
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tibial component, which is held in
place by a ridged plastic peg driven
into an undersized hole drilled in
the tibia (Fig. 1). The peg provides
initial stability and the flat cut sur
face of the intercondylar eminence
provides rotatory stability. The Insall-Burstein knees were all ce
mented in place (Fig. 2).

Results
The results are shown in Table I.

Of the unicompartmental group
(cases 1 to 5), one patient scored
excellent, two good, one fair and
one poor. Two of the five can use
the replaced knee as the lead leg
when climbing stairs. In the InsallBurstein group two scored excel
lent, two good, one fair and one
poor. Five of the six can use the
replaced knee as the lead leg on
stairs.
No knees have loosened and none
have been revised. The only radiolucency seen is under the medial tibial

FIG. 1. Bicompartmental unicompartmental knee in place for 4 years and
functioning reasonably well. Femoral components are cemented. Tibial components
are plastic and held in place with ridged plastic peg.

FIG. 2. (a) Posterior cruciate ligament
was absent in this medial unicompart
mental knee. Tibia tended to sublux
posteriorly on femur, (b) Joint was
revised to Insall-Burstein posterior
stabilized knee.

Table I. Data and Results in 11 Patients
Case
no.

Sex

Age,
yr

1
2

F
F

55
72

Patellectomy
Patellectomy

3

F

57

4
5
6

M
F
F

67
44
70

7

F

54

8

F

75

Patellectomy + high tibial
osteotomy
Patellectomy
Patellectomy
Patellectomy +
unicompartmental knee
Patellectomy + high tibial
osteotomy
Patellectomy

9

M

61

10
11

M
F

74
73

Previous operation

Patellectomy + total knee
replacement
Patellectomy
Patellectomy

Surgical findings

Knee used

Complications

Results

Cruciate ligaments OK
Absent anterior band anterior
cruciate ligament
Cruciate ligaments OK

BUP
BUP

None
None

G
E

BUP

G

Ankylosed knee
Absent anterior cruciate ligament
Absent posterior cruciate ligament

BUP
BUP
IB

Avulsion of the anterior band of the
anterior cruciate ligaments
Severe wound breakdown
Deep vein thrombosis
None

IB

Tibial crack fracture

F

None
Lateral patellar ligament
subluxation
None
None
None

IB

None

E

IB

None

P

IB
IB

None
None

G
G

BUP = bicompartmental unicompartmental prosthesis, IB = Insall-Burstein prosthesis. G = good, E = excellent, F = fair, P = poor.
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plateau in the patient who had a
crack fracture of the tibia stabilized
by one screw (Fig. 3).

Discussion

FIG. 3. Crack fracture of tibial cortex
in case of revision of tibial osteotomy
occurred when stem hole was punched
out. It was stabilized with one screw.
Use of burr is probably preferable
when preparing canal for prosthetic
stem after previous osteotomy. There
is some radiolucency under medial tibi
al plateau.

This is the first report in the
literature of the use of bicompartmental unicompartmental knee
prostheses implanted in the absence
of the patella. Although our num
bers of patients are small, which
tends to skew results, it is also the
largest reported series of posterior
stabilized knee prostheses used in
the absence of the patella.
Bicompartmental unicompart
mental prostheses do work in the
absence of the patella, but only if
both cruciate ligaments are present.
The operation is technically more
difficult than an Insall-Burstein

knee replacement and the results
are not superior. There seems little
reason, therefore, to use bicompart
mental knee prostheses to treat
patients with severe osteoarthritis
in the absence of a patella.
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Perioperative Cefazolin Prophylaxis in
Hip Fracture Surgery
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Richard Buckley, MD, FRCSC;* Gary N.F. Hughes, MD, FRCSC, FAAOS;t Tom Snodgrass, BSc;$
Shirley A. Huchcroft, PhDJ
Antibiotics given perioperatively are thought to decrease the occurrence of
postoperative wound infection. The duration of treatment for hip fracture surgery is
empirical. This randomized, double-blind, single-hospital clinical study was carried
out to assess the effect of both antibiotic use and duration of use on wound
infections in hip fracture surgery. Wound infection rates in three groups of patients
were compared: those who received four doses of cefazolin (108 patients), those who
received one dose of cefazolin and three doses of placebo (83 patients) and those
who received four placebo doses (121 patients). Results showed an infection rate of
1.6% for the four-dose group, 2.4% for the one-dose group and 3.7% for the placebo
group. These differences were not statistically significant, even when both treatment
groups were combined and compared with the placebo group. The authors conclude
that until more patients are added, empirical use of antibiotics should be continued
in patients who undergo hip fracture surgery.

On croit generalement que les antibiotiques administres en peroperatoire diminuent
l’incidence des infections de plaie postoperatoires. En ce qui concerne la chirurgie
des fractures de la hanche, la duree de traitement est empirique. La presente etude
clinique, randomisee, a double insu et realisee dans un seul hopital, a ete menee
dans le but d’evaluer l’effet de l'antibiotherapie et de sa duree sur les infections de
plaie consecutives a la chirurgie des fractures de la hanche. Les taux d’infections de
plaie ont ete compares chez trois groupes de patients: ceux qui recurent quatre
doses de cefazoline (108 patients), ceux qui refurent une dose de cefazoline et trois
doses de placebo (83 patients) et ceux a qui on donna quatre doses de placebo (121
patients). Les resultats ont montre un taux d’infections de 1.6% pour le groupe qui
re?ut quatre doses, de 2.4% pour ceux qui recurent une dose et de 3.7% pour le
groupe placebo. Aucune de ces differences n’atteint le seuil de signification
statistique, meme lorsque tous les patients traites sont regroupes et compares au
groupe placebo. Les auteurs concluent que d’ici a ce qu’on ait augmente les effectifs
de l’etude, l’utilisation empirique des antibiotiques devrait etre poursuivie chez les
patients qui subissent une operation pour fracture de la hanche.
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ound infection is an infre
quent complication of hip
fracture surgery, but, as recently as
15 years ago, infection rates rang
ing from 9.4% to 16%1-4 were docu
mented in a number of studies in
which the follow-up was meticu
lous. What are the reasons for this
discouragingly high rate of infec
tion in clean wounds after hip sur
gery? Hip surgery is performed
most often in patients with systemic
disease in their seventh to ninth
decades who are poor surgical risks
and have chronic disease.4
Recently, antibiotics have been
used prophylactically to decrease
wound infection rates in hip frac
ture surgery (0.7% to 9%).5-10 How
ever, in many of these reports, the
study design and statistical analysis
were open to question. For exam
ple, total joint surgery was included
with hip fracture surgery,5 multiple
antibiotics were used,610 antibiotics
were given over different prospec
tive time periods (from one dose to
2 weeks)5-10 and many types of hip
operation were performed.8-9 Stan
dardization of protocol is difficult
because of multiple factors, which
include the type of fracture, type of
antibiotic, duration of antibiotic ad
ministration and implant selection.
However, the principles of effective
prophylaxis are becoming more
finely tuned.1112 The trend in antibi
otic use in orthopedic implant sur
gery is to give high-dose, single
dose, first-generation cephalos
porin.12' 14 Effective selection of an
timicrobial agents, low toxicity and
good tissue levels are all important
factors in effective prophylaxis.

'S

c

x

T *'

-

CEFAZOLIN IN HIP SURGERY

In this single-hospital, prospec
tive, clinical study, cefazolin is eval
uated as a prophylactic agent
against wound infection after hip
fracture surgery. The principal area
of interest was whether or not cefa
zolin decreased early postoperative
wound infection rates, and whether
single-dose cefazolin was as effec
tive as multiple-dose cefazolin in
preventing early postoperative
wound infections.

Patients and Methods
All adults admitted to the Footh
ills Hospital, Calgary, with an inter
trochanteric or subcapital hip frac
ture between Dec. 1, 1985 and Dec.
1, 1988 were eligible for study.
There were 387 such patients.
Twenty-five patients were excluded
for one of the following reasons:
cephalosporin allergy, a pathologic
fracture due to tumour, previous
surgery on the fractured hip, treat
ment with an antibiotic other than
cefazolin, or a preoperative course
in hospital longer than 7 days. This
left 352 patients in the trial after
informed consent was obtained.
The patients were allocated blind
ly and at random to one of the
following three groups: group 1 —
cefazolin, 2 g intravenously when
anesthesia was induced, then 1 g
every 6 hours intravenously for
three doses, making a total of four
doses of cefazolin; group 2 — cefa
zolin 2 g intravenously upon induc
tion of anesthesia, then saline for
three doses; group 3 — saline intra
venously for four doses. No-one
involved in the patient’s primary
care was aware of the group to
which each patient had been as
signed. An unpublished retrospec
tive study, done previously at the
Foothills Hospital by staff of the
Division of Orthopedic Surgery,
demonstrated infection rates in hip
fracture surgery without antibiotics
of 12% and with four doses of

antibiotics of 4%. This was used as
a model for our prospective study.
We decided to compare three
groups because we did not know
whether a single preoperative dose
would result in a low rate of infec
tion. We selected a sample size of
about 120 patients in each of three
groups in the study. Such a sample
size would detect a difference in
infection rates of 9% with a proba
bility of an a-type error of less than
0.10 and a /3-type error of less than
0.20. Before the study began, we
decided that upon analysis of the
first 180 patients, if there was a
statistical difference between
groups the trial would be discontin
ued.
Surgery and Follow-up
The fractured hip was treated by
either hip pinning (with compres
sion screw or multiple pins) or an
Austin-Moore hemiarthroplasty.
Postoperatively, at the surgeon’s
discretion, a Hemovac drain was
placed for subcutaneous tissue
drainage. All patients had their
wounds checked by the hospital
wound-study nurse, and all patients
had a complete follow-up 6 weeks
after operation. Uniform clinical
criteria were used to define infec
tion.15 Wounds were considered un
infected if they healed primarily and
definitely infected if there was a
purulent discharge, whether or not
organisms were cultured. Wounds
that were inflamed without dis
charge and wounds that drained
culture-positive serous fluid were
considered possibly infected and the
patient was followed up until the
wound either healed or drained pus.
Material was cultured from all
wounds in which infection was
questionable.
For the first 14 patients, serum
and bone levels or cefazolin were
examined intraoperatively. This was
done by the cylinder-plate bioassay

technique.16 Serum levels 15 min
utes after 2-g intravenous bolus
dose yielded mean levels of 121
Mg/ml. Bone levels 1 hour after the
bolus dose averaged 33 /ug/ml.
These levels of cefazolin are at least
10 times the MIC90 (minimal inhibi
tory concentration-90) for common
wound pathogens including Sta
phylococcus aureus.17-19
Statistical Analysis
Using the x 2 test with the Yates
correction or Fisher’s two-tailed
exact test, we compared propor
tions of patients in each group who
had a wound infection. Due to the
low infection rate, the cefazolin
groups (1 and 2) were combined in
an effort to increase the power of
detecting a statistical difference be
tween those who received cefazolin
and those who received the placebo.
All statistical procedures with re
spect to wound infections were per
formed using these two groups
(1 /2 and 3). Since age in all three
study groups was skewed to the
upper limit, the Kruskal-Wallis
one-way analysis of variance was
used to assess the comparability of
the three groups.

Findings
Of the 352 patients initially in
cluded in the trial, 40 were exclud
ed because the trial protocol was
not completed. This left 312 pa
tients who completed the 6-week
study. Group 1 comprised 108 pa
tients, group 2, 83 patients and
group 3, 121 patients. The three
groups were similar in sex (x2 =
0.586, df = 2, p = 0.75) and age (H
= 0.297, df = 2, p = 0.86) distribu
tion (Table I).
Of the 312 fractures, 121 were
treated by Austin-Moore hemiar
throplasty — 56 in group 1, 32 in
group 2 and 33 in group 3. The
remaining 191 were treated by hip
CJS, VOL. 33. NO. 2, APRIL 1990
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pinning; of these, 170 had a com
pression screw — 57 in group 1, 46
in group 2 and 67 in group 3; the
remaining 21 had multiple pins
placed — 8 in group 1, 5 in group
2 and 8 in group 3. No difference
existed between groups with regard
to the presence of a Hemovac drain
(X 2 = 0.33, df = 2, p = 0.85)
(Table II). The type of operation
was not evenly distributed between
the three groups (x2 = 5.95, df =
2, p = 0.05). The fact that the type
of operation performed was not a
predictor of wound infection indi
cated that this variable was not a
confounder in the study.
Eight postoperative wound infec
tions occurred — two (1.6%) in

group 1, two (2.4%) in group 2 and
four (3.7%) in group 3. The infec
tions were all superficial except for
one in group 3, a deep infection in a
96-year-old woman which was im
plicated in her death 14 days after
operation. All the infections were S.
aureus (sensitive to cephalothin),
and all superficial infections cleared
after a course of intravenous antibi
otics. All infected patients (except
the one who died) were discharged
from the study after 6 weeks with
healed wounds. Because of the
small number of infections in each
group we had to combine the antibi
otic treatment groups (1 and 2) to
make a comparison with the control
group (3). This comparison demon

Table 1. Sex and Age
Sex

Age, yr

Group

No.

Male

Female

Mean ± SD

Range

1 (4 doses)
2 (l dose)
3 (placebo)

121
83
108

32
22
3

89
61
75

76.3 ±14.9
77.1 ± 12.1
76.1 ± 13.4

18-100
3 3- 94
29- 96

Totals

312

87

225

Table II. Type of Operation and Hemovac Drainage
Operation
Austin-Moore

Multiple
pins

Compression
screw

Yes

No

121
83
108

56
32
33

8
5
8

57
46
67

67
49
63

54
34
45

312

121

21

170

179

133

Group

No.

1
2
3
Totals

Table III. Wound Infection
Wound infection
Group

1,2
3
Totals

Yes (%)

No

Total no.

4 (2.0)
4 (3.7)

200
104

204
108

8

304

312

Table IV. Type of Operation and Wound Infection
Operation

Group

Austin-Moore
(infection)

Multiple pins
plus compression
screw (infection)

Totals (infection)

1,2
3

88 (2)
33 (2)

116 (2)
75 (2)

204 (4)
108 (4)

Totals

121 (4)

191 (4)

312 (8)
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strated no statistically significant
difference by Fisher’s two-tailed
exact test (p = 0.46) between those
hip fractures treated with antibiot
ics and those without (Table III).
The average age of the infected
patients was 84.2 years, 8 years
older than that of noninfected hip
fracture patients. This was not sta
tistically significant using a pooled
variance estimate (t = 1.61, df =
310, p = 0.11).
The type of operation performed
had little effect upon the likelihood
of a wound infection developing
(Table IV). There was no difference
in infection rates between the Austin-Moore hemiarthroplasties (intracapsular surgical approach) and
the hip pinnings (extracapsular sur
gical approach) (Fisher’s exact test,
p = 0.72).
Fifteen deaths occurred (4.8%), 3
in group 1, 4 in group 2 and 8 in
group 3. The cause of all deaths
was cardiopulmonary except for the
one patient in group 3 who died of
multiorgan system failure; her deep
wound infection possibly contribut
ed to her death. All patients who
died were in their ninth or tenth
decade of life.
There were no anaphylactic reac
tions, allergies or renal toxicity re
lated to cefazolin administration.
There were no cefazolin cross-reac
tions with patients who claimed a
history of “penicillin rashes”. No
patient’s hospital stay was length
ened because of a drug-related com
plication.
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Discussion
Postoperative infections after hip
fracture surgery are devastating,
particularly in patients who are de
mented and debilitated. Historically,
the infection rate has been between
10% and 15% in hip fracture pa
tients14 and at the Foothills Hospi
tal between 1983 and 1984 the rate
was 12% without antibiotics. In the
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1980s, antibiotics have been used in
all surgical subspecialties to de
crease postoperative wound infec
tions, but the principles of antimi
crobial prophylaxis are still being
elucidated.18 Few well-designed tri
als to assess the role of periopera
tive antibiotics in preventing post
operative wound infections in hip
fracture patients have been con
ducted.67-9
First-generation cephalosporins
have been shown to be more effec
tive and less troublesome than
other cephalosporins,18-20 but the
number of doses needed perioperatively is unknown. Antibiotics stud
ied have been given in dosage
schedules ranging from one dose to
2 weeks.5-10 Burnett and col
leagues,7 in a double-blind prospec
tive study of hip fracture patients,
had a placebo infection rate of 4.7%
and a cephalothin-treated infection
rate of 0.7%. Cephalothin was used
for 3 days. Tengve and Kjellander6
reported a placebo infection rate of
16.9% and a cephalothin-treated in
fection rate of 1.8%. Cephalothin
and cephalexin were used for 2
days. These studies suggested defi
nite value of first-generation ceph
alosporins, but the dosage schedule
used was for 2 or more days.
Conte and colleagues21 used sin
gle-dose cephalothin in cardiovascu
lar surgery and proved its efficacy
in a double-blind study. Hedstrom
and associates,10 in a double-blind
study with hip fracture patients,
found no difference between their
two groups (1 day of cefuroxime
and 1 day of cefuroxime plus 6 days
of cephalexin). Gatell’s group8-9
noted a higher infection rate in
patients who received one dose of
cephamandole than in those who
received five doses during AustinMoore surgery. The second-genera
tion cephalosporin was used be
cause of a high institutional inci
dence of gram-negative infections.
With all of these studies in mind, it

was our objective to determine
whether single-dose prophylaxis
was as effective as multiple-dose
prophylaxis.
Our study failed to demonstrate a
significant difference in wound in
fection rates in the antibiotic
groups compared with the placebo
group. Infection rates in all three
groups were much lower than his
torical figures from the 1970s and
from our own retrospective review
of 1983-84. We believe that the
surgical wound environment has be
come more antiseptic, possibly be
cause of surgical draping, technique
or some other factor. This may be
supported by our placebo infection
rate of only 3.7% which is lower
than any recent study involving hip
fractures.6-7 Because of the low pla
cebo infection rate, the study does
not have the power to demonstrate
a statistically significant difference
between groups. Indications from
other studies certainly point to anti
biotics as being helpful in wound
infection prophylaxis in hip fracture
surgery.5-10 In no study over the
last 20 years has there been a
suggestion that antibiotics increase
infection rates.
One dose of cefazolin may be as
effective as four doses of cefazolin,
but our study sample size was too
small to draw any conclusions. Until
there is definitive proof of single
dose antibiotic effectiveness, four
doses of a first-generation cephalos
porin can easily be justified on a
cost basis. The first-generation
cephalosporins cost only dollars a
day and the alternative is a small
risk of developing a devastating
wound infection. We feel there is a
trend toward having a smaller risk
of infection with antibiotic than
without.
In this study, no difference exist
ed between the operation performed
and the rate of wound infection.
Other researchers have found that
certain procedures and approaches

to the hip are associated with a
higher infection rate.1-3 Sample size
must be much larger than ours to
reach conclusions in this area, but
trends suggest that hemiarthro
plasties are associated with a higher
infection rate.
All of the infections grew S.
aureus as the primary wound patho
gen. No gram-negative bacteria
were isolated. Even with antibiotics,
there seems to be a low basal rate
of infection. Other studies have
demonstrated this with rates be
tween 0.7% and 1.8%.6-7 Perhaps
these elderly, debilitated patients
are unable to defend against specif
ic, virulent S. aureus or there are
other, as yet undetermined, patho
genetic factors. No major complica
tions occurred with cefazolin use,
making it a safe prophylactic antibi
otic.
In conclusion, cefazolin adminis
tered perioperatively for prophylax
is to patients operated on for frac
tures of the hip did not decrease
postoperative wound infection. Very
large studies, possibly multicentre
trials, will be needed to elucidate
this difficult problem of prophylaxis
in settings in which wound infec
tions are rare.
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Cesarean Section in Ontario: Practice
Patterns and Responses to Hypothetical
Cases
Janet M. Barnsley, MES;* Eugene Vayda, MD, FRCPC;* Jonathan Lomas, MA;t
Murray W. Enkin, MD, FRCSC;t Karin Domnick Pierre, MSc;* Geoffrey M. Anderson, MD, MSc;J
Betsy A. MacKinnon, MSct
A 40% random sample of Ontario’s obstetricians were asked to respond to
hypothetical scenarios for previous cesarean section, breech presentation and
dystocia, and to describe their practice patterns. Their responses confirmed findings
from other studies, which reported differences between physicians’ responses to
hypothetical cases and their actual practice. In this study, 18% chose a cesarean
section for the hypothetical case of a patient who had previously undergone
cesarean section and 2% chose a cesarean section for the hypothetical case of breech
presentation. However, in practice, the obstetricians reported that they do cesarean
section on 71% of their previous section patients and on 57% of their breech
patients. Physicians in teaching hospitals were less likely than those in community
hospitals to choose cesarean section for a woman who had previously undergone
cesarean section both hypothetically and in practice. For breech presentation, no
difference was found. The discrepancy between responses to the hypothetical cases
and practice patterns could not be attributed to the absence of anesthesia services or
to restrictive hospital policies.

Un echantillon aleatoire compose de 40% des medecins obstetriciens de l’Ontario a
ete soumis a un questionnaire concernant la marche a suivre dans des cas
hypothetiques de femmes ayant deja subi une cesarienne, de presentations de siege
et de dystocie; on leur demanda egalement de decrire leur profil de pratique. Leurs
reponses confirment les resultats d’autres etudes, a savoir qu’il existe des
differences entre leurs reponses a des cas hypothetiques et leur pratique reelle.
Dans cette etude, 18% ont choisi une cesarienne dans le cas hypothetique d’une
patiente qui avait deja eu une cesarienne et 2% choisirent une cesarienne dans
l’hypothese d’une presentation de siege. Par contraste, en pratique, les medecins
obstetriciens rapportaient qu’ils executent une cesarienne dans 71% de femmes
ayant deja subi une cesarienne et dans 57% de femmes ayant un presentation de
siege. Les medecins pratiquant dans un hopital universitaire etaient moins
susceptibles que ceux des hopitaux communautaires de choisir la cesarienne en
presence d’antecedents de cesarienne, aussi bien face a une situation hypothetique,
qu’en pratique. Aucune difference n’a ete constatee en ce qui concerne la
presentation de siege. La divergence entre les reponses a des cas hypothetiques et le
profil de pratique ne peut etre expliquee par l’absence de services d’anesthesie ou
par des politiques hospitalieres restrictives.
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he debate over the appropriate
use of cesarean section (CS)
has escalated recently because the
procedure has become an increas
ingly frequent response to obstetric
conditions such as breech presenta
tion, previous CS, dystocia and fetal
distress. The criteria suggested for
CS differ, depending on whether
they focus on clinical practice,1-5
health care expenditures,6-8 con
sumer concerns,9-13 medicolegal
considerations9-11 or implications
for medical education.14
Between 1970 and 1979, CS
rates in Canada more than doubled,
from 6.0 to 13.9 per 100 live
births.15 Recent data for Ontario16
show a further increase from 16.5
per 100 live births in 1979 to 19.9
in 1984, with increases reported in
both teaching and community hos
pitals.117-18
Of the major indications for CS,
previous section was the indication
in approximately 40%, breech pre
sentation in 10% and dystocia in
more than 18% of the sections
performed in the 1980s1-16 Previous
CS and breech presentation were
responsible for 74% of the increase
in the CS rate between 1979 and
1984 (Table I).
Two consensus conferences9-10 at
tempted to determine whether CS
or a trial of labour should be the
preferred method of management
for previous section, breech presen
tation and dystocia. These confer
ences examined research evidence
on the impact of CS, trial of labour
and vaginal delivery on infant and
maternal mortality and morbidity.

T
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As part of the background for the
Canadian consensus conference, a
survey of Ontario obstetricians col
lected information on the use of CS
in patients who had previously had
CS, in those who had breech pre
sentation and those who had dys
tocia. The survey included back
ground information, responses to
hypothetical cases, and the selfreported practices of Ontario obste
tricians. This report examines the
responses to questions on previous
CS and breech presentation. Lack
of agreement as to the diagnosis
and treatment of dystocia was ex
tensive; as a result no conclusions
could be drawn.

Methods
A 40% random sample was select
ed from the Ontario Medical Associ
ation (OMA) mailing list for the
section on obstetrics and gynecolo
gy in August 1985. The question
naire, mailed to 234 physicians
practising obstetrics or gynecology,
or both, yielded a response rate of
81.3% after 42 invalid responses
were removed. Data on the respon
dents are summarized in Table II.
When compared to the Ontario
Physician Manpower Data Centre
register of obstetricians and gyne
cologists, survey respondents were
similar in age, and country and
decade of graduation.
With the help of representatives
from the Society of Obstetricians
and Gynaecologists of Canada and
the Association of Professors of
Obstetrics and Gynaecology, a hy
pothetical case was developed for
uncomplicated previous CS and for
breech presentation. No information
was introduced that would indicate
the need for an emergency CS (e.g.,
placenta previa) in either case. The
obstetricians were asked to respond
to the hypothetical scenarios and
then to describe their actual prac

tice patterns (i.e., the proportion of
patients with breech presentation
and a history of CS whose infants
they currently deliver by cesarean
section).

was by lower segment cesarean sec
tion for breech presentation. She
would prefer a vaginal delivery on
this occasion. The question was:
“Would you permit a trial of labour
for this patient or would you sched
ule her for elective CS?”

The Hypothetical Cases
Breech Presentation
Previous Cesarean Section

This hypothetical case was as
follows: A 22-year-old woman, para
1 gravida 2, is at the end of 36
weeks of gestation and has had an
uncomplicated pregnancy. The
fetus is in vertex presentation, aver
age size for dates. Her first delivery

The breech presentation hypo
thetical case was as follows: A
34-year-old woman, para 1, gravida
2, enters hospital in active labour.
Her cervix is 4 cm dilated, with
membranes intact. An x-ray film
confirms the examination findings
of breech presentation and shows

Table I. Percentage of All Infants Delivered by Cesarean Section by Diagnostic Categories (1979
and 1984, Ontario)

1979

1984

% change
due to diagnostic
category

5.7
1.7
3.3
1.2
4.6

7.9
2.1
3.7
1.8
4.5

+63
+11
+11
+17
- 3

16.5

20.0

Year
Category
Previous cesarean section
Breech presentation
Dystocia
Fetal distress
Other
Totals*

99*

'Due to rounding.

Table II. Sample Data
Data
Gender
Male
Female
Country of training
Canada
British Isles
Other
Started practice of obstetrics
Before 1950
1950 - 1959
1960 - 1969
1970 - 1979
1980 or later
Practice arrangements
Solo practice
Group practice
University affiliation
Mixed
Number of deliveries performed in last 12 mo
<100
101 - 200
201 - 300
> 301
Mean no. of deliveries

% (N = 156)
96
4
70
21
9
4
18
33
27
18
66
14
13
7
17
42
30
11
206

CJS, VOL. 33, NO. 2, APRIL 1990

129

BARNSLEY, ET AL.

that it is a frank breech with wellflexed head. The fetus is average
size. Her first baby weighed 7 lbs.
and delivery was uncomplicated.
The question was:“ Would you
allow this woman to continue in
labour or would you schedule her
for an emergency cesarean sec
tion?”

Results
Previous Cesarean Section

The majority of respondents
(82%) indicated that they would
permit a trial of labour. Respon
dents who began practising obstet
rics in the 1980s, had university
affiliation, had anesthesia services
available within 15 minutes, and
were associated with a teaching
hospital were most likely to permit
a trial of labour.
In response to the question,
“What proportion of previous ce
sarean deliveries that you see at
present do you deliver by cesarean
section?” , 30% of obstetricians re
ported performing a repeat CS on
50% or less of their patients, 22%
of obstetricians performed CS on
50% to 74%, and 48% reported
performing CS on more than 75%
of patients who had previously un
dergone CS. Of this last group,
one-half performed a CS on all their
patients who had a history of CS.
Responses to the hypothetical
case were not congruent with actual
practice as reported by respondents.
Of the 107 obstetricians who re
ported performing CS on more than
50% of women who had previously
undergone CS, 77% selected a trial
of labour for the woman in the
hypothetical case.
Breech Presentation

The responses to the hypotheti
cal breech case were overwhelming
130

CJS, VOL. 33, NO. 2, APRIL 1990

ly in favour of allowing the woman
to continue in labour; 98% of re
spondents selected this option. In
response to the question, “What
proportion of breeches that you see
at present do you deliver by cesare
an section?”, 24% indicated that
they perform CS on over 50% of
cases of breech presentation and
23% that they perform CS on 75%
or more of patients with breech
presentation. Again, reported prac
tices differed from the responses to
the hypothetical case. Of the 69
obstetricians who reported perform
ing CS on more than 50% of breech
cases, 95% indicated that they
would allow the hypothetical pa
tient to continue labour.
In addition, physicians’ overall
reported behaviour did not match
their responses to the hypothetical
cases. 18% chose a CS for the
hypothetical case in which the pa
tient had previously had a CS and
2% chose the procedure for the
hypothetical breech case. However,
in practice, respondents reported
performing a CS on an average of
71% of their patients who had pre
viously had a CS and 57% of pa
tients who had a breech presenta
tion.
Facilities

The availability of anesthesia ser
vices and the teaching status of the
hospitals were examined for those
obstetricians who said they per
formed a CS on more than 75% of
women who had already had a CS
or had a breech presentation. Al
most half (46%) reported on-site
anesthesia services, 30% had access
to such services within 15 minutes
and 20% within 16 to 30 minutes.
Less than 5% had to wait more than
30 minutes and none reported a
delay of more than 60 minutes.
Although anesthesia services
were generally available, the likeli
hood of CS appeared to be related

to the waiting time for anesthesia.
Of obstetricians in hospitals where
the wait for anesthesia services was
more than 15 minutes, 80% per
formed a repeat CS on over 75% of
previous section cases compared
with only 37% when services were
available in 15 minutes or less (x2
= 19.14, p < 0.001). The differ
ences were less marked but still
notable for breech presentation;
40% of respondents who had to
wait more than 15 minutes for
anesthesia services reported doing a
CS on more than 75% of women
with breech presentations compared
with only 20% of obstetricians
whose wait was 15 minutes or less.
Of all respondents, 30% worked
in teaching hospitals and 70% in
community hospitals. Obstetricians
from teaching hospitals were less
likely to do repeat CS than those
working in community hospitals;
only 21% of teaching-hospital ob
stetricians compared with 61% of
those from community hospitals re
ported doing repeat sections on
more than 75% of their patients
who had previously had a CS. For
breech presentation there was less
difference; 19% of teaching hospital
respondents and 27% of community
hospital respondents performed CS
on more than 75% of their patients
who had a breech presentation.
Physicians in teaching hospitals
were also less likely than their
colleagues in community hospitals
to choose a CS in the hypothetical
case of a woman having had a
previous CS. For breech presenta
tion, however, there was no differ
ence between teaching and com
munity hospital obstetricians.

Discussion
This survey confirmed an earlier
finding that there are differences
between physician responses to hy
pothetical cases and actual practice

PRACTICE PATTERNS FOR CESAREAN SECTION

patterns. Reported differences be
tween teaching and community hos
pitals for repeat CS are also con
firmed. A Canadian study,19 which
compared physicians’ surgical prac
tices and their responses to hypo
thetical cases demonstrated discrep
ancies. The difference between re
sponses to the hypothetical cases
and actual practice is explained, in
part, by the relatively unequivocal
nature of the hypothetical cases.
Moreover, a hypothetical case al
lows the respondent to give a “text
book” response, assuming an ideal
situation and the availability of
necessary facilities. Hypothetical
cases also do not reflect external
forces such as malpractice, patient
preference and peer pressure.
Despite the relationship between
the frequency of CS and the avail
ability of anesthesia services, nei
ther the increasing CS rate nor the
frequency of CS reported in this
survey can be fully attributed to the
availability of anesthesia. In prac
tice, even with anesthesia available
in 30 minutes or less, more than
half of those who have previously
had a CS or who have a breech
presentation are delivered by CS.
The facilities and services that
should be available before allowing
a trial of labour in cases of previous
section or breech presentation were
addressed in the final statement of
the panel from the Canadian Na
tional Consensus Conference on As
pects of Cesarean Birth.10 The
statement contained a section enti
tled ’’Designation of appropriate
hospital facilities”, in which the
following paragraph appeared:

The panel recognized that rupture of
the lower uterine segment may occa
sionally be catastrophic for the woman
and her infant, although this event
occurs much less frequently than other
acute obstetric emergencies. Therefore,
hospitals providing obstetric care
should ensure the availability of blood,

operating rooms, neonatal resuscita
tion, and nursing, anesthetic and surgi
cal personnel so that a cesarean section
can be started within approximately 30
minutes for any woman in labour, in
cluding a woman undergoing a trial of
labour.

The facilities and services re
quired for safe obstetric care gener
ally are the same as those required
for trial of labour in a woman who
has previously had a CS or who has
a breech presentation. If a trial of
labour cannot be carried out be
cause of inadequate facilities, the
consensus statement indicated that
such hospitals should re-examine
their ability to deal with all obstet
ric practice.
For breech presentation, the
trend toward delivery by CS may
prove to be self-perpetuating. If
obstetricians have limited oppor
tunities to manage breech presenta
tions by vaginal delivery, CS could
become the standard method for
breech delivery. In the hypothetical
case of breech presentation, respon
dents must have assumed the tech
nical skill necessary for a vaginal
delivery.
The administrative rules in hospi
tals could influence physicians’
practice patterns by specifying obs
tetric policies. However, evidence
from a concurrent survey of CS
policies in Ontario hospitals did not
support this hypothesis. Of the hos
pitals surveyed, only 50% had ex
plicit obstetric policies for patients
having a previous CS and only 40%
for breech presentation.
We found that responses of ob
stetricians to uncomplicated hypo
thetical cases did not appear to
agree with the self-reported practice
patterns. They reported performing
CS on the majority of their patients
who had undergone a CS previously
or who had a breech presentation.
Although reasons for disagreement
between hypothetical cases and ac

tual practice have been suggested,
factors responsible for repeat CS
and CS for breech presentation are
less obvious. The high rates do not
appear to be attributable to the lack
of anesthesia services or restrictive
hospital policies. Patient and peer
pressures and the fear of litigation
may play a part. The Canadian
consensus statement10 could serve
to increase the acceptance of trial of
labour for uncomplicated deliveries
in women having previously under
gone CS or having breech presenta
tion and to stabilize or reduce CS
rates for these two conditions.
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secretion.

INDICATIONS AND CLINICAL USE

13. E nkin MW: Having a section is having a
baby. B irth and the Family J 1977; 4:
9 9 -1 0 5

PEPCID® (famotidine) is indicated in the treatment
of the following conditions where a controlled
reduction of gastric secretion is required for ulcer
healing:
1. Treatment of acute duodenal ulcer;
2. Prophylactic use in duodenal ulcer;
3. Treatment of acute benign gastric ulcer;
4. Treatment of pathological hypersecretory
conditions (e g., Zollinger-Ellison syndrome).

14. B a sk e tt TF: Trends in operative obstet
rical delivery: implications for specialist
training. Ann Roy Coll Physicians Surg
Can 1 9 8 8 ; 21: 1 1 9 -1 2 1

PEPCID® I.V. is indicated in some hospitalized
patients with pathological hypersecretory con
ditions or intractable ulcers, or as an alternative to
the oral dosage forms for short-term use in patients
who are unable to take oral medication.

CONTRAINDICATIONS
H y p e rs e n s itiv ity to any co m p o n e n t o f th is
medication.

15. W adhera S, Nair C: Trends in cesarean
section deliveries. Canada, 1 9 6 8 -1 9 7 7 .
Can J Public Health 1982; 73: 4 7 -5 1

16. A nderson GM, L omas J: Determinants
of the increasing cesarean birth rate.
Ontario data 1979 to 1982. N Engl J
M ed 1 9 8 4 ; 311: 8 8 7 -8 9 2

17. Idem: Explaining variations in cesarean
section rates: patients, facilities or poli
cies? Can Med Assoc J 1985; 132: 2 5 3 6, 2 5 9

18. V ayda E, B arnsley JM, Mindell WR, et
al: Five-year study of surgical rates in
Ontario's counties. Can Med Assoc J
1 9 8 4 ; 1 3 1 :1 1 1 -1 1 5

19. V ayda E, Mindell WR, Mueller CB, et
al: Measuring surgical decision-making
with hypothetical cases. Can Med Assoc
J 1 9 8 2 ; 127: 2 8 7 -2 9 0

132

CJS, VOL. 33, NO. 2, A PR IL 1990

PRECAUTIONS
Patients with Severe Renal Insufficiency

Dosing intervals may need to be prolonged in
p a tie n ts w ith advanced renal in s u ffic ie n c y
(creatinine clearance<10 mL/min.) to adjust for the
longer elimination half-life of famotidine. (See
CLINICAL PHARMACOLOGY and DOSAGE AND
ADMINISTRATION.)

PEPCID® (famotidine) is usually well tolerated;
m ost adverse reactions have been mild and
transient. The adverse reactions listed below have
been reported during clinical trials in 2333 patients.
In those controlled clinical trials in which PEPCID®
was compared to placebo, the overall incidence of
adverse experiences in the group which received
PEPCID®, 40 mg at bedtime, was similar to the
placebo group. No antiandrogenic or other adverse
hormonal effects have been observed.
The following adverse reactions have been reported
at a rate of greater than 1% in patients on therapy
with PEPCID® in controlled clinical trials, and may
be causally related to the drug: headache (4.6%),
dizziness (1.2%), constipation (1.2%) and diarrhea
( 1. 6% ) .
Other reactions have been reported in clinical trials
but occurred under circumstances where a causal
relationship could not be established. However, in
these rarely reported events, that possibility cannot
be excluded. Therefore, these observations are
listed to serve as alerting information to physicians.
Gastrointestinal

8.0%

Nausea
Vomiting
Anorexia
Abdominal discomfort
Dry mouth

1.6%
0.9%
0.5%
0.3%
0.2%

Nervous System/Psychiatrlc

7.3%

Insomnia
Somnolence
Anxiety
Paresthesia
Depression
Libido decreased

0.6%
0.4%
0.3%
0.3%
0.2%
0.1%

Respiratory

Bronchospasm

4.4%

<0,1%

Body as a Whole

3.0%

Fatigue
Asthenia
Fever

0.6%
0.3%
0.2%

Musculoskeletal

1-7%

Musculoskeletal pain
Arthralgia

0.1%
0.1%

Drug Interactions

Skin

1-7%

Studies with famotidine in man, in animal models,
and in vitro have shown no significant interference
with the disposition of compounds metabolized by
the hepatic microsomal enzymes, e.g., cytochrome
P450 system. Compounds tested in man have
in c lu d e d w a rfa rin , th e o p h y llin e , p h enyto in ,
diazepam, am inopyrine and antipyrine. Ind o
cyanine green as an index of hepatic blood flow
and/or hepatic drug extraction has been tested and
no significant effects have been found.

Pruritus
Rash
Alopecia
Flushing
Acne
Dry skin

0.4%
0.3%
0.2%
0.2%
0.1%
0.1%

Use in Gastric Ulcer

Gastric malignancy should be excluded prior to
initiation of therapy of gastric ulcer with PEPCID®.
Symptomatic response of gastric ulcer to PEPCID®
therapy does not preclude the presence of gastric
malignancy.
Use In Pregnancy

Reproductive studies have been performed in rats
and rabbits at oral doses of up to 2000 and
500 mg/kg/day, respectively (approximately 2500
and 625 times the maximum recommended human
dose, respectively), and have revealed no evidence
of impaired fertility or harm to the fetus due to
PEPCID®. There are, however, no adequate orw ellcontrolled studies in pregnant women.
Since the safe use of PEPCID® in pregnant women
has not been established, the benefits of treatment
with PEPCID® should be weighed against potential
risks.

Cardiovascular

1.0%

Palpitations

0.2%

Special Senses

0.9%

Taste disorder
Tinnitus
Orbital Edema
Urogenital

0.1%
0.1%
<0.1%
0.9%

The adverse reactions reported for PEPCID®
Tablets may also occur with PEPCID® I.V. In
addition, transient irritation at the injection site has
been observed with PEPCID® I.V.
Laboratory Abnormalities

Laboratory parameters may be affected during
treatment with PEPCID®, but the changes are
u su a lly not con sid ere d serious. Among the
laboratory changes that were reported during
clinical trials were increases in AST, ALT, BUN, and
serum creatinine. These changes were rarely of
clinical significance.

Only three patients had to be discontinued from
therapy because of laboratory adverse experiences,
however laboratory abnormalities were present at
baseline.

RECONSTITUTION
Parenteral Products
Dilution of PEPCID® I.V.
for Infusion

SYMPTOMS AND TREATMENT
OF OVERDOSAGE
There is no experience to date with deliberate
overdosage. Doses of up to 640 mg/day have been
employed in patients w ith pathological hyper
secretory conditions w ith no serious adverse
effects. In the event o f overdosage, treatment
should be sym ptom atic and supportive. Un
absorbed material should be removed from the
g a strointe stin al tra c t, the p a tie n t should be
monitored, and supportive therapy should be
employed.
The oral LD50 of famotidine in male and female rats
and mice was >5000 mg/kg.

DOSAGE AND ADMINISTRATION
DUODENAL ULCER
Acute Therapy
The recommended adult oral dosage of PEPCID®
(famotidine) for acute duodenal ulcer is 40 mg once
a day at bedtime. Treatment should be given for
4-8 weeks, but the duration of treatment may be
shortened if healing can be documented. Healing
occurs within 4 weeks in most cases of duodenal
ulcer.
Maintenance Therapy
For the prevention of recurrence of duodenal ulcer,
it is recommended that therapy with PEPCID® be
continued with a dose of 20 mg once a day at
bedtime, fo r a duration of up to 6-12 months
depending on the severity of the condition.
BENIGN GASTRIC ULCER
Acute Therapy
The recommended adult oral dosage for acute
benign gastric ulcer is 40 mg once a day at bedtime.
Treatment should be given for 4 to 8 weeks, but the
duration of treatment may be shortened if healing
can be documented.
PATHOLOGICAL HYPERSECRETORY CON
DITIO N S (SUCH AS ZO LLIN G E R -E LLISO N
SYNDROME)
The do sage o f PEPCID® in p a tie n ts w ith
pathological hypersecretory conditions varies with
the individual patient. The recommended adult oral
starting dose fo r pathological hypersecretory
conditions is 20 mg q6h. In some patients, a higher
starting dose may be required.
Doses should be adjusted to individual patient
needs and should continue as long as clinically
indicated. Doses up to 160 mg q6h have been
ad m inistered to som e p a tie n ts w ith severe
Zollinger-Ellison syndrome.
Intravenous Administration
In some hospitalized patients with pathological
hypersecretory conditions or intractable ulcers, or
in patients who are unable to take oral medication,
PEPCID® I.V. may be administered. The recom
mended dosage is 20 mg every 12 hours.
Intravenous injection therapy should be changed to
oral treatment as soon as the acute situation is
under control.
Concomitant Use with Antacids
Antacids may be given concomitantly if needed.
Dosage Adjustment for Patients with Severe Renal
Insufficiency
In patients with advanced renal insufficiency, i.e.,
with a creatinine clearance less than 10 mL/min„
the elimination half-life of PEPCID® may exceed
12 hours reaching approximately 24 hoursinanuric
patients.
To avoid excess accumulation of the drug, the
dosing interval of PEPCID® may be prolonged to
36-48 hours as indicated by the patient's clinical
response.

PHARMACEUTICAL INFORMATION
COMPOSITION
Tablets
Each tablet for oral administration contains either
20 mg or 40 mg of famotidine.
Injection
Each mL of the solution for intravenous injection
contains 10 mg of famotidine and the following
in a ctiv e in g re d ie n ts : L -a s p a rtic acid 4 mg,
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The multidose injection also contains benzyl
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BOOK REVIEWS
continued from page 88

text focuses on reconstructive mi
crosurgery, which incorporates both re
plantation surgery and free tissue trans
fers. The subject matter, therefore, is
chiefly of interest to plastic and ortho
pedic surgeons, subspecialists in the
area of head and neck surgery and
neurosurgeons interested in peripheral
nerve surgery.
The text is divided into 10 sections;
the portion on free tissue transfers and
peripheral nerve surgery is the strong
est. The chapters are quite brief, usual
ly four to five pages long, with a wide
range of references and very clear sche
matic illustrations. The value of this
text is that it is all-encompassing and
highly specialized and emphasizes the
most recent advances. I would recom
mend it to those with a special interest
in reconstructive microsurgery or repair
of peripheral nerves. It is beautifully
organized and is a superb text for
obtaining new ideas. There is little
doubt that this book belongs in the
library of any surgeon doing recon
structive microsurgery.
Rollin K. Daniel, MD, FACS
Ste. 308,
1441 Avocado,
Newport Beach.
CA 92660

PRINCIPLES OF BILIARY LITHO
TRIPSY. Edited by Alexander S. Cass
and LeRoy H. Stahlgren. 104 pp. IIlust. Futura Publishing Company, Inc.,
Mount Kisco, NY. 1989. $25 (US).
ISBN 0-87993-349-6
Extracorporeal shock-wave lithotripsy
was first used to treat gallstones in
Germany in 1985. Many trials are now
under way in North America and Eu
rope to validate this new technique.
In this book, the authors first review
the physics and mechanics of lithotriptors. They discuss the different methods
of shock-wave generation, which in
clude the spark-gap electrode generator
system and the microexplosive, laser,
134
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piezoelectric and electromagnetic de
vices. With the most up-to-date lithotriptors, the patient does not have to lie
in a water bath for coupling of the
shock waves. Water is separated from
the patient by a thin membrane.
The second chapter is devoted to the
use of lithotriptors for kidney stones. It
is a concise review of indications, re
sults and side-effects of the procedure.
Dr. Robert D. Mackie, one of the 11
contributors describes, briefly, in chap
ter 3, bile physiology and gallstone
formation. He explains how sludge and
small stones may be protected from
expulsion from the gallbladder by the
tenacious mucous coat and how factors
promoting bile stasis in the gallbladder
may also contribute to gallstone forma
tion.
In chapter 4, ultrasonography is de
scribed as the best gallstone imaging
method for performing the procedure. I
find ultrasonography very useful except
in obese patients in whom neither the
gallbladder nor the gallstone can be
visualized.
After a brief overview, in chapter 5,
of gallstone management either with
biliary salts, solvents or surgery, chap
ters 6 and 8 deal specifically with biliary
extracorporeal shock-wave lithotripsy.
Patient selection, results of treatment
and side-effects are presented.
Most investigators limit lithotripsy to
symptomatic patients having no more
than three radiolucent stones, none
exceeding 3 cm in diameter. We con
firm the high stone fragmentation rate
(greater than 90%) described. Over the
last 8 months, we have treated 30
patients who had a solitary radiolucent
stone in the gallbladder, not exceeding
3 cm in diameter. We noticed that small
stones were more rapidly destroyed
than larger ones. Although that treat
ment may have to be repeated once,
twice or even three times before suffi
cient fragmentation (less than 5 mm in
size) is obtained, patient acceptance of
this technique is high because it is
performed under intravenous analgesia
with minimal pain and virtually no
complications of clinical importance.
We now perform the procedure on an
outpatient basis.
We believe bile salts should be con
sidered a necessary adjuvant therapy to

solubilize remaining fragments. The au
thors report a stone clearance rate
similar to that for renal lithotripsy, that
is, more than 90%, a figure similar to
ours. Only a few of our patients have
completed treatment. In many cases
small residual fragments are in the
process of being dissolved by bile salts.
Although long-term follow-up data
are insufficient to predict stone recur
rence after lithotripsy, one may look for
guidance to the results after dissolution
therapy. In this book the authors men
tion a possible 5-year recurrence rate of
close to 50%.
Presently available lithotriptors with
their technical characteristics and cost
are described in chapter 7 which also
deals with investment and operating
costs, coverage and reimbursement in
the United States. Since the technique
is still considered experimental, there is
presently no reimbursement in Canada
for extracorporeal shock-wave lithotrip
sy.
This book is a concise review of
presently available data and should
serve as introduction for any one inter
ested in this new field of nonsurgical
treatment of gallstones.
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Yves-Marie Dion, MD, MSc, FRCSC
Professor o f Clinics,
Universite Laval,
Department o f Surgery,
Hopital St-Franpois d Assise,
Quebec, PQ

ORTHOPAEDICS AND FRACTURES.
A Question and Answer Study Guide.
E. Edmund Graham. 255 pp. Illust.
Butterworths, Stoneham, Mass. 1988.
$16.95 (US). ISBN 0-407-01188-9
C. Edmund Graham, visiting orthopedic
surgeon at the Prince of Wales Hospital
in Sydney, Australia, has authored this
interesting new text.
The format is one of columns of
questions on the left side of the page
with answers on the right. The author
recommends spending no more than 10
seconds on each question before mov
ing to the next. Peeking, of course, is
continued on page 156
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Augmentation Ileocystoplasty in Children
With Myelodysplasia
Eric M. Webber, MD;* Paul G. Crofts, MD;* Carole Pomeroy, BSc;* Gerald U. Coleman, MD, FRCSCit
William J. Arnold, MD, FRCPC;$ Hjalmar W. Johnson, MD, FAAP, FRCSCt
Over the past 8 years 20 children suffering from myelodysplasia were selected to
undergo augmentation ileocystoplasty for urinary incontinence refractory to
treatment by clean, intermittent catheterization and anticholinergic agents, or as
part of urinary undiversion.
The children ranged in age from 5 to 17 years, and the follow-up ranged from 6
months to 7 years. Three children underwent undiversion, two had vesicostomy
closure and six had bladder outlet repair at the time of augmentation. In one patient,
surgery was technically impossible.
Postoperatively 16 children were fully continent on clean, intermittent
catheterization and anticholinergic medication. Three boys failed to achieve
satisfactory continence.
Delayed perforation, a potentially serious complication, occurred in two patients
several months postoperatively.

Au cours des 8 dernieres annees, 20 enfants souffrant de myelodysplasie ont ete
choisis pour subir une ileocystoplastie d’augmentation de volume, pour une
incontinence urinaire resistante aux traitements par catheterisme propre intermit
tent ou par medication anticholinergique, ou dans le cadre d’une derivation urinaire.
L’age des enfants a varie de 5 a 17 ans, et le suivi s'etalait sur de 6 mois a 7 ans.
Au moment de l’ileocystoplastie, trois enfants ont subi une derivation, deux ont eu
une fermeture de vesicostomie et six eurent une reparation de l'orifice vesiculaire.
La chirurgie fut techniquement impossible chez un patient.
En postoperatoire, 16 enfants sont devenus parfaitement continents, soit par
catheterisme propre intermittent, soit par medication anticholinergique. Trois
garfons n’ont pu atteindre une continence satisfaisante.
Une perforation tardive, complication potentiellement serieuse, est survenue chez
deux patients plusieurs mois apres l'operation.

he majority of children who
have a neurogenic bladder sec
ondary to myelodysplasia achieve
satisfactory urinary continence with
clean, intermittent catheterization
and anticholinergic medication. In
the past, patients refractory to this

T

therapy often underwent urinary di
version or suffered the ongoing
inconvenience and social embarrass
ment of incontinence. Now that the
long-term results of diversion are
available,1"3 attempts to maintain
urinary tract continuity in conjunc
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tion with procedures to achieve
continence have come to the fore
front. In this paper, we report our
8-year experience with 20 children
who had a neurogenic bladder sec
ondary to myelodysplasia and were
selected for treatment by augmenta
tion ileocystoplasty.
P atien ts and M ethods
The meningomyelocele clinic at
the B.C. Children’s Hospital carries
out regular follow-up of 220 chil
dren suffering from myelodysplasia;
this includes those with menin
gomyelocele, sacral agenesis and
spinal cord tumour. Of these chil
dren, 108 are maintained on clean,
intermittent catheterization and an
tibiotics for prophylaxis, with anti
cholinergic agents as necessary to
maintain continence. The remaining
children suffer from persistent uri
nary incontinence despite frequent
catheterization and maximal doses
of anticholinergic medication. Sev
enteen of these children were select
ed for augmentation ileocystoplasty
between 1980 and 1988. In addi
tion, three children with myelodys
plasia who had previously had uri
nary diversion (ileal loop conduit)
underwent ileocystoplasty at the
time of undiversion.
The children ranged in age from
5 to 17 years. Augmentation ileo
cystoplasty was successfully per
formed on 19 children — 14 girls,
ranging in age from 5 to 17 years
(mean 12 years), and 5 boys, rang
ing in age from 6 to 17 years (mean
11 years). In one boy, surgery was
technically impossible.
Preoperatively, all patients were
CJS, VOL. S3, NO. 2, A P R IL 1990
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assessed by history and physical
examination, with emphasis on the
method of urinary management,
motivation and compliance with
therapy. Radiologic evaluation in
cluded renal and abdominal ul
trasonography, voiding cystoure
thrography and, in those children
who had undergone urinary diver
sion, loopography. The serum con
centrations of urea and creatinine
were used to assess renal function.
In patients with abnormal upper
urinary tracts or serum creatinine
levels, renal function was also eval
uated by nuclear renography.
Urodynamic studies included cystometrography, to evaluate bladder
capacity and pressures, and urethral
pressure profilometry, to estimate
outlet resistance. Preoperative blad
der capacity ranged from 75 to 250
ml (mean 180 ml). A maximal
urethral pressure of less than 25
cm H20 was taken as an indication
for bladder outlet repair. Five chil
dren (three girls, two boys) had
previously undergone bladder outlet
repair — Burch urethrovesical sus
pension for girls and a modified
Young-Dees repair for boys — but
had remained incontinent. Bladder
cycling was instituted on those who
had undergone diversion.
Augmentation cystoplasty was
performed by anastomosing an iso
lated, detubularized segment of dis
tal ileum to the dome of the bladder
as described by Goodwin and col
leagues.4 In those who had previ
ously undergone urinary diversion,
the segment of ileum constituting
the ileal loop was used as a patch to
augment the bladder. At the time of
augmentation, three children under
went urinary undiversion and two
had vesicostomy closure. Six girls
with decreased outlet resistance
(maximal urethral pressure less
than 25 cm H20) on preoperative
urodynamic studies underwent
Burch urethrovesical suspension
(Table I). Two patients had success136
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ful antireflux procedures (one ure
teral reimplantation and one subureteric Teflon injection) at the time
of augmentation for coexisting vesi
coureteral reflux.

Results (Table II)
The augmentation ileocystoplasty
was successfully carried out in 19
of the 20 children. In one child
extensive adhesions from previous
abdominal surgery prevented ade
quate mobilization of the ileum. A
second attempt at mobilization of
the sigmoid colon was also unsuc
cessful and the procedure was again
abandoned. This child remains in
continent on clean, intermittent
catheterization and anticholinergic
medication.
The 19 patients have been fol
lowed up for an average of 25
months (range from 6 to 74
months). All are on clean, intermit
tent catheterization and, on this
protocol, 16 (84%) who underwent
augmentation ileocystoplasty have
achieved full urinary continence, in
cluding 6 girls who underwent con
comitant bladder neck suspensions.
Ten patients require anticholinergic
medication to prevent nocturnal en
uresis. Three boys have some de
gree of incontinence. Two of them
had unsuccessfully undergone a
Young-Dees bladder neck recon
struction. Compliance with clean,
intermittent catheterization is a
problem for one patient and the
other two are being considered for
implantation of an artificial sphinc
ter.
In accordance with our clinic pol
icy for myelodysplastic children on
Table I. Associated Procedures
Procedure
Urinary undiversion
Vesicostomy closure
Antireflux procedure
Bladder outlet repair
Female
Male

No.
3
2
2
6
6
0

clean, intermittent catheterization,
all the children receive antibiotics
prophylactically. There is a 30% to
35% incidence of asymptomatic bacteruria, and the need for and effects
of this prophylaxis are currently
being investigated in a prospective
study.
Fifteen patients who underwent
urodynamic testing postoperatively
showed on average a doubling of
their preoperative bladder capacity.
The mean postoperative bladder ca
pacity was 380 ml (range from 100
to 750 ml). All three incontinent
boys also showed at least a dou
bling of bladder capacity.
Renal function remained normal
postoperatively in 17 children who
had normal function preoperatively.
One of two patients with impaired
renal function preoperatively
showed a progressive decline in
function, while in the other renal
function remained stable. In 10
children who had a normal upper
urinary tract preoperatively, radi
ologic follow-up showed no change,
and there was no worsening of
hydronephrosis in the remaining pa
tients. In two patients who required
antihypertensive medication preop
eratively, the pressure remained
well controlled on the same medica
tion postoperatively.
The average postoperative hospi
tal stay was 20 days (range from 13
to 49 days). Early complications in
hospital were rare. One wound in
fection occurred in the first week. A
partial small-bowel obstruction ocTable II. Results and Complications
Result/complication

No. (%)

Continent
Incontinent
Complications
Early
Wound infection
Partial bowel obstruction
Urine leak
Late
Pyelonephritis
Decreased renal function
Delayed perforation

16(84)
3(16)

1 (5)
1(5)
1(5)
2(11)
1(5)
2(11)

AUGMENTATION ILEOCYSTOPLASTY

curring 4 days postoperatively re
solved with conservative, nonopera
tive management. In one patient
who underwent undiversion and
ileocystoplasty, a urine leak devel
oped from a ureteroureterostomy
and persisted for 40 days. Mucus
production is common in the early
postoperative period and requires
frequent, regular irrigations of the
augmented bladder to prevent cath
eter blockage. In patients who have
an especially heavy production of
mucus we have used the mucolytic
agent acetylcysteine in the bladder
irrigation solution. Mucus produc
tion uniformly declines within a few
months.
Late complications seldom oc
curred. Two children with an abnor
mal upper urinary tract preoperatively had pyelonephritis, requiring
hospital admission and treatment
with intravenously administered an
tibiotics. Two patients required ad
mission for evaluation and treat
ment of abdominal pain. In both
instances this settled spontaneously
and no cause was found. Postopera
tive diarrhea has not been a prob
lem.
Two patients suffered delayed
perforation of the augmented blad
der. This potentially fatal complica
tion occurred 17 months postopera
tively in one patient. The child
presented with fever and abdominal
pain which progressed to peritonitis
and septic shock. At laparotomy a
small perforation at the ileovesical
anastomosis was identified and re
paired primarily. The subsequent
clinical course was uncomplicated.
The other perforation occurred in a
patient who underwent a 3-hour
nonurologic surgical procedure
without bladder catheterization intraoperatively and for 8 hours post
operatively. During that time pro
gressive abdominal pain developed
and upon catheterization only a
small volume of urine was obtained.
Laparotomy confirmed a perforation

which was repaired primarily.

Discussion
Clean, intermittent catheteriza
tion has proven to be a safe, effec
tive method of providing urinary
continence in the majority of myelodysplastic children with neurogenic
bladders,5 especially when combined
with anticholinergic agents and an
tibiotics. Patients remaining incon
tinent despite these measures com
monly have high-pressure, lowcapacity bladders or decreased out
let resistance, or both. Bladder aug
mentation, with or without bladder
outlet procedures, has become in
creasingly popular in the manage
ment of these difficult cases, and
has been safely performed for 40
years.67 The segment of bowel used
does not appear to influence the
postoperative result.8-11 The de
creased uninhibited contractions re
cently demonstrated in bladders re
constructed with detubularized
bowel would appear to favour this
approach.12 We used a cup patch of
ileum in all cases and were not
limited by mesenteric length, al
though we could not mobilize any
segment of bowel in one case. In
the patients who underwent undi
version we did not implant the
ureters into the bowel segment of
the augmented bladder but per
formed ureteroureterostomies to
the stumps of the native ureters.
Preoperative assessment is essen
tial to determine the precise nature
of the incontinence and to ensure
that increasing bladder capacity will
improve continence. In addition,
preoperative urodynamic studies
identify those patients who will ben
efit from bladder outlet procedures.
In patients with normal outlet re
sistance and a small capacity blad
der for their age, we have per
formed augmentation ileocystoplas
ty alone. Those who have maximal
urethral pressures of less than 25

cm H20 require a bladder outlet
procedure which can be combined
with augmentation in those patients
who also have small capacity blad
ders. The degree of motivation of
the child and family, as well as the
ability and determination to perform
self-catheterization regularly for life
must play an important part in
patient selection for augmentation,
because this procedure will surely
result in ineffective bladder empty
ing. A successful outcome requires
an increase in functional bladder
capacity with an absence of
high-pressure, uninhibited, detrusor
contractions and adequate outlet
resistance. These factors must be
coupled with regular bladder empty
ing by clean, intermittent catheter
ization and can be assisted by the
use of anticholinergic agents as
needed. In our series, use of these
techniques resulted in complete
continence in 16 (84%) of 19 pa
tients. This is comparable to the
results of others who reported con
tinence rates ranging from 82% to
100%.1013-15 Bladder capacity was
on average doubled in our series.
Six of 14 girls also underwent urethrovesical suspension procedures;
all were subsequently continent.
Those remaining incontinent after
augmentation ileocystoplasty in our
series were all boys. The reasons for
lack of success can be attributed to
poor compliance to clean, intermit
tent catheterization and medication
by one patient and to an incompe
tent bladder neck despite a prior
Young-Dees reconstruction in two
others. These boys might benefit
from placement of an artificial
sphincter.
There have been relatively few
complications associated with aug
mentation ileocystoplasty in our se
ries. We maintain all our patients
on antibiotics for long-term sup
pression of infection and have had
only two cases of pyelonephritis,
both in patients with persistent veCJS, VOL. 33, NO. 2, APRIL 1990
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sicoureteric reflux; renal function
deteriorated in one patient.
Delayed perforation of the aug
mented bladder is a potentially fatal
complication that must be borne in
mind when patients with an aug
mented bladder present with ab
dominal pain or fever. The underly
ing cause may be chronic overdis
tension of the augmented bladder
associated with chronic bacteriuria
and catheter trauma. In these perfo
rations the cystogram may give
negative results and because of im
paired sensation in myelodysplastic
patients who undergo augmentation
cystoplasty they may be difficult to
diagnose.1617

Conclusions
Augmentation ileocystoplasty is
an effective treatment in carefully
selected myelodysplastic patients
who have persistent incontinence
despite frequent, clean, intermittent
catheterization and pharmacologic
manipulation. Full preoperative
evaluation of the patient’s personal
ity and urodynamic studies to iden
tify those who may benefit from
bladder outlet procedures is essen
tial to ensure the best result. The
potential risk of delayed perforation
of the augmented bladder must al
ways be considered and careful
long-term follow-up provided.
Long-term commitment by the pa
tient, family and health care person
nel is necessary for success.
We thank Drs. J.S.T. Masterson and
P.J. Moloney for allowing us to include
their patients in this paper.
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Severe Secretory Diarrhea With Elevated
Gastrin-Releasing Peptide Controlled by
Somatostatin Analogue: a Case Report
Ritha Alhindawi, MD;* Mervyn Deitel, MD, FRCSC;*t John Kempston, MD, FRCPC;J
Mansour Bendago, MD*
Gastrin-releasing peptide immunoreactivity has been seen in functioning endocrine
tumours which are recognized as a major cause of secretory diarrhea. The authors
describe a case of a 52-year-old woman who had secretory diarrhea (5 L/d) with
markedly elevated gastrin-releasing peptide levels associated with islet cell
hyperplasia. No tumour could be identified. The diarrhea was controlled by
somatostatin analogue.

Une immunoreactivite au peptide qui libere la gastrine a ete observee dans des cas
de tumeurs endocrines fonctionnelles, lesquelles sont reconnues comme cause
importante de diarrhee secretaire. Les auteurs decrivent le cas d’une femme de 52
ans qui souffrait de diarrhee secretaire (5 L/j); il y avait une augmentation marquee
des taux de peptide qui libere la gastrine reliee a une hyperplasie des cellules des
llots de Langerhans. Aucune tumeur n’a pu etre identifiee. La diarrhee fut maitrisee
grace a un analogue de la somatostatine.

ecretory diarrhea due to endo
crine tumours such as gas
trinoma, glucagonoma and vipoma
has been reported.1 An elevated
level of secondary peptides, includ
ing gastrin-releasing peptide (GRP),
substance P, neurotensin and pan
creatic polypeptide (PP) has been
associated with these tumours.2
However, no case of secretory diar
rhea with GRP hypersecretion alone
has been reported.

S

Case Report
A previously healthy, 52-year-old

white woman was transferred to St.
Joseph’s Health Centre in January
1987 from another hospital. She
had a 2-month history of diarrhea
(up to 5 L/d) and weight loss (11
kg). Physical examination revealed
moderate dehydration. Admission
electrolyte values were potassium
2.0 mmol/L, sodium 120 mmol/L,
chloride 92 mmol/L and calcium
1.94 mmol/L. In hospital, her diar
rhea continued at a rate of more
than 2 L/d, even under fasting
conditions. Preliminary investiga
tions (Table I) suggested a secretory
diarrhea of unknown etiology.
Small-bowel biopsy showed infiltra
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tion of the lamina propria with
chronic inflammatory cells. Biopsy
cultures were normal. Gastric secre
tory analysis and the pentagastrin
test gave normal results. No ab
sorption of D-xylose was found. The
stool osmotic gap was 12
mOsm/kg. Computed tomography
of the entire body did not disclose a
tumour.
Endocrine hormonal assay (EHA)
(Table II) was measured by plasma
radioimmunoassay (RIA) by Dr.
T.M. O’Dorisio, Core Peptide Labo
ratory, Ohio State University Hospial, using, respectively, rabbit anti
sera no. 674 to synthetic porcine
vasoactive intestinal polypeptide
(VIP), rabbit antiserum 615-1054
B-248-19 to human PP, rabbit anti
body D-4 to somatostatin (1-14),
rabbit antibody TR 208 to neuro
tensin, rabbit antisera R-1C to sub
stance P, rabbit antiserum LR-16 to
synthetic GRP3 and goat antiserum
G 1701 to human calcitonin.4
Serum gastrin RIA was performed
by Dr. P. Wong, Immunoassay Lab
oratory, Toronto General Hospital,
using rabbit gastrin antibody.5 The
endocrine hormonal assay showed
mild elevation of PP on admission
and 1 month later (Table II).
A trial of a pancreatic enzyme
supplement (Cotazyme 20 tab/d)
was not helpful. The patient was
put on loperamide 4 mg four times
daily, with no improvement. The
volume of diarrhea averaged 3.5
L/d. Methylprednisolone, 20 mg
three times daily intravenously for 4
CJS, VOL. 33, NO. 2, APRIL 1990
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the avidin-biotin-peroxidase com
plex technique), but negative for
gastrin, VIP and serotonin. Immunostaining was also negative for
human luteinizing hormone alpha
subunit, which is the biologically
inactive glycoprotein component of
several hormones and is thought to
be a marker of malignancy in pan
creatic endocrine tumours.6
Diarrhea continued as before, and
2 weeks postoperatively she was
started on somatostatin analogue
(SMS 201-995), the dose gradually
being increased to 1000 tig subcu
taneously twice daily. At this point,
the diarrhea decreased to 670 m l/d
and she started to gain weight.
Since admission, she had been sup
ported with total parenteral nutri
tion. She was discharged home in
September 1987, on ambulatory
home total parenteral nutrition and
somatostatin analogue, 1000 tig
subcutaneously twice daily.
At follow-up in January 1988,
the diarrhea had decreased to 550
m l/d and she had gained 8 kg. The

weeks, reduced the volume of diar
rhea to 2.7 L/d. Five months after
her admission, lower abdominal
pain, distension and vomiting devel
oped and the diarrhea continued.
Endocrine hormonal assay found
elevated levels of PP and substance
P. Abdominal x-ray films were com
patible with intestinal obstruction
(Fig. 1). After she was managed
conservatively for 10 days without
improvement, a thorough explor
atory laparotomy was done; no ab
normality was found except that the
pancreas was somewhat firm to pal
pation. The body and tail of the
pancreas and the spleen were re
moved.
Histologic examination of the
pancreas showed interstitial fibrosis
and infiltration with chronic inflam
matory cells. Islet cell hyperplasia
was seen in several areas (Fig. 2).
No mitotic figures or abnormalities
were seen on electron microscopy.
The islets showed positive immunostaining for neuron-specific
enolase and chromogranin (using

T a b le 1. P re lim in a ry In v e s tig a tio n s
Finding

In v e s tig a tio n
S to o l c u ltu re s

N e g ative , in c lu d in g

S m a ll-b o w e l series and b a riu m e n e m a
G a s tro d u o d e n o s c o p y , s ig m o id o s c o p y , c o lo n o s c o p y
S m a ll- a n d la rg e -b o w e l b io p s y and b io p s y c u ltu re s
C o m p u te d to m o g ra p h y o f to ta l b o d y
A o r tic a n g io g ra p h y w ith s e le c tiv e c a th e te riz a tio n o f c e lia c tru n k and
s u p e rio r m e s e n te ric a rte ry
T h y r o id fu n c tio n te s ts
S e ru m c o rtis o l le v e ls (a m and p m )
R e p e a te d u rin e to ta l m e ta n e p h rin e , v a n illy lm a n d e lic a c id and
5 -h y d ro x y in d o le a c e tic acid m e a s u re m e n ts

N o rm a l
N o rm a l
See te x t
M ild fa tty liv e r

Clostridium difficile

somatostatin analogue was gradual
ly decreased, so that by August
1988, at which time she was taking
250 tig twice daily, the diarrhea had
decreased to 30 m l/d. Repeated
EHA found serum GRP and sub
stance P to be markedly elevated
(Table II), but the PP level had
returned to normal. Neurotensin
levels were moderately elevated.
In September 1988, she was ad
mitted to hospital with sudden tem
perature (39°C) and chills, due to
TPN catheter sepsis with Candida
albicans. The Hickman catheter was
removed, the fever resolved rapidly
and she was discharged eating oral
ly, on somatostatin analogue 100
Hg twice daily. Subsequently, the
analogue was decreased to 50 tig
twice daily, and when last seen in
April 1989 she was having soft,
formed stools.

Discussion
The continuous diarrhea of more
than 2 L /d while fasting and a
stool osmotic gap of 12 mOsm/kg
substantiate that abnormal intesti
nal secretion was responsible for
this diarrhea. The lack of substan
tial improvement with steroid thera
py contrasts with the results ob-

N o rm a l
N o rm a l
N o rm a l
N o rm a l

T a b le li. E n d o c rin e H o rm o n a l A ssa y (E H A )
1988

1987
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V a s o a c tiv e in te s tin a l
p o ly p e p tid e
P a n c re a tic p o ly p e p tid e

< 30
< 31

< 30
268
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887

< 31
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S o m a to s ta tin
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<31
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714

< 31
263
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435

6010

5590

1350

3050

7710
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1 2 .5
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37

G a s trin -re le a s in g p e p tid e
C a lc ito n in
G a s trin
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< 31

Aug

S ept

N o rm a l,
p g /m l

< 170
< 150
< 100
< 140
< 100
< 500
< 100
< 50

FIG. 1. Upright film showing air-fluid
levels and poverty of gas in colon.

SECRETORY DIARRHEA WITH ELEVATED GRP

tained by Priest and Alexander,7
who used steroids in the manage
ment of diarrhea due to islet cell
tumours with good results.
Elevated PP levels raised the sus
picion of a pancreatic apudoma.8
The clinical picture and electrolyte
values on admission as well as the
picture suggestive of intestinal ob
struction raised the suspicion of
vipoma,9 but the normal level of
VIP ruled out this diagnosis. In
some cases of Zollinger-Ellison
syndrome, the diarrhea may precede
the ulcer symptoms by up to 8
years,10 but in our patient the nor
mal serum gastrin level ruled out
this diagnosis.
Nishiyama and colleagues11 de
scribed a patient with refractory
watery diarrhea and hypokalemia
due to islet cell hyperplasia and
increased immunohistochemical re
activity to serotonin. We, thus, sug
gest that in our patient the islet cell
hyperplasia with hypersecretion of

GRP and of substance P (primarily
or secondarily to GRP) was respon
sible for the diarrhea, since both
GRP and substance P stimulate gas
trointestinal motility. Moreover,
substance P stimulates water and
electrolyte secretion.10 However, be
cause the diarrhea existed before
the elevation of these hormones,
the hyperplastic pancreas or an en
docrine tumour elsewhere was like
ly secreting other unknown hor
mones, which were responsible for
the diarrhea and pancreatic hyper
plasia by direct action or by increas
ing GRP secretion. This hypothesis
agrees with that of Bostwick and
Bensch12 who found positive GRP
staining in most neuroendocrine tu
mours and concluded that GRP
should be used as a marker for
these tumours.
Woltering and associates2 de
scribed a case of insulinoma and a
case of glucagonoma with mild ele
vation of secondary peptides (GRP,

FIG. 2. Area showing hyperplasia of islet cells (arrows) (hematoxylin and eosin,
original magnification X 400).

PP, substance P and neurotensin);
however, in our patient the normal
levels and the negative immunostaining for glucagon, gastrin, VIP
and serotonin ruled out these diag
noses. Furthermore, in our patient
the GRP levels were much more
elevated than in Woltering’s cases.2
Our decision to remove the body
and tail of the pancreas agrees with
the recommendation of Verner and
Morrison1 and others11 that subtotal
pancreatectomy should be per
formed if laparotomy reveals a
grossly normal pancreas but no
other site of tumour, because these
tumours could be tiny and detect
able only by histologic examination.
Somatostatin analogue, SMS
201-995, is a synthetic octapeptide
with a much longer half-life than
naturally occurring somatostatin
and can be active when given sub
cutaneously.1314 It effectively treats
the clinical manifestations of hor
monal excess caused by neuroendo
crine tumours of the gastro-enteropancreatic axis, by decreasing blood
flow and reducing all gastrointesti
nal secretions. It also affects water
and electrolyte transport in the
small intestine toward absorption
and decreases the release of gut
hormones.2'13”16 The latter effect
could explain the decrease of PP
after the administration of SMS
201-995. The dose was increased
until a substantial beneficial effect
was achieved at 1000 n g twice daily
and this agrees with the action of
Ellison and colleagues14 who also
increased the dose until a desirable
effect was achieved.
In summary, in our patient no
tumour and no elevated primary
peptide was found, but the GRP
levels were markedly elevated ac
companying islet cell hyperplasia.
We conclude that hypersecretion of
GRP was probably responsible for
this diarrhea.
The authors are indebted to patholo
gists Kalman Kovacs, Segundo Mariz
CJS, VOL. 33. NO. 2. APRIL 1990
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and Fred Harris, and to gastroenterolo
gist Joseph G.D. Anderson for valuable
assistance and also to Thomas M. O’Dorisio, Ohio State University in Colum
bus, for the hormonal analyses.
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SESAP VI Critique
Items 82-84
The sudden onset and severe pain associated with a perforated duodenal ulcer usually cause the patient to seek
medical attention shortly after the development of symptoms. Simple ulcer plication is adequate and safe
treatment for the acute problem. Both retrospective and prospective studies indicate a high recurrence rate,
however, especially for patients with a long-standing history of ulcer disease. Numerous studies show a
reduction in recurrence, morbidity, and mortality when definitive procedures are performed in good-risk patients.
In a recent prospective randomized double-blind trial, 35 patients with simple closure had a recurrence rate of
63% versus a recurrence rate of 3.8% for 24 patients randomly assigned to undergo simple closure plus proximal
gastric vagotomy. The higher recurrence rate and higher morbidity often associated with simple closure may be
attributed to the procedure being performed in poor-risk patients. However, an immediate, nonresective
definitive operation such as proximal gastric vagotomy can be both safe and effective for patients who have
perforations associated with chronic duodenal ulcer disease. Although other definitive procedures to manage
peptic ulcer disease have been described, the low mortality and morbidity associated with proximal gastric
vagotomy make this procedure appealing. Several reports indicate that the long-term ulcer recurrence rate after
proximal gastric vagotomy is in the range of 10% to 20%.
82[B]83[B]84[A]
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Perforated Duodenal Ulcer in the Elderly
Patient
N. Werbin, MD; H. Kashtan, MD; I. Wasserman, MD; T. Wiznitzer, MD, FACS

Acute perforation of a duodenal ulcer in a patient over of 70 years of age is
associated with a high death rate. During a 10-year period, 35 such patients were
operated on; in all omentopexy was performed. Two courses of the disease were
observed: the first (19 patients) was defined by acute disease of less than 24 hours’
duration preceding surgery; the second (16 patients) was of longer duration,
starting with various abdominal complaints and presenting more severely only after
the first 24 hours. Postoperative death rates were 0% in the first group and 50% in
the second. Other factors that were studied, including diabetes mellitus, presence of
concomitant malignant diseases and intake of ulcerogenic drugs, had no significant
effect on the outcome in these patients.

Chez les personnes de plus de 70 ans, les perforations aigues d’ulceres duodenaux
sont reliees a un fort taux de mortalite. Au cours d’une periode de 10 ans, 35
patients repondant a cette description ont ete operes; une omentopexie fut pratiquee
dans tous les cas. La maladie a offert deux tableaux cliniques differents. Dans le
premier cas (19 patients), on a observe une atteinte aigue apparaissant moins de 24
heures avant l’operation; dans le deuxieme cas (16 patients), Devolution se fit sur
une plus longue periode, debutant par divers malaises abdominaux qui s’aggraverent seulement apres les premieres 24 heures. Le taux de mortalite postoperatoire
fut de 0% dans le premier groupe et de 50% dans le second. Chez ces patients, les
autres facteurs etudies, dont la presence de diabete sucre, d’un cancer ou la prise de
medicaments ulcerogenes, n'ont montre aucune influence significative sur Tissue de
la maladie.

ree perforation of a duodenal
ulcer is an emergency that
should lead to surgery within
hours. Time is an important factor
both in survival and in the selection
of a surgical procedure.1 There is
still debate2-3 over the proper surgi
cal approach, that is omentopexy or
a definitive, acid-reducing proce
dure, but it is relevant only if the
patient’s condition is stable. There

F

can be no such a debate when the
patient is old, suffers from possibly
life-threatening diseases and pres
ents late in the course of acute
illness. In these instances, a short,
life-saving procedure, omentopexy,
is indicated.4
In a retrospective study we re
viewed all patients over the age of
70 years who were operated for
perforated duodenal ulcer in our
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Patients and Methods
During the 10-year period 35
patients over the age of 70 years
were operated for free perforation
of a duodenal ulcer. There were 18
men and 17 women and the mean
age was 77.5 years (range from 70
to 94 years) (Table I).
Nine patients had a history or
evidence of malignant disease (ex
cluding the upper gastrointestinal
tract) and four of them were being
treated for their malignant disease
at the time of admission. Seven
patients had diabetes mellitus and
seven had been treated with ulcero
genic drugs before the perforation
occurred.
Nineteen patients underwent op
eration within 24 hours of the onset
of pain or other symptoms; the
other 16 were operated on after
more than 24 hours. All patients
underwent omentopexy. Seven had
an additional gastrostomy.
The results were analysed by the
X 2 and Student’s t tests.

Results
No breakdowns in the omen
topexy repair were observed. The
overall death rate was 22.8% (8 of
35), and included one patient who
was discharged apparently in good
condition but was readmitted severCJS, VOL. 33, NO. 2, A P R IL 1990
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Table I. The Influence of Time and Sex on Operative Death Rate of Perforated Duodenal Ulcer in
the Elderly Patient
Male

Female
Deaths

Time, h

No.

%

No.

%

_

Totals
Deaths

No.

%

Deaths

No.

%

No.

%

No.

%

_

_

<24
>24

11
7

61.2
38.8

0
3

42.9

8
9

47.1
52.9

0
5

55.5

19
16

54.3
45.7

0
8

50.0

Totals

18

100.0

3

16.6

17

100.0

5

29.4

35

100.0

8

22.8

al days later in septic shock origi
nating from a urinary tract compli
cation. The other causes of death
were acute myocardial infarction
(two), pulmonary embolism (one),
massive pneumonia (one) and sepsis
(three cases).
Five (29.4%) of 17 women died
compared with 3 (16.7%) of 18 men
(NS). The mean age of the women
who died was 82.6 years and of the
men 75 years (NS).
Three (33.3%) of nine patients
with concomitant malignant diseas
es died compared with 5 (19.1%) of
the 26 patients without malignant
disease (NS).
Two (28.6%) of 7 patients who
had taken ulcerogenic drugs before
admission died postoperatively com
pared with 6 (21.4%) of the 28
patients who had not taken these
drugs (NS). Three (42.9%) out of 7
diabetic patients died postoperative
ly compared with 5 (17.9%) of the
28 nondiabetic patients (NS); all
deaths were in those in whom the
time between the onset of symp
toms and surgery was longer than
24 hours — a death rate of 50%.
There was no death in patients who
were treated within 24 hours from
the onset of symptoms (p < 0.001).
More women than men were op
erated on longer than 24 hours
from the onset of the disease — 9
(52.9%) of 17 and 7 (38.9%) of 18,
respectively.

Discussion
More than one-third of patients
144
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with acute perforation of an ulcer
are elderly,5 and their relative num
ber will probably increase in the
future, due to aging of the popula
tion.
From our experience with perfo
rated ulcers in elderly patients, we
can suggest two hypothetical
courses of the disease. The first,
and the more benign one, consists
of acute free perforation that leads
the patient to seek early medical
help, resulting in early surgical in
tervention and a low death rate (0%
in our series). The second course
begins with a clinical picture that
does not cause the patient to seek
help immediately — perhaps a
sealed perforation with localized
peritonitis that only in a later stage
progresses to reperforation and ad
mission to hospital with severe dif
fused peritonitis. We cannot prove
this assumption, but most of the
patients who were admitted late in
the course of their disease described
a mild gradual onset of pain in
contrast to those admitted within
few hours.
Boey and colleagues1 pointed out
three risk factors that predict the
outcome of surgery in perforated
duodenal ulcer. According to their
series, in the presence of major
medical illness, preoperative shock
and long-standing perforation, the
postoperative death rate may reach
100%. We had a high death rate
(50%) that was related only to one
risk factor. Therefore, these pa
tients should be carefully assessed
to determine the feasibility of sur
gery. Alternatives to surgery in the

management of acute duodenal
ulcer perforation are well known,16
and in some patients these might be
the treatment of choice.
The course of the disease for
diabetic patients in our series was
not more severe, as is recognized in
other acute diseases such as chole
cystitis or appendicitis.7
We did not compare definitive
surgery with omentopexy and we
do not have any follow-up data to
suggest that a definitive procedure
would have been more appropriate,
but we can rely upon the literature8
and upon our own immediate good
results to suggest that no more
than minimal surgery is indicated in
these patients.
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Dermatobia hominis Myiasis
Masquerading as an Infected Sebaceous
Cyst
Drew B. Schembre, MD;* Charles R. Spillert, PhD;* M. Yusuf Khan, MD;f
Eric J. Lazaro, MD, FACS, FRCSCt
In an apparently routine case, what appeared to be infected sebaceous cysts of the
scalp turned out to harbour botfly larvae imported from a tropical country. Although
the parasite Dermatobia hominis is not indigenous to the United States, cutaneous
myiasis caused by the fly is fairly common in Central and South America, and
several cases have been reported in people returning or emigrating from these
regions. The authors therefore suggest that infection resulting from D. hominis
invasion be considered in persons who present with furuncular lesions and give a
history of travel to endemic areas.

Dans ce cas apparemment sans histoire, ce qui semblait etre un kyste sebace infecte
du cuir chevelu s’avera contenir des larves de mouches de la famille des Oestrides
contractees dans un pays tropical. Bien que le parasite, le Dermatobia hominis, ne
soit pas indigene aux Etats-Unis, la myiase cutanee causee par cette mouche est
relativement frequente en Amerique Centrale et en Amerique du Sud, et plusieurs
cas ont ete signales chez des personnes revenant ou emigrant de ces regions. Les
auteurs suggerent done d’entretenir la possibility d’une infestation a D. hominis
chez les personnes porteuses de lesions furonculeuses, dont l’anamnese revele un
voyage dans une region endemique.

he parasite Dermatobia hominis
is not indigenous to the United
States, but cutaneous myiasis
caused by it has been seen in per
sons returning or emigrating from
indigenous areas of Central and
South America. We describe a case
in which the parasite was found in
sebaceous cysts at the time they
were surgically excised.

T

Case Report
A 33-year-old man

presented

complaining of two “bumps” on his
scalp which had grown slowly and
had become increasingly painful
over several days. He noted that
they itched constantly and had re
cently begun to discharge clear yel
low fluid. He did not remember
being bitten by insects or receiving
any injury to the area. He denied
any constitutional symptoms such
as fever, chills, lymphadenopathy or
weight loss, and indicated that his
health was otherwise excellent.
Four weeks earlier, he had returned
from a vacation to Belize, a small
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country on the Gulf coast of Central
America.
Physical examination was re
markable only for two round, raised
lesions, 1 to 2 cm in size and about
2 cm apart, on the superior right
parietal area of the scalp. The
lumps were uniformly tender, ery
thematous and oozed serosanguineous fluid.
Radiologic studies of the head
gave normal results. The initial di
agnosis was infected sebaceous
cysts and incision and drainage of
the cysts was scheduled. Under
local anesthesia, a small incision
was made over each cyst. In both
lesions there was no cheesy materi
al but, instead, two fragments of
firm, dark-red tissue, one measur
ing 2 cm in diameter, the other 1
cm, which were easily removed. The
specimens were submitted for histopathological examination. The
wounds were left open and dress
ings applied. Tissue samples were
later reported as larvae from the
human botfly Dermatobia hominis
(Fig. 1).

Discussion
Although Dermatobia hominis is
found throughout South and Cen
tral America, in North America,
furuncular myiasis caused by this
insect remains a disease imported
by immigrants and international
travellers.1 Over the past 10 years,
only a few cases of botfly myiasis
CJS. VOL. 33, NO. 2. APRIL 1990
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have been reported in North Ameri
ca. As in our case, due to the rarity
of this affliction, it is almost always
initially diagnosed as an infected
cyst.1-3
Dermatobia ho minis, better
known as the human botfly, is a
comparatively large, winged insect,
15 to 18 mm long, having a yellow
face, dark-blue thorax and a metall
ic-blue abdomen. The term “human
botfly” is a misnomer, for although
the fly occasionally affects humans,
it is more commonly found in do
mestic and wild animals.4
The life cycle of D. hominis is
interesting in that the female does
not bring her eggs directly to the
host, but instead captures a mos
quito or other blood-sucking ar
thropod and glues a batch of 14 to
25 ovoid eggs to its abdomen. The
mosquito seems to be the favourite
vector of the Central American bot
fly, while its southern cousins pre
fer as their intermediaries flies that
bite, such as Stomoxys and Siphona, or even ticks. When the
mosquito or fly lands on a warm
blooded host, the larvae emerge and
invade the skin. The puncture sites

FIG. 1. Larva of Dermatobia hominis
which was removed from lesion (origi
nal magnification X 37.5).
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created by the vector usually pro
vide the portals of entry, although
the larvae are capable of burrowing
into the skin on their own. While
penetration often takes less than 1
hour, the larvae can remain viable
for up to 20 hours. Development
requires from 46 days to 3 months,
after which the larvae work their
way out of the skin and fall to the
ground to pupate in the soil.5
Hands, ankles, head and other ex
posed areas are most commonly
involved, but larvae have been re
ported in such obscure places as the
spermatic cord and in the left hemi
sphere of an infant, where the para
site presumably settled after migrat
ing through a patent anterior fontanelle.3-4
Symptoms may present as early
as the first week or may go unno
ticed for many days. Dermatobia
hominis invasion commonly pres
ents as one or more small raised
lesions which resemble mosquito
bites. Patients usually first experi
ence mild pruritis, which, with time,
becomes increasingly severe, partic
ularly at night. By the third week,
the site may resemble a small furun
cle which exudes a moderate
amount of serous or serosanguineous fluid. As the larva continues to
grow, local destruction of tissue
and production of toxic byproducts
cause throbbing pain and muscle
soreness, in addition to nearly cons
tant pruritis. Actual movement and
rotation of the parasite may cause
excruciating pain.4 By the time
symptoms compel the patient to
seek medical attention, the lesion
frequently resembles a local pyo
genic infection. Associated lym
phangitis or lymphadenitis may oc
cur, although constitutional symp
toms, if present at all, are usually
mild.1
On close observation, the posteri
or end of the larva can often be
seen protruding through the skin
opening which it must keep patent

in order to breathe. On Gram’s
staining of the drainage from this
opening many polymorphonuclear
leukocytes and specks of ambercoloured fecal material are often
seen but rarely is there any superin
fection.1 The mature larvae measure
18 to 24 mm in diameter and have a
characteristic inverted flask shape.
Before the larvae emerge, the
swollen lesion may attain the size of
a ping pong ball, but emergence
itself rarely involves any sensation.5
Traditional methods for removing
the parasite involve blocking the
larval air supply with tobacco juice,
butter or mineral oil to stimulate
premature emergence.35 However,
particularly when the larva is dead,
a different technique is advisable.
Injection of lidocaine or other aque
ous anesthetic into and around the
lesion anesthetizes both the area
and the parasite. After several min
utes, a small linear incision can be
made to expose the larva, which
may then be removed with forceps.
The wound should then be irrigated
thoroughly with sterile saline. If no
infection is evident, the wound may
be closed with interrupted dermal
sutures. If there is any suspicion of
remaining foreign material or bac
terial infection, The wound should
be left open and a dry dressing
applied tightly.5
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HISTORY OF SURGERY

T w o Heroes of the Class of Onety-Seven:
Part II
Peter B. Samuels, MD, MSc, FRCSC, FACS
Frederick Banting and Norman Bethune were linked in time, place of birth, as
classmates in medical college, veterans of World War I and heroes to different
worlds. Both were surgeons, sharing the decisiveness that is characteristic of the
profession. Both had their surgical ambitions frustrated. Banting, a failed
orthopedist, was sidetracked to research; Bethune, a successful surgeon inactivated
by tuberculosis, was directed by his interest in his disease to thoracic surgery.
Frustrated in his battle for socialized medicine, Bethune went to war against the
Fascists in Spain and the Imperialists in China. Banting discovered insulin, but did
little else in original research. However, he organized research in Canadian
universities which studied pilot safety in air warfare in World War II.
The two heroes died within 2 years of each other, Bethune of an infection
contracted at surgery on wounded Chinese soldiers and Banting in a plane crash
while on a secret mission carrying his research results to Great Britain.

Frederick Banting et Norman Bethune partageaient plusieurs points communs: nes
au meme moment et dans la meme region, ils devinrent compagnons de classe a la
faculte de medecine, veterans de la premiere guerre mondiale et heros de deux
mondes differents. Les deux etaient chirurgiens, partageant l’esprit de decision qui
characterise la profession. Les deux virent leurs ambitions de chirurgiens deques.
Banting, un orthopediste rate, devia vers la recherche; Bethune un chirurgien qui
avait du succes mais qui avait ete arrete par la tuberculose, se dirigea, consequence
de son interet pour sa maladie, vers la chirurgie thoracique. Frustre dans sa bataille
pour socialiser la medecine, Bethune s’engagea dans la guerre contre les fascistes
d’Espagne et les imperialistes de Chine. Banting decouvrit l’insuline, mais il ne
contribua pas beaucoup plus a la recherche innovatrice. Toutefois, il organisa dans
les universites canadiennes la recherche sur la securite des pilotes engages dans les
combats aeriens au cours de la deuxieme guerre mondiale. Ces deux heros
moururent a 2 annees l’un de l’autre, Bethune d’une infection contractee au cours
d’une operation sur un soldat chinois, Banting dans l’ecrasement de son avion, en
mission secrete, alors qu’il allait livre les resultats de ses recherches en Grande-Bretagne.

part of this sto
I nry,thebothpreceding
Banting and Bethune
had gone beyond their medical call
ing to enter a political arena. In this
part, Bethune enlists his talents in

the battle against fascism, leading
him to active work in conflicts in
Spain and China. Banting rejoins
the Canadian Army but is not per
mitted to join the action he seeks
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and instead is put in charge of
Canada’s military medical research.

Blood to the Front
In July 1936, the outbreak of
civil war in Spain gave Bethune the
opportunity to fight directly against
Fascism and, at the same time,
provide care for many war casual
ties. He immediately offered his
services to the Canadian Red Cross
but was rebuffed. There was no
intention on the part of the Red
Cross to afford aid to the Republi
can government in Spain. Bethune
read in a Canadian socialist maga
zine of a plan to establish a Spanish
hospital and medical aid committee,
so he left for Toronto the next day,
after wiring the editor of the publi
cation that he was coming. He
found the idea that the editor had
proposed had no basis in fact. But
since he was looking for money to
go to Spain, he wasted no time.
Working with the editor, he inter
ested prominent antifascists of var
ied political hues and worked with
them to form the Committee to Aid
Spanish Democracy. Bethune com
mitted himself to this enterprise. He
was, by this time, a Communist
party member. He resigned his posi
tion at Sacre-Coeur Hospital in
Montreal in October 1936 and
sailed from Quebec City with a
quantity of medical supplies and
money and with an introduction to
the Spanish prime minister, Cavellero. His battle with the establishCJS. VOL. 33. NO. 2, A P R IL 1990
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ment had become a full-time battle
against Fascism.
In early November, Bethune ar
rived in Madrid and met with his
contact, Henning Sorensen, a Cana
dian journalist. Not long after, he
was interrogated by the military
police as a suspected Fascist and
possible fifth columnist. Bethune’s
gestalt — British upper class mili
tary moustache, close cropped hair
— was not that of a revolutionary.
Bethune soon evaluated the state
of the military medical service. It
was too disorganized to afford him
a significant place. A glaring defi
ciency in their set up was at once
apparent to him. What they needed
was a blood transfusion service, a
bank filled with typed blood from
volunteers. He contacted the Span
ish authorities who received his idea
with enthusiasm, so he left Spain
for France and England where he
collected equipment and learned the
latest techniques in blood typing,
storage and transfusion.
On his way back, the French
customs extracted a heavy duty on
the equipment. When Bethune con
tacted the Canadian Embassy he
was sabotaged by diplomats who
declared that the Committee to Aid
Spanish Democracy had no official
status in Canada and was a Com
munist organization. Bethune was
furious and did not hesitate to name
names when he returned to Canada
after his Spanish service.
In December, just a month after
his first arrival, the Servicia Canadiense de Transfusion de Sangre
was under way. It grew so rapidly
that within months his service sup
plied blood to every military sector.
One great innovation was to bring
the blood to the wounded soldier in
the field or in the casualty dressing
station, saving many lives that
would have been lost during a pro
longed evacuation to a military hos
pital. Another innovation was to set
up a roster of regular civilian do
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nors of all blood types so that a
supply of blood was always on
hand. An extension of his idea of
bringing blood to the wounded sol
dier in the field were the medics of
World War II. His ideas were em
braced by the western allies but
rejected by the Fascist forces. The
paramedic ambulance services of
the present day are extensions of
Bethune’s original ideas. The Israeli
army has carried Bethune’s idea to
its logical extension. They send
physicians into the conflict with
each fighting group.
Bethune’s ambulances (he drove
one of them at every opportunity)
aided in the evacuation of civilians
from the advancing front. He loved
danger and for him a brush with
death was particularly exhilarating.

Revolutionary War Surgeon
In 1937, the military incorporat
ed his previously independent orga
nization into a general transfusion
service with Bethune under the di
rectorship of two Spanish doctors.
Bethune had become a star with the
foreign press and that stirred re
sentment. His presence became an
embarrassment to the Canadian
Communist bureaucracy and he was
prevailed upon to return to Canada
to make a fund-raising tour.
He was a forceful speaker who
had a just and urgent cause. Be
thune’s speaking tour spanned Can
ada and the United States and was a
great success. But he was a mixed
blessing for the doctrinaire Commu
nists who exploited his reputation
and fund-raising abilities but feared
his unorthodox approach and his
intolerance of party discipline.
In 1937, Japan invaded China, a
country that was already a battle
ground with the Kuomintang under
Chang Kai Shek fighting both the
various warlords and the Commu
nists under Mao Zedung. Bethune

recognized that this revolutionary
situation in the most populous
country in the world was a momen
tous event. He convinced the disen
chanted Canadian and American
Communists to arrange for him to
go to China so that he could set up
medical care for Mao Zedung’s
forces. When his plan was ap
proved, Bethune used his persua
sive powers to obtain funds for the
expedition from wealthy liberals in
the United States and Canada. As
soon as money became available, he
secured supplies which he knew
from experience would be essential
in setting up a medical corps.
Bethune’s supporters arranged
for a Canadian nurse, Jean Ewen,
who had worked at mission hospi
tals in China and was sympathetic
to the Communist cause, and an
American doctor, who proved to be
an alcoholic, to accompany him. On
the Pacific voyage, the American
doctor, who for some reason was
placed in charge of the funds, drank
most of the money away. When the
party arrived at Hong Kong, he left,
taking the remaining money with
him, for he had had no intention of
making the difficult and dangerous
trip to join Mao’s rebel forces in the
north of China.
Undeterred, Bethune and Jean
Ewen set off on the long journey to
the north. They flew from Hong
Kong to Hankow and from there
started out by train to join Mao’s
forces in Yenan. Jean was subjected
to a baptism of fire shortly after
they left, but stood up to it well,
reassured by the ever-brave Be
thune. Forced from the trains by
Japanese bombing, they progressed
slowly on foot and by mule train
encountering strafing attacks by Ja
panese bombers. Frequently under
bombardment by Japanese artillery,
it took them 3 months to travel the
800 miles to Sian.
Bethune tended to wounded sol
diers and civilians as best he could.

CLASS OF ONETY-SEVEN

On Mar. 3, 1938, they made con
tact with the 8th Route Army in Ho
Chin. Staying just ahead of the
invading Japanese, they arrived in
Sian on Mar. 19 after walking 225
miles, stopping only to rest and
acquire supplies. A week after their
arrival they set out for Yenan, the
headquarters of the Communist
forces. They reached them on Mar.
30. Shortly after they arrived, Bethune was summoned to a historic
meeting with Mao Zedung.
Mao was the younger of the two
by 3 years. Despite their different
native cultures there were similari
ties between the two. Both were
from farm country and had been
rebellious in their student years.
Despite this they both became
teachers. Mao came early to his
battle with the establishment and
led a revolutionary movement
against it. Bethune had made a
tentative approach and was gradual
ly transformed from an eccentric

En route to Chin-Ch'a-Chi with Dr. Brown a n d soldiers.
Young Ho is on top of the truck. When the truck was stuck,
Bethune jum ped out of the cab and, up to his ankles in the
m ud, began to push. The C hinese were am azed. They were
accustomed to foreigners w ho let the C hinese do the dirty'
work.

FIG. 1. Bethune and Brown in China.
(Reproduced by permission from Stew
art R: The Mind of Norman Bethune,
Fitzhenry & Whiteside, Toronto,
1977 .)

conservative to a dedicated Commu
nist. Both were charismatic, literary
and poetic. Mao, of course, was a
master of Marxism and practical
politics, whereas Bethune was ideal
istic and interested in politics only
when it enhanced his personal
goals.
Bethune convinced Mao that Bethune’s place was in the north with
the troops who were in direct con
tact with the Japanese. It was ar
ranged that he would be sent to
join the troops in the Chi border
region. He worked in Yenan for
several months taking care of
troops. Dr. Richard Brown, a sur
geon from an Anglican mission,
volunteered to join him. They left
by truck carrying supplies that Be
thune had left in Hong Kong and
that Brown had retrieved and
brought to him (Fig. 1). When
Bethune arrived at the front, he
immediately established headquar
ters and began to set up facilities
for the care of vast numbers of
troops and civilians under his care.
Bethune was a veteran of two
wars. World War I was essentially a
static war with opposing front lines
and movement of wounded to hos
pital establishments at the rear. In
the Spanish Civil War there was
more mobility. But nothing pre
pared Bethune for the extreme mo
bility of guerilla warfare. He con
vinced the Chinese military to help
him build a model hospital only to
see it overrun and destroyed by the
Japanese in the tidal flow of the
forces.
However, Bethune was pragmatic
and quick to react to a new situa
tion. He devised mobile operating
equipment that could be packed up
like a visiting circus and moved on
mule and horseback to the next site
where it was needed and could
quickly be broken down and taken
away when necessary.
His acceptance and his influence
on the Chinese devolved from his

character. Peasants who made up
the 8th Route Army could not
speak to Bethune, but they could
see that when a truck bogged down
in the mud Bethune’s shoulder was
there helping to free it. They saw
that this Caucasian who saved Chi
nese lives through his surgical skill
was learned, inventive and a natural
leader and dressed in the clothes of
an ordinary Chinese soldier and ate
the food that they ate.
Bethune lived the role of a revo
lutionary hero to the hilt. His workfilled days and the sheer necessity
of his presence spared him from the
usual conflicts in which bureaucra
cy embroiled him. Faced with an
impossible situation he was able
through the power of his personali
ty and originality to forge the be
ginnings of medical care for the
rag-tag Chinese communist troops.
Filth was a major enemy and he set
his helpers to clean up the sur
roundings, the sick, the wounded
and themselves. He combatted med
ical ignorance by giving illustrative
lectures and by precept and exam
ple. He set up schools for practical
nursing, wound tending and mili
tary surgery. Within months he was
able to train cadres who could
staunch hemorrhage, clean wounds,
splint limbs and salvage the sal
vageable by primitive but essential
treatment. Chinese physicians of
varying levels and backgrounds he
quickly trained for military surgery.
Typing away on his portable
typewriter every moment that he
could spare, he wrote texts of bat
tlefield care, nursing manuals and
operative procedures. He made do.
He had the cooperation of a fantas
tically hard-working, intelligent and
thoroughly motivated group of Chi
nese soldiers.
Bethune understood motivation
well. He introduced wound stripes
and widow’s medals, and letters of
condolences were sent to the rela
tives of the fallen.
CJS, VOL. 33, NO. 2, APRIL 1990
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With his mobile operating unit he
and Dr. Brown stayed close to the
casualties. They operated long
hours on the wounded, soon ex
hausting their precious supply of
anesthetics, antiseptics, suture
materials and dressings. Brown had
another commitment and after 3
months he had to leave and Bethune was alone. Bethune wrote to
a friend, “We are completely sur
rounded by Japanese, north, east,
west and south. They hold all the
towns on the railway. In this great
area of 13 million people with
15 000 armed troops I am the only
qualified doctor.” 1 On one occasion,
Bethune operated for 69 consecu
tive hours. His letters to his friends
pleading that he be sent magazines
and books underlines his almost
complete isolation. In another letter
he wrote, “ I don’t think I have been
so happy in a long time. I am
content. I am doing what I want to
do. Why shouldn’t I be happy? See
what my riches consist of. First, I
have important work that occupies
every minute of my time from 5:30
in the morning to 9:00 at night. I
am needed. More than that, to
satisfy my bourgeois vanity I have a
cook, a personal servant, my own
house, a fine Japanese horse sad
dled. I have no money nor the need
of it. I am treated like a kingly
comrade. Everything is given to me.
No wish, no desire is left unful
filled.”2-3
The greatest legacy that Bethune
left to the Chinese was the impor
tance of good technique. He
stressed the importance of patient
care and produced manuals on how
to do it couched in terms that his
sparsely educated soldiers could un
derstand.
It is probable that Bethune’s
demonstrations of the worth of
properly trained paramedical per
sonnel led to the use and accep
tance of the “barefoot doctors”
who minister to the immediate
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needs of the commune in China
today yet recognize and refer more
serious cases.
The constant work, primitive liv
ing conditions and inadequate food
aged and weakened Bethune. Pho
tographs taken of his arrival in
China in the winter of 1938 show a
sturdy man in middle years with a
distinguished bearing. One and a
half years later he seemed frail and
elderly. In this weakened state, op
erating without gloves on, in in
fected cases, his fingers often be
came infected and finally, late in
October, one infection led to septi
cemia and death on Nov. 12, 1939.
His death was commemorated 5
weeks after he died in an essay by
Mao Zedung. This was the begin
ning of his enshrinement in the
pantheon of heroes of the Chinese
people. His passing was noted in
Canada only by those nearest and
dearest to him. His heroism was
recognized by the Chinese at once
and, in 1940, a splendid tomb and
memorial park were dedicated to
him. He is commemorated in a
number of postage stamps showing
him at work operating; his biogra
phy, Pai Ch’Uen is available on
every newsstand in China. In 1952,
his story was told to the western
world by Ted Allen and Sidney
Gordon in a book The Scalpel, the
Sword* and the Canadian govern
ment has belatedly and grudgingly
acknowledged his contributions.
The Bethune Foundation, with
headquarters in Montreal, was es
tablished to commemorate Bethune
and perpetuate his ideals.
While Bethune had been strug
gling to initiate antisepsis in filthy
troops and filthy habitations and to
provide primitive wood and iron
splints for broken limbs, Banting
was applying his practical mind to
the organization of research to
make flying higher and faster safe
for the pilot. The limiting factor in
the speed and the maneuverability

of military aircraft was not the
machine, but the man.

The Last Adventure
The work in aviation medicine
went well. A newly devised “G” suit
was able to protect pilots from the
stresses of dives and aerobatics.
New measures against decompres
sion sickness and night blindness in
pilots had been devised. Banting
knew that his role in expediting the
cooperation of the Canadian univer
sities, which had led to these inno
vations, had been fulfilled. He want
ed to be back in the conflict; like
Bethune, he sought the camarade
rie of arms. His rapport with British
scientists was not very good. They
tended to favour Best, who had a
truly formalized training, much of it
under the aegis of British scientists.
Best had been scheduled to go and
confer with the British scientific
establishment in order to effect a
coordinated war effort, but family
problems prevented him from tak
ing this trip. Banting immediately
seized the opportunity to substitute
for Best as the emissary to the
British establishment.
It is not known if Banting fully
understood the hazards of flying
the North Atlantic in winter in a
Hudson bomber being ferried to
Great Britain. Not many of these
flights had been accomplished and
there had been three crashes. Ban
ting was nervous about the flight,
but in any case, he said his good
byes, left Toronto and waited at the
Newfoundland Air Station in the
middle of February for the plane
that was to take him to Great
Britain. While there he relaxed and
made friends with the medical and
aviation personnel at the station. To
one of them he intimated a forebod
ing he had mentioned to his friends
in Montreal and Toronto. He said,
“Wilson, I’m scared.”5 He carried
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with him on the flight no essential
data, no samples of the Canadian
“G” suit. Any number of persons
could have undertaken the trip.
Shortly after takeoff in the Hudson
bomber, Banting’s premonition
proved true. One engine failed and
the other faltered. The pilot turned
back. He ordered his three passen
gers to bail out, but Banting did not
have a parachute. Besides, the
chances of survival either in the
water or on land in the midst of a
midwinter blizzard was question
able. The plane crashed in the fro
zen waste of Newfoundland, hard
against a solitary tree in the area.
The pilot survived and two of the
three passengers died on impact.
Banting was gravely injured and
although he regained consciousness
he died 16 hours later. He made a
great effort to dictate to the pilot
the crux of the Canadian findings.
It was a futile effort, but he tried to
the last to carry out his duty.
Banting’s loss was immediately
and profoundly felt throughout
Canada and the world. For Canada,
it was especially poignant. Banting
had presented the world with a gift
whose magnitude was recognized at
once. The man and his country
were identified for all time as the
source of this bounty.
Banting and Bethune, linked in
time, place of birth, as college class
mates, veterans of World War I and
heroes to different worlds, ended
their lives while relatively young
and in possession of all their pow

ers. They died in the pursuit of
goals which were all-important to
each. Professor Bliss of Toronto
has suggested that the strong
Methodist upbringing of Banting
and the Evangelical ministers who
parented Bethune may have con
tributed to the fervour with which
they pursued their goals and their
dedication even to the point of
sacrificing their lives.6 Yet neither
of these men observed the conven
tional forms of the Christian reli
gion and Bethune was anti-reli
gious. As to self-sacrifices, their
letters and diaries close to their
deaths reveal a strong love for life
and continued plans on how they
were going to live it.
They were both physically tough
and proud of it, decisive, generous,
unforgiving and vindictive. They
were both fearless romantics who
were supremely pragmatic.
These men were surgeons. Sur
geons are said to have identifiable
character traits. Even the most be
nign surgeon is, in a sense, aggres
sive. On occasion they are contem
plative but they are always decisive.
In both of these men their surgical
ambitions were frustrated and their
reaction to the frustration deter
mined their great contributions. Be
thune, a successful surgeon inacti
vated by tuberculosis, was directed
by his ailment to thoracic surgery.
Frustrated by society in his battle
for socialized medicine he went to
war directly against the crystallized
enemy, the Fascist in Spain and the

Imperialist in China. Banting, after
his first peak, was an adequate but
not an exceptional research worker.
He took up the challenge of the war
against Fascism by organizing re
search to implement all-important
air warfare, then flew off to present
the results of several years’ en
deavours to his colleagues. There
are any number of emissaries who
could have been sent, but he, like
Bethune, wanted to be in the thick
of the action. Both of them never
hesitated to risk life and limb in the
pursuit of their ideals. What Leo
Eloesser wrote in memory of Be
thune can be applied to both men,
“What better end could any man
have than this fellow member of
ours who spent his life and met his
death in the service of his ideals —
Humanity and Freedom.”7
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CEFOTAN +IM /IV
(cbfotbtane disodique sterile U.S.P.)

Un choix rentable pour
un traitement parenteral aux
cephalosporines tres efficace
CLASSIFICATION THERAPEUTIQUE
Antibiotique
ACTION
Le cbfotbtane disodique est un antibiotique semi-synthbtique de la famille
des cephalosporines (cbphamycines), resistant aux beta-lactamases. Des
etudes in vitro indiquent que I’effet bactericide du cetotetane rbsulte de son
action au niveau de la synthbse de la paroi cellulaire bacterienne par inhibition
de la reticulation du peptidoglycane. Des etudes avec le cetotetane marque
au ,4C ont montre qu'au moment d'atteindre les proteines fixatrices cibles de
la penicilline (PBP) dans la paroi interne, I’antibiotique marque se lie principaiement aux PBP 3 et ensuite aux PBP 1A et 1B. Le cetotetane, comme
d'autres cbphamycines, ne se lie pas aux PBP 2.
La demi-vie d’eiimination plasmatique du cetotetane est de 3 b 4,6 heures suite
A I’administration intraveineuse ou intramusculaire. Chez les sujets normaux,
de 51 e 81 % de la dose administree sont excretes inchanges par le rein dans
les 24 heures. La principale autre voie d’eiimination est la voie biliaire.
INDICATIONS ET USAGE CLINIQUE
CEFOTAN (cetotetane disodique) est indiqub dans le traitement des infections
suivantes causees par des souches sensibles des germes specifies :
Infections urinaires causees par E. c o li et les K lebsiella (y compris K. pneu
moniae), Proteus m irabilis et Proteus A indole positif.
Infections des voies respiratoires interieures causees par Streptococcus
pneum oniae (precedemment D. pneum oniae), Staphylococcus aureus (y
compris les souches productrices et non productrices de penicillinase),
H aem ophilus influenzae (y compris les souches resistantes A I’ampicilline),
les Klebsiella (y compris K. pneum oniae) et E. coli.
Infections cutanees causees par Staphylococcus aureus (y compris les
souches productrices et non productrices de penicillinase), Staphylococcus
epiderm idis, Streptococcus pyogenes et le genre Streptococcus (b I’exclusion
des enterocoques) et E. coli.
Infections gynecologiques causees par Staphylococcus aureus (y compris
les souches productrices et non productrices de penicillinase), Staphylococ
cus epiderm idis, le genre Streptococcus (A I'exclusion des enterocoques), E.
coli, Proteus mirabilis, Neisseria gonorrhoeae, les cocci gram-positifs et les
bacilles gram-negatifs anabrobies, les Bacteroides (A I’exclusion de B. distasonis, B. ovatus et B. thetaiotaom icron).
Infections intra-abdominales causees par E. coli, les bacilles gram-negatifs
anaerobies, les Bacteroides (excluant B. distasonis, B. ovatus et B. thetaiotaom icron).
Infections des os et des articulations causees par Staphylococcus aureus.
Une culture bacteriologique doit etre faite dans le but d ’isoler et d’identifier
I’agent pathogene et de determiner sa sensibility A CEFOTAN. Le traitement
peut etre amorce avant que les tesultats de I’antibiogramme ne soient connus.
Par la suite, une fois les tesultats de I’antibiogramme connus, le traitement
doit etre adapte en consequence.
CONTRE-INDICATIONS
CEFOTAN (cetotetane disodique) est contre-indique chez les patients qui
ptesentent des reactions allergiques de type 1 (p. ex. urticaire, oedeme de
Quincke, bronchospasme ou choc anaphylactique) aux antibiotiques du
groupe des cephalosporines.
MISES EN GARDE
AVANT D’UTILISER LE TRAITEMENT CEFOTAN (cetotetane disodique), BIEN
SE RENSEIGNER AUPRES DU PATIENT POUR DETERMINER S’lLA DEjA
MANIFEST^ UNE REACTION ALLERGIQUE AU CEFOTETANE DISODIQUE,
AUX CEPHALOSPORINES, AUX PENICILLINES OU A D’AUTRES MEDICA
MENTS. CEFOTAN DOIT ETRE ADMINISTRE AVEC CIRCONSPECTION
AUX PATIENTS QUI SONT SENSIBLES A LA PENICILLINE. LES ANTIBIO
TIQUES, Y COMPRIS CEFOTAN, DOIVENT ETRE ADMINISTRES AVEC
PRUDENCE A TOUT PATIENT QUI A MANIFESTS UNE FORME QUELCONQUE D’ALLERGIE, SURTOUT AUX MEDICAMENTS. SI CEFOTAN
ENTRAiNE UNE REACTION ALLERGIQUE, EN CESSER L’ADMINISTRATION. LES CAS DE REACTIONS ALLERGIQUES AIGUES PEUVENT
NECESSITER L’ADMINISTRATION D’EPINEPHRINE ET LE RECOURS A
D’AUTRES MESURES D’URGENCE.
LA COLITE PSEUDO-MEMBRANEUSE A Et EASSOClEE A L’UTILISATION
DES CEPHALOSPORINES, YCOMPRIS CEFOTAN, (ET AD’AUTRES ANTI
BIOTIQUES A LARGE SPECTRE); PAR CONSEQUENT, IL EST IMPORTANT
DE TENIR COMPTE DE CE DIAGNOSTIC CHEZ LES PATIENTS QUI PRESENTENT DE LA DIARRHEE DUE A L’USAGE D’ANTIBIOTIQUES.
Le traitement par des antibiotiques A large spectre peut modifier la flore
intestinale normale du c6lon et ainsi favoriser la proliferation de Clostridium.
Des etudes indiquent que la toxine produite par C lostridium difficile est Tune
des principales causes de colite assoctee A I’usage d’antibiotiques.
Les cas de colite Ibgbre peuvent tepondre A I’artet du traitement seul.

Dans les cas modetes ou graves, un apport comptementaire en liquides, en
electrolytes et en proteines est indiqub. Si I’arret du traitement ne soulage pas
la colite ou si le cas est grave, I’administration orale de vancomycine constitue
le traitement de choix de la colite pseudo-menbraneuse due A C. d ifficile
associee A I’usage d'antibiotiques. D’autres causes devraient 6galement etre
prises en consideration.
PRECAUTIONS
G e n e ra te s : I’utilisation prolong6e de CEFOTAN (cetotetane disodique)
peut entrainer la proliferation de germes tesistants et de germes initialement
sensibles au medicament. La surveillance adequate des patients est essentielle. En cas de surinfection pendant le traitement, prendre les mesures
appropriees.
CEFOTAN peut etre associe A une baisse de I’activite prothrombique. Les
patients A risque sont ceux qui souffrent d ’insuffisance tenale ou hbpatique,
de carence alimentaire, les personnes Sgbes et les personnes atteintes du
cancer. Les temps de prothrombine doivent etre surveiltes chez les patients A
risque et on doit administrer de la vitamine K au besoin.
CEFOTAN doit etre administte avec circonspection chez les patients qui ont
des antecedents de maladie gastro-intestinale, surtout de colite.
II peut se produire une reaction du type disulfirame, caracterisee par des
bouffbes de chaleur, de la transpiration, des cbphalbes et de la tachycardie,
s’il ya ingestion d’alcool (bibre, vin, etc.) dans les 72 heures suivant I’adminis
tration de CEFOTAN. Les patients doivent etre mis en garde contre I’ingestion
de boissons alcoolisbes suite A Tadministration de CEFOTAN.
Les patients souffrant d'insuffisance rbnale (dont la clairance de la crbatine
est infbrieure ou bgale A 30 ml/min) doivent recevoir une posologie spbciale,
telle que recommandbe sous POSOLOGIE et ADMINISTRATION.
Interactions m bdicam enteuses
En raison du potentiel nbphrotoxique et ototoxique des aminosides, la fonction
rbnale doit etre surveillbe de prbs, particulibrement chez les patients qui
regoivent des doses blevbes d’aminosides ou qui sont sous traitement prolongb. Bien qu’b ce jour, rien de tel ne se soit produit avec I’administration de
CEFOTAN, une augmentation de ia nbphrotoxicitb a btb notbe suite A I’administration concomitante de cbphalosporines et d’aminosides. Toutefois, A ia
dose recommandbe, il est peu probable que CEFOTAN soit associb A une
augmentation de la nbphrotoxicitb.
Interactio ns mbdicam enteuses lors d ’analyses de laboratoire
Un rbsultat faussement positif de glycosurie peut se produire avec des
solutions de Benedict ou de Fehling.
Des concentrations blevbes de cbfotbtane peuvent fausser les rbsultats des
taux de crbatinine sbriques et urinaires obtenus par la rbaction de Jaffb, et
entrainer une augmentation artificielle des taux de crbatinine notbs.
G rossesse
L’innocuitb de CEFOTAN dans le traitement d e fection s chez la femme
enceinte n’a pas btb btablie. L’usage de CEFOTAN chez la femme enceinte
doit faire I’objet d’une bvaluation des avantages par rapport aux risques
possibles pour la mbre et le foetus. Des btudes portant sur la reproduction ont
btb menbes chez les rats et les si nges A des doses jusq u'b 20 fois supbrieu res
A la dose de cbfotbtane recommandbe chez I’humain et n’ont rbvblb aucune
anomalie de la fertilitb ni atteinte du foetus. Par contre, il n’existe aucune
btude comparative adequate portant sur la femme enceinte. Etant donnb que
les btudes sur la reproduction animale ne sont pas toujours representatives
de la rbponse humaine, ce mbdicament ne doit etre administrb pendant la
grossesse qu’en cas d’absolue nbcessitb.
A lla item e nt
Le cbfotbtane est excrbtb A faible concentration dans le lait maternel. On doit
administrer CEFOTAN avec prudence chez la femme qui allaite.
N ourissons e t enfants
L’innocuitb et I’efficacitb du cbfotbtane n’ont pas btb btablies chez les
enfants.
REACTIONS in d E s ir a b l e s
Lors d ’btudes cliniques, les effets secondaires suivants ont btb associbs au
traitement CEFOTAN (cbfotbtane disodique).
G astro-intestinaux ; des symptomes gastro-intestinaux se sont produits
chez 1,5 % des patients, les plus frbquents btant la diarrhbe (1 sur 80) et la
nausbe (1 sur 700).
H bm a tolog iques: des rbsultats hbmatologiques anormaux se sont produits
dans 1,4 % des cas et comprenaient de I'bosinophilie (1 sur 200), des tests de
Coombs directs positifs (1 sur 250) et de la thrombocytose (1 sur 300). Une
thrombocytopbnie et une leucopbnie transitoires ont btb notbes.
H bpatiques : une blbvation du taux d ’enzymes hbpatiques s’est produite
dans 1,2 % des cas et comprenait une augmentation de la transaminase
glutamino-pyruvique (SGPT) (1 sur 150), de la transaminase glutamique
oxalo-acbtique (SGOT) (1 sur 300), de la phosphatase alcaline (1 sur 700) et
de la lacticodbshydroxygbnase (LDH) (1 sur 700).
A lle rg iq u e s : des rbactions d’hypersensibilitb ont btb rapportbes chez 1,2 %
des patients et comprenaient des rashes (1 sur 150) et des dbmangeaisons
(1 sur 700). Au cours de la pbriode qui a suivi la mise en marchb de CEFOTAN,
des rbactions anaphylactiques ont btb notbes.
L o c a u x : des effets locaux ont btb rapportbs chez moins de 1% des patients
et comprenaient une phlbbite au point d'injection (1 sur 300) et de I'inconfort
(1 sur 500).
YM PT6M ES ET TRAITEMENT DU SURDOSAGE
ce jour, aucun cas de surdosage avec CEFOTAN (cbfotbtane disodique)
n'a btb rapportb. En cas de surdosage, traiter le sujet de fapon symptomatique.
CEFOTAN peut btre bliminb par dialyse.

POSOLOGIE ET ADMINISTRATION
POSOLOGIE : adultes: la posologie adulte usuelle est de 1 ou 2 g de
CEFOTAN (cefotetane disod ique) administtes par voie intraveineuse ou intramusculaire aux 12 heures durant 5 4 10 jours. La posologie juste et la voie
d’administration doivent etre determin6es d ’aprbs I’etat du patient, la gravity
de I’infection et la sensibilite de I'agent pathogene. Le traitement peut etre
amorce avant que les tesultats de I’antibiogramme ne soient connus.
A d m in istra tio n intraveineuse : la voie intraveineuse est preferable chez
les patients qui ptesentent une bacteriemie, une septicbmie bacterienne ou
d’autres infections graves ou 4 potentiel fatal, ou chez les patients 4 risque,
particuiierement en presence de choc avbrb ou imminent.

RENSEIGNEMENTS PHARMACEUTIQUES
Chimie
Marque de com merce :
CEFOTAN t
Denomination com mune : cefotetane disodique sterile USP
Nom chimique :
CEFOTAN est le sel disodique de [6R-(6cr, 7a ))-7[[[4-(2-amino-1 -ca rboxy-2-oxoethylidene)-1,
3-dithietan-2-ylJcarbonyl] amino]-7-methoxy-3[((1 -methyl-1 H-tetrazol-5-yl)thio] methyl]-8-oxo5-thia-1 -azabicyclo [4.2.0]oct-2-ene-2-acide
carboxylique.

GUIDE POSOLOGIQUE GENERAL DE CEFOTAN
Type d ’infe ction

Dose
quotidienne

Frequence et
voie d ’a d m inistra tion

1 44g

500 mg aux 12 heures, IV ou IM
1 ou 2 g aux 24 heures, IV ou IM
1 ou 2 g aux 12 heures, IV ou IM

>-> ►

Infections urinaires

\\
'

A*

>

Autres foyers d’infection

244 g

1 ou 2 g aux 12 heures, IV ou IM

Infections graves

4g

2 g aux 12 heures, IV

Infections k potentiel fatal

6gt1

3 g aux 12 heures, IV

t t La posologie quotidienne maximale ne doit pas excbder 6 g.
INSUFFISANCE RENALE
En presence d’une insuffisance renale, recourir 4 un schema posologique
reduit. Le tableau posologique suivant peut etre utilise.
GUIDE POSOLOGIQUE CHEZ LES INSUFFISANTS RENAUX
C lairance de la
cre atinine m l/m in.

Dose

Frequence

> 30
10 4 30
< 10

dose usuelle recommandee**
dose usuelle recommandbe**
dose usuelle recommand6e**

aux 12 heures
aux 24 heures
aux 48 heures

** La dose est determinhe par le type et la gravite de I’infection, et par la
sensibility de I’agent pathogbne.
On peut dgalement maintenir I’intervalle constant aux 12 heures mais teduire
de moitie la dose usuelle recommandbe chez les patients dont la clairance de
la creatinine est de 10 4 30 ml/min, et la teduire au quart chez les patients dont
la clairance de la creatinine est inferieure k 10 ml/min.
Si seuls les taux seriques de creatinine sont disponibles, la clairance de la
creatinine peut etre calcuiee k I’aide de la formule suivante. Les taux seriques
de creatinine doivent representer la fonction renale k un etat d ’equilibre.
C lairance de la creatinine (m l/m in ):

Hommes :

Femmes :

Unites tradltionnelles

Unites S.l.

poids (kg) x (140 - 4ge)

poids (kg) x (140 - 4ge)

72 x creatinine serique
(mg/100 ml)

0,8 x creatinine serique
(/zmol/l)

0,9 x valeur chez les hommes

Le cefotetane est dialysable et recommande pour les patients qui sont sous
hemodialyse intermittente, au quart de la dose usuelle recommandee toutes
les 24 heures entre les jours de dialyse, et k la moitie de la dose usuelle
recommandee les jours de dialyse.
Enfants
L’innocuite et I’efficacite n’ont pas

ete etablies chez I’enfant.

ADMINISTRATION
Voie intraveineuse
Pour I’administration intraveineuse intermittente, injecter en 3 k 5 minutes
une solution d’eau sterile pour injection contenant 1 ou 2 g de CEFOTAN. Le
produit peut bgalement §tre injecte k I’aide d ’un dispositif de perfusion sur
une pbriode de temps plus btendue dans le systeme de tubulures par lequel
le patient report dkjk d’autres solutions intraveineuses.
Pour ce genre de perfusion, il est preferable d ’utiliser des aiguilles k ailettes
ou des aiguilles du type utilise pour les veines du cuirchevelu. Toutefois, lors
de la perfusion de la solution contenant CEFOTAN, il est conseilte d ’interrompre temporairement I’administration d’autres solutes par la meme voie
de perfusion.
N O TE : les solutions de CEFOTAN ne doivent pas §tre ajoutees k des solutions
contenant des aminosides. Si CEFOTAN et des aminosides doivent etre
administtes Sun m§me patient, les administrer sepatement et non pas en une
seule injection mixte.
Voie intram usculaire
CEFOTAN doit etre injecte en pleine masse musculaire, dans la fesse par
exemple (gluteus maxim us). S’assurer de bien retirer legbrement le piston de
la seringue pour bviter que la solution ne sort injectee par inadvertance dans
un vaisseau sanguin.

Molecule : Ci7HisN7Na20aS4
Poids moteculaire : 619,56
Description
Poudre de couleur blanche k jaune p4le hautement soluble dans I’eau. La
solution varie de incolore k jaune selon la concentration et renferme environ
80 mg (3,5 mEq) de sodium par gramme de cefotetane actif. Le pH des solu
tions frafchement reconstituees se situe habituellement entre 4,5 et 6,5.
RECONSTITUTION
Usage in tra m u scu la ire
Reconstituer avec de I’eau sterile pour injection, de la solution saline isotonique
USP, du chlorhydrate de lidocaine k 0,5 %, ou du chlorhydrate de lidocaine k
1,0 %. Bien agiter pour dissoudre et laisser reposer jusqu’4 ce que la solution
sort claire.
Q u a n tite
Volum e
C o n ce n tra tio n
Teneur du
m oyenne
d e d ilu a n t
d ispo nible
flacon
4 a jo u te r (ml)
ap prox, (ml)
a p prox, (m g /m l)
19

2

2,5

40 0

2 g

3

4,0

500

Usage intra ve in e u x
Reconstituer avec de I’eau sterile pour injection, du chlorure de sodium k 0,9 %
pour injection ou du dextrose k 5 % pour injection. Bien agiter pour dissoudre
et laisser reposer jusqu’4 ce que la solution sort claire.
Teneur du
flacon

Q u a n tite
d e d ilu a n t
4 a jo u te r (ml)

Volum e
d ispo nible
ap prox, (ml)

C o n ce n tra tio n
m oyenne
a p prox, (m g /m l)

19

10

10,5

95

29

10 - 20

11 • 21

182 - 95

Une solution pteparbe avec de I’eau sterile pour injection peut etre dilu te
davantage avec I’une des « solutions pour perfusions intraveineuses »
suivantes jusqu’4 I’obtention du volume requis.
Solutions p o u r p e rfu s io n s intraveineuses
Chlorure de sodium k 0,9 % pour injection
Dextrose k 5 % pour injection
Dextrose k 10 % pour injection
Solution de Ringer
Solution de Ringer-lactate
Chlorure de sodium k 0,9 % et dextrose k 5 % pour injection
Chlorure de sodium k 0,225 % et dextrose k 5 % pour injection
Solution de Ringer et dextrose k 5 % pour injection
Solution de Ringer-lactate et dextrose k 5 % pour injection
Sucre inverti k 10 % pour injection
Bicarbonate de sodium k 5 % pour injection
Lactate de sodium pour injection, solution molaire 4 1 /6
Solution d’lsolyte-S
C om patibilife e t s ta b ility
Reconstitub tel que dbcrit plus haut (Reconstitution), CEFOTAN conserve une
activity satisfaisante durant 24 heures k la temperature ambiante (25°C) ou
durant 72 heures au rbfrigbrateur (5°C).
Toute portion inutilisbe doit etre jetee. CEFOTAN ne doit pas etre melange avec
d’autres agents antimicrobiens.
N O TE : lorsque la solution et son contenant le permettent, les medicaments
parenteraux doivent etre verifies visuellement avant leur administration pour
deceler toute decoloration ou la presence de particules.
FORMES POSOLOGIQUES
Presentation
CEFOTAN (cefotetane disodique) est offert sous la forme d’une poudre seche,
de couleur blanche k jaune p4le, dans des flacons renfermant I’equivalent de
1 et 2 g de cefotetane actif pour administration intraveineuse ou intramuscu
laire. La dose de 1 g (N° 961) est offerte en flacons de 10 ml, et la dose de 2 g
(N° 962), en flacons de 20 ml. Les flacons doivent etre entreposes k des
temperatures inferieures k 25°C k I’abri de la lumiere.
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sterile ceftizoxime sodium

THERAPEUTIC CLASSIFICATION
Antibiotic
ACTION
In vitro studies indicate that the bactericidal action of ceftizoxime results from inhibition of
cell-wall synthesis in aerobic and anaerobic gram-positive and gram-negative organisms. In
vitro, ceftizoxime shows a strong affinity for penicillin-binding proteins la, lbs and 3 of E. coli.
INDICATIONS AND CLINICAL USES
CefizoxTM (sterile ceftizoxime sodium) may be indicated in the treatment of the infections
listed below when caused by susceptible strains of the designated microorganisms:
LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus sp. (including S.
pneumoniae but excluding enterococci); Klebsiella sp.; Proteus mirabilis; Escherichia coli;
Haemophilus influenzae (including ampicillin-resistant strains); Staphylococcus aureus
(including penicillinase-producing but excluding methicillin-resistant strains); Serratia sp.;
and Enterobacter sp.
URINARY TRACT INFECTIONS caused by Escherichia coli; Staphylococcus epidermidis;
Pseudomonas aeruginosa; Proteus mirabilis; Klebsiella sp.; Serratia marcescens; and
Enterobacter sp.
Due to the nature of the underlying conditions which usually predispose patients to Pseudo
monas infections of the urinary tract, a good clinical response accompanied by bacterial
eradication may not be achieved despite evidence of in vitro sensitivity.
INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli; Staphylococcus epidermidis;
Streptococcus sp. (excluding enterococci); Klebsiella sp.; Bacteroides sp. (including B.
fragilis)', Peptococcus sp.; and Peptostreptococcus sp.
SEPTICEMIA caused by Streptococcus sp. (excluding enterococci but including S. pneu
moniae ]>; Staphylococcus aureus (excluding methicillin-resistant strains); Escherichia coli;
Bacteroides sp. (including B. fragilis); Klebsiella sp.; and Serratia marcescens.
SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus (excluding methicillinresistant strains); Staphylococcus epidermidis; Escherichia coli; Klebsiella sp., (including K.
pneumoniae); Streptococcus sp. (excluding enterococci but including Group A B-hemolytic
Streptococcus pyogenes); Proteus mirabilis; Serratia sp.; Enterobacter sp.; Bacteroides sp.
(including B. fragilis); Peptococcus sp., and Peptostreptococcus sp.
BONE AND JOINT INFECTIONS caused by Staphylococcus aureus (excluding methicillinresistant strains); Proteus mirabilis; Peptococcus sp.; and Peptostreptococcus sp.
Specimens for bacteriologic culture should be obtained prior to therapy in order to identify
the causative organisms and to determine their susceptibilities to ceftizoxime. Therapy with
CefizoxTM may be initiated before results of the susceptibility studies are known. However,
m odification of the treatment may be required once these results become available.
CONTRAINDICATIONS
CefizoxTM (sterile ceftizoxime sodium), is contraindicated in persons who have shown
hypersensitivity to ceftizoxime or other members of the cephalosporin group of antibiotics.
WARNINGS
Before therapy with CefizoxTM (sterile ceftizoxime sodium) is instituted, careful inquiry
should be made to determine whether the patient has had previous hypersensitivity
reactions to cephalosporins, penicillins, or other drugs. CefizoxTM should be given
cautiously to penicillin-sensitive patients. Antibiotics, including CefizoxTM, should be
administered with caution to any patient who has demonstrated some form of allergy,
particularly to drugs. If an allergic reaction to CefizoxTM occurs, its administration should
be discontinued. Serious acute hypersensitivity reactions may require epinephrine and other
emergency measures.
Pseudomembranous colitis has been reported with the use of CefizoxTM (and other anti
biotics). Therefore, it is important to consider this diagnosis in patients administered
CefizoxTM w ho develop diarrhea.
Treatment with broad-spectrum antibiotics alters normal flora of the colon and may permit
overgrowth of Clostridia. Studies indicate a toxin produced by Clostridium difficile is one
primary cause of antibiotic-associated colitis.
Mild cases of co litis may respond to drug discontinuance alone. Moderate to severe cases
should be managed with fluid, electrolyte and protein supplementation as indicated. When
the co litis is not relieved by drug discontinuance or when it is severe, consideration may be
given to the administration of oral vancomycin or other suitable therapy. Other possible
causes o f co litis should also be considered.
PRECAUTIONS
General: Transient elevations of BUN and serum creatinine have been observed in clinical
studies. However, there is no other evidence that CefizoxTM (sterile ceftizoxime sodium) has
produced alterations in renal function. Renal status should be periodically evaluated,
especially in seriously ill patients.
Prolonged use o f CefizoxTM may result in the overgrowth of nonsusceptible organisms
including species originally sensitive to the drug. Careful observation of the patient is
essential. If superinfection occurs during therapy, appropriate measures should be taken.
CefizoxTM should be administered with caution to individuals with a history of gastro
intestinal disease, particularly colitis.
Impaired Renal Function: Since ceftizoxime is excreted primarily in the urine, patients with
impaired renal function (i.e., creatinine clearance £1.32 mUs or ^ 7 9 mL/min) should be
placed on a special dosage schedule recommended under DOSAGE AND ADMINISTRATION.
Normal dosages in these individuals are likely to produce excessive serum concentrations
of ceftizoxime.
Drug Interactions: The concomitant administration of some cephalosporins and amino
glycosides has caused nephrotoxicity. The effect of administering CefizoxTM concomitantly
with aminoglycosides is not known.
Pregnancy: The safety of CefizoxTM in pregnancy has not been established. The use of
CefizoxTM in pregnant women requires that the likely benefit from the drug be weighed
against the possible risk to the mother and fetus. The pharmacokinetics of CefizoxTM jn
pregnant patients has not been investigated. Reproduction studies performed in rats and
rabbits have revealed no evidence of impaired fertility or harm to the fetus caused by cefti
zoxime. Animal reproduction studies, however, are not always predictive of human
response.

Labour and Delivery: The safety and efficacy of CefizoxTM Use during labour and delivery
has not been investigated.
Nursing Mothers: Ceftizoxime is excreted in human milk in low concentrations (less than
4% of serum concentrations at 1 hour after dosing). The clinical significance of this is
unknown; therefore caution should be exercised if CefizoxTM \$ to be administered to a
nursing woman.
Infants and Children: The safety of CefizoxTM jn infants less than 6 months of age has not
been established. In children six months of age and older, treatment with CefizoxTM h^S ,
been associated with transient elevated levels of eosinophils, SGOT, SGPT and CPK
(creatine phosphokinase). The CPK elevation may be related to intramuscular J
administration.
Elderly Patients: The elimination of ceftizoxime may be reduced due to an age-dependent
reduction in renal function.
ADVERSE REACTIONS

* ~

CefizoxTM (sterile ceftizoxime sodium) is generally well tolerated.
Adverse
Reaction

Incidence
<1%

^

Incidence
> 1 % b u t< 5 %

Hypersensitivity:

Rash
Pruritus
Fever

*

Transient elevation of SGOT,
SGPT and alkaline phosphatase

Liver:
Blood:

Neutropenia
Leukopenia
Thrombocytopenia

Renal:

Transient elevation
of BUN and creatinine

Transient eosinophilia
Thrombocytosis
Positive direct Coombs’ test

Injection site: burning, cellulitis,
phlebitis (with IV administration),
pain, induration, tenderness,
parasthesia

Local:

Genitourinary:

Vaginitis

Gastro
intestinal:

Diarrhea, Nausea, Vomiting, Pseudomembranous colitis

■<

No disulfiram-like reactions have been reported with CefizoxTM
TREATMENT OF OVERDOSAGE
No case of acute overdosage has been reported to date; consequently there is no speciwfc,
information available on symptoms or treatment. In cases of suspected overdosage,
supportive therapy should be instituted according to symptoms. Serum ceftizoxime level^
can be reduced by hemodialysis.
DOSAGE AND ADMINISTRATION
^
CefizoxTM (sterile ceftizoxime sodium) may be administered either intramuscularly or intra
venously after reconstitution.
Dosage and route of administration should be determined by the condition of the patient,
severity of the infection and susceptibility of the causative organism(s). The intravenous
route may be preferable for patients with bacterial septicemia, or other severe or
•
threatening infections.
The usual course of treatment should be 7-14 days, and should normally continue at least 4&
hours after evidence of bacterial eradication has been obtained. For B-hemolytic strepto
coccal infections, a minimum of 10 days of treatment is recommended.
DOSAGE
Adults: The recommended daily dosage of CefizoxTM is 1 to 12 grams administered iit
equally divided doses every 8 or 12 hours (see Table 1 below).
TABLE 1
'

\

Type of Infection
Uncomplicated
Urinary Tract

Daily Dose
(Grams)

Frequency and Route

1

500mgq12h, IVorIM

Other Sites

2-3

1 g q8h orq12h, IV or IM

Severe or
Refractory

3-6

1 g q8h, IV or IM, to
2g q8h or q12h, IV or IM*

Life-Threatening

9-12

3 o r4 g q8h IV

-~S

-

‘ When administering 2 g intramuscularly, the dose should be divided and injected in
different large muscle masses.
Because of the serious nature of urinary tract infections due to Pseudomonas aeruginosa and because many strains are only moderately susceptible to CefizoxTM, higher dosage
may be appropriate when urinary tract infections are caused by these organisms. Other
therapy should be instituted if the response is not prompt.
Adults with Impaired Renal Function: In patients in whom the creatinine clearance isj
1.32 mUs (79 mL/min) or less, the dosage of CefizoxTM must be reduced. Following an initial
loading dose of 500 mg to 1.0 g IM or IV, the maintenance dosing schedule presented in
Table 2 should be followed in patients with reduced renal function.
1 A

TABLE 2
Renal
Function

Creatinine
Clearance
mL/s
mL/min

Mild
Impairment

0.83-1.32

Moderate to severe
impairment
Hemodialysis
patients*

R e c o n s titu tio n T a b le fo r S t a n d a r d V ia ls - I.M . In je c tio n
Less Severe
Infections

Life-Threatening
Infections

50-79

500 mg
q8h

750 mg to 1.5 g
q8h

5-49

250 or 500 mg
q12h

500 mg to 1.0 g
q12h

500 mg q48h or
250 mg q24h

500 mg to 1.0g
q48h or 500 mg
q24h

0-0.07

'In patients undergoing hemodialysis no additional supplemental dosing is required.
DOSING, H OWEVER, SHOULD B E SC H ED U LED SO THAT THE PATIENT R E C E IV E S THE
►DOSE AT T HE END O F THE DIALYSIS. When started 24 hours after administration of 1 g of
CefizoxTM, hemodialysis has been shown to reduce serum levels by 50%.
► When only the serum creatinine level is available, creatinine clearance may be calculated
from the following formulae (for patients 18 years and over only). The serum creatinine level
^should represent renal function at the steady state.
M a le s :
- Creatinine Clearance
(mL/min)

Vial
Size

Diluent to be
Added to Vial

Approximate
Available
Volume

Approxim ate
Average
Concentration

19
29

3.0 mL
6.0 mL

3.7 mL
7.4 mL

270 mg/mL
270 mg/mL

Shake well until dissolved.
F o r In tra v e n o u s In je c tio n : Reconstitute only with Sterile W ater for Injection.
R e c o n s titu tio n T a b le fo r S ta n d a r d V ia ls - I.V . In je c tio n
Vial
Size

Diluent to be
Added to Vial

Approximate
Available
Volume

Approximate
Average
Concentration

1g
2g

10 mL
20 mL

10.7 mL
21.4 mL

95 mg/mL
95 mg/mL

Shake well until dissolved.
F o r In tra v e n o u s In fu s io n : Reconstitute as for intravenous injection. Further dilute the
reconstituted solution to 50 to 100 mL with one of the “ Solutions for Intravenous
Infusion” (see below).

Weight (kg) x (140 -age)
72 x serum creatinine (mg/100 mL)

►
Creatinine Clearance
(mUs)

T A B L E 4: S o lu t io n s fo r In t r a v e n o u s In fu s io n

Weight (kg) x (140 -age)
49 x serum creatinine ( /xmol/L)

F e m a le s : 0.85 of the above values
In fa n ts a n d C h ild re n : The following dosage schedule is recommended:
TABLE 3
^Age Group
k Infants (6 mo-2 yrs.),
and
Children (2-12 yrs.)

Unit Dosage

Frequency and Route

50 mg/kg IV or IM

q6horq8h, IV or IM

The pediatric dosage should not exceed the maximum adult dosage for serious infections.

Sodium Chloride Injection
5 % or 10% Dextrose Injection
5 % Dextrose and 0 .9 % , 0.45% or 0 .2 % Sodium Chloride Injection
Ringer’s Injection
Lactated Ringer’s Injection
10% Invert Sugar in Sterile W ater for Injection
5 % Sodium Bicarbonate in Sterile W ater for Injection
5 % Dextrose in Lactated Ringer’s Injection O N LY when reconstituted with 4 % Sodium
Bicarbonate Injection.
S T A B IL IT Y O F S O L U T IO N S
S to ra g e : All reconstituted solutions and those further diluted should be used within 24
hours if stored at room temperature or within 48 hours if refrigerated. These storage limits
are from the time of the initial reconstitution.
In c o m p a tib ility : CefizoxTM should not be added to blood products, protein hydrolysates
or amino acids. CefizoxTM should not be mixed together with an am inoglycoside.
DOSAGE FO RM S

A D M IN IS T R A T IO N
In tra m u s c u la r: The reconstituted solution of CefizoxTM should be injected well within the
body of a relatively large muscle, such as the gluteus. When administering 2 g IM doses, the
^ jjjose should be divided equally and then injected into different large muscle masses.
In tra v e n o u s : Injection (bolus): The reconstituted solution of CefizoxTM should be injected
,slowly over 3 to 5 minutes, directly or through the tubing system by which the patient is
receiving another compatible intravenous solution. During administration of the solution
containing CefizoxTM, it is desirable to temporarily discontinue administration of the other
■^solution.
k Intermittent or continuous infusion: The further diluted reconstituted solution of CefizoxTM
w should be administered over a 20 to 30 minute period.
j

N O T E : CefizoxTM solutions should not be physically mixed with any other drug. There is a
isnown incompatibility with aminoglycoside antibiotics. Therefore, they should not be
physically mixed with CefizoxTM solutions nor administered at the same site.
P H A R M A C E U T IC A L IN F O R M A T IO N
C H E M IS T R Y

A v a ila b ility : CefizoxTM jS available as a sterile powder in Standard Vials of 1 gram or
2 grams, containing ceftizoxime as sodium salt.
S to ra g e : CefizoxTM powder for injection should be stored at room temperature (15°-30°C).

FOOTNOTES
'As indicated in the manufacturer's product monograph. Cefizox. Smith Kline & French Canada Ltd.. 1988
2As indicated in the manufacturer's product monograph cefoxitin. Merck Sharp & Dohme Canada. 1985
3Lou M.A. etal.: 14th International Congr. Chemother.. Kyoto. Japan. Ju n e 1985, pp 2378-2379.
4Neu H.C., Chin N X : The activity and beta-lactamase stability of cefotetan compared to other beta-lactam antibiotics
Chemioterapia 1985:4:271-277
5Fu K . P , Neu H.C.: Antibacterial activity of ceftizoxime. a B-lactamase-stable cephalosporin. Antimicrob. Aqents
Chemother. 1980:12:583-590.
6Thornsberry C.: Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotics
against clinically important bacteria. Am. J. Med. 1985:79 (Suppl. 2A): 15-20.
7Drulak M.W., Chow A .W .: Comparitive in vitro activity of ceftizoxime cefoperazone and cefoxitin against anaerobic
bacteria. Antimicrob. Agents Chemother. 1981:20:683-685.

T ra d e N a m e : C E FIZO XTM

8Aldridge K.E. etal.: Comparison of the activities of penicillin G and new B-lactam antibiotics against clinical isolates of
Bacteroides species. Antimicrob. Agents Chemother 1984;26(3):410-413.

F J o p e rN a m e : C e ftiz o x im e S o d iu m

9Adapted from Parker D.D.: Abstr. Annu. Meet. Am. Soc. Microbiol.,Atlanta. GA. March 1987 Abstract no. A-107, p 18

k

C h e m ic a l N a m e : Sodium [6R-(6c*, 7B(Z)]]-7-[[(2,3-dihydro-2-imino-4-thiazolyl)
(5nethoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabilcyclo[4.2.0]
oct-2-ene-2«P'
carboxylate
cai

_ > § tru c tu ra l F o rm u la :
COOM.

^

O C H ’

JO T
E
*

%
—
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-4HkJ

M
o le c u la r F o rm u la : C -| 3 H i 2 N 5 0 5 S 2 N a
Me
M o le c u la r W e ig h t: 4 0 5 .3 8

10Kitzmann R. Cost analysis of the ecomomic effect of replacement of cefoxitin with ceftizoxime. Presented at the 45th
Annual Meeting, American Society of Hospital Pharmacists. San Francisco, California.
1’Guastell C. Cost savings realized from interchanging ceftizoxime for cefoxitin. Am J Hosp Pharm 1988
Nov;45:2376-2377.
12Wikler M.A. et al.: Efficacy of ceftizoxime administered twice daily for the treatment of serious infections in hospitalized
patients. Infect. Med. 1986;(Suppl.):9-12.
13Data on file. Smith Kline & French Canada Ltd.
14Sanford J .P : Guide to Antimicrobial Therapy. West Bethesda, MD:Antimicrobial Therapy Inc.. 1988:50.
15Richards DM Heel RC. Ceftizoxime: A review of its antibacterial activity, pharmacokinetic properties and therapeutic
use. Drugs 1985:29:281-329.
16DiPiro J. May JR . Use of cephalosporins with enhanced antianaerobic activity for treatment and prevention of
anaerobic and mixed infections. Clin Pharm 1988 Apr:7:285-302.
,7Bellomo S. Antimicrobial activity of cefizoxime sodium: Comparision with cefoxitin. Hosp Formul 1988:23
(Suppl. D): 18-27

D e s c rip tio n : Ceftizoxime Sodium is a white to pale yellow crystalline powder.

'c o m p o s itio n : CefizoxTM vials contain ceftizoxime sodium (expressed in terms of free
k acid). The sodium content of each gram of CefizoxTM js approximately 60 mg (2.6 mEq
■ sodium ion).

Solutions
range from colourless to pale yellow, depending upon the diluent
[ ?ihd
So volumeof CefizoxTM
used. The solution should be discarded if it becomes cloudy. The pH of

t

3P<

I

freshly reconstituted solutions usually ranges from 6.0 to 8.0.
fre

B*As
Ksolution of 1 g CefizoxTM in 13 m L Sterile Water for Injection is isotonic.
R E C O N S T IT U T IO N

^ ST A N D A R D V IA LS (1 GRAM and 2 GR A M S)
F o r In tr a m u s c u la r In je c tio n : Reconstitute with Sterile Water for Injection or Bacteriosta
tic Water for Injection.

S M ITH KLINE S fR E N C H C A N A D A LTD. 1 98 8
Mississauga, Ontario L5N 2V7
w *

■ ■under licence of
Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan

BOOK REVIEWS
continued from page 134

easy, but the author’s format avoids
wasting time in seeking an answer
through an index or searching papers
and textbooks. It is, in fact, a method
for reviewing knowledge at the last
minute before an examination or in
limited spare time. Almost all aspects of
orthopedics and fractures are covered in
the 255 pages of this soft-cover book.
The coverage is not, however, in great
depth; this would be impossible in a
text this long. The questions the author
poses are the kind encountered at oral
examinations. A pictorial section at the
end, consisting of x-ray fdms also has
questions and answers.
Although this book is a useful addi
tion to the orthopedic literature, it is
not clear at which level of training or
expertise it would be most effective. It
would certainly be extremely helpful for
orthopedic nurses, medical students and
those preparing for board and fellow
ship examinations in related specialties.
It may fall short of the depth of knowl
edge required by senior orthopedic resi
dents.
These comments aside, the book is a
very interesting and informative way of
reviewing an extensive subject.
Charles Sorbie, MB, ChB, FRCS(Edin),
FRCSC
Professor and Head,
Department o f Surgery.
Queen's University,
Kingston, Ont.

PEDIATRIC NEUROSURGERY. Sur
gery of the Developing Nervous Sys
tem. 2nd edition. Edited by Robert L.
McLaurin, Joan L. Venes, Luis Schut
and Fred Epstein. 604 pp. Illust. W.B.
Saunders Company Canada Limited,
Toronto, 1989. $215.95. ISBN
0-7216-2748-X.
Under the auspices of the pediatric
section of the American Association of
Neurological Surgeons and with four
outstanding editors the first edition
(1982) has been updated with extensive
156
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new information to reflect the dramatic
expansion of pediatric neurosurgery in
the intervening years.
Written by 75 contributors, the book
contains 54 chapters, divided into six
parts: developmental abnormalities, hy
drocephalus, trauma, neoplasms, infec
tions, and vascular diseases and miscel
laneous diseases. There is an excellent
index at the end of the book and a
manageable number of references, both
classic and current, at the end of each
chapter.
The illustrations, all black and white,
are selected with great care, and most
of them serve well their purpose to
enhance the clarity of the text. In some
cases, however, the point would have
been more clearly made had colour
illustrations been used. The high-qual
ity editing and the work of the illustra
tion coordinator rescues the text from
the undesired variety of styles in writ
ing, art work and photography, the
usual drawbacks of multiauthored
books.
Although this book is outstanding in
most of its features, I found the ac
count of miscellaneous diseases, partic
ularly the chapters on epilepsy and on
movement disorders, incomplete. Sur
gery for these two conditions has
gained renewed interest lately and this
could have been emphasized in a more
detailed discussion of some of the treat
ment modalities. On the other hand,
developmental abnormalities, trauma
and neoplasms are superbly handled
and they represent the greatest strength
of this very informative book.
Enlarging the scope of the first edi
tion of this basic reference book on
diseases of the nervous system in the
pediatric age group was timely and the
editors did a great service to those who
deal with sick children. This new, much
improved volume should be a standard
text in the library of neurologists, neu
rosurgeons and pediatricians.
Leslie P. Ivan, MD, FRCSC, FACS
Coordinator o f Postgraduate Surgical
Education,
University o f Ottawa,
Ottawa Civic Hospital,
1053 Carling Ave.,
Ottawa. Ont.
K1Y4E9

NEUROLOGICAL EMERGENCIES.
S.D. Shorvon. 108 pp. Illust. Butterworths, Stoneham, Mass. 1989. $22.95
(US). ISBN 0-407-00873-X
This book in 10, short, well-written
chapters covers all the principal neuro
logic emergencies. It gives the reader a
feel of how physicians actually go about
treating the entities involved.
Unfortunately, it really does not give
sufficient information to undertake the
specific therapies and investigations
suggested. For example, I think one
would be inclined to forego oculovestibular testing rather than proceed pre
cisely according to the description in
the text. The treatments for a number
of entities do not correspond to what is
currently suggested in North America.
For example, in the chapter on coma
the possibility of narcotic overdose is
not sufficiently emphasized.
The section on meningitis does not
point out the important role of thirdgeneration cephalosporins nor is the
reader made aware of the difficulties
associated with cerebrospinal fluid pen
etration of gentamicin. The chapter on
brain abscesses emphasizes the impor
tance of urgent surgical intervention
whereas in North America most brain
abscesses are treated initially with anti
biotics. The chapter on acute spinal
cord injuries does not consider the
important use of high-dose steroids,
particularly when a metastatic tumour
is involved.
In the chapter on status epilepticus
diazepam is given a predominant role,
contrary to the position taken in North
America. Paraldehyde is mentioned as a
first-line medication, whereas in Canada
it is considered a third-line medication,
if used at all. The doses of phenytoin
recommended may be too high for some
smaller adults and inadequate for many;
doses are best expressed in mg/kg.
Furthermore, the table that describes
the medications used in status epilep
ticus contains errors in organization
that make it unusable. According to the
author, this book is designed for the
general practitioner, emergentologist or
the resident in neurology or neurosurg
ery. I would suggest this book may give
a family doctor an overview of what is

happening in the treatment of emergen
cy neurologic conditions. It certainly is
not adequate for the emergentologist or
for a resident in neurology or neuro
surgery.
H.E. Rabinovitch, MD, CM, FRCPC
Ste. B l l ,
770 Broadview Ave..
Ottawa. Out.

THE DOCTOR AND THE LAW. 2nd
edition. H.E. Emson. 240 pp. Illust.
Butterworths Canada Ltd., Toronto,
1989. $49.50. ISBN 0-409-88875-3.

Coincidentally, this compact and de
lightful publication came across my
desk while 1 was searching for an
informative source of reference material
in the wide arena of medicolegal issues.
This is the second edition of the
book by Dr. Emson, Professor and
Head of Pathology at the University of
Saskatchewan School of Medicine.
Physicians and surgeons need a
ready reference to medicine and law,
and this book fills their requirements.
Scanning the table of contents, I found
a full list of topics of a general and
specific nature in the areas of making
law, the adversary system, licensure,
ethics and discipline. Excellent but brief
sections cover federal and provincial law
with rights and responsibilities. Struc
ture of courts, giving evidence, coro
ners and examiners are some chapter
contents, which are briefly yet succinct
ly given in a light and readable fashion.
Subjects often discussed and ques
tions often put to the Canadian Medical
Protective Association have to do with
malpractice and negligence, consent
and report. Individual chapters on these
subjects are informative and practical
and will serve as a basis for practice and
teaching.
The sections on sex and the law, life
issues, alcohol and drugs are covered
rapidly, but I find that the author is
always trying to be practical, which
makes up for the limited space and
constraint of time that prevents indepth coverage of deep and controver
sial issues.

No other book that I have seen
covers all these areas including the
doctor’s place in hospital and office as
well in 235 pages. A section of notes
and basic references are given to those
wishing further study, and a reasonable
index helps the reader to locate points
of interest.
In reading through this book, I often
found myself reflecting on the basic
aspects of surgical practice in relation
to the ever-present concepts of law and
ethics which are as real as diagnosis
and treatment in today’s society.
Books like The Doctor and the Law
are now important reading for the medi
cal and surgical practitioner. This book
belongs on our study or office desk.
Nis Schmidt, MD, MSc, FRCSC
Clinical Professor,
Department o f Surgery,
University o f British Columbia,
St. Paul's Hospital.
1081 BurrardSt.,
Vancouver, BC,
V6Z1Y6

PIONEERS OF CARDIOLOGY IN
CANADA 1820-1970. The Genesis of
Canadian Cardiology. Harold N. Segall. 525 pp. Illust. Hounslow Press,
Willowdale, Ont. 1988. $45. ISBN 0 88882-1 0 5 -0

Consideration of the cardiovascular spe
cialties in 1989 brings to mind hightechnology laboratories (in which angi
ography, cardiac ultrasonography and
radionuclide imaging take place), so
phisticated surgical approaches to con
genital and acquired diseases of heart
and vessels, and aggressive pharmaco
logic approaches to the therapy of
acute myocardial infarction and cardiac
failure. Reading this book makes one
realize how recently most of our cur
rent approaches have been developed.
In the 150 years covered in this book,
however, some enormously important
discoveries were made, discoveries that
laid the foundations for the modern
diagnosis and treatment of cardiovascu
lar disease.
Because this book developed from
the work of the archivist of the Canadi
an Cardiovascular Society, the reader
might expect a parochial viewpoint. In

fact, Dr. Segall cleverly weaves in his
descriptions of the important interna
tional figures and their contributions.
The enormous genius and influence of
such individuals as William Osier,
Thomas Lewis and Paul Dudley White
are apparent as is the significance of
the development of electrocardiography
and roentgenography, and the advances
made possible by the understanding of
cardiac embryology.
The basic information for this book
was provided by those members of the
Canadian Cardiovascular Society who
responded to a questionnaire circulated
in the mid-1960s. Dr. Segall used this
and his own extensive personal knowl
edge of Canadians interested in the
cardiovascular system to produce this
overview of the development of cardio
logy and cardiac surgery in Canada.
Some gaps, of course, exist since the
response to the questionnaire (as usual)
was not complete. Overall, however, the
book provides an important record of
Canadians’ contributions to progress in
this discipline.
Specific chapters are devoted to such
areas as the development of electrocar
diography, cardiac roentgenology, car
diac surgery and cardiac catheteriza
tion, to the concepts of monitoring,
pacing and coronary care — the last
two being disciplines to which Canadi
ans have made prominent contributions.
This book is of value to all who are
interested in our medical past; it is
particularly pertinent to those involved
in the cardiovascular sciences. Al
though the organization is somewhat
disjointed and there is some repetition,
the style overall is personal and engag
ing. It is written by a senior, highly
respected member of the cardiovascular
community who has experienced many
exciting developments during his more
than 90 years. He has been successful
in transmitting much of that excitement
in his book. I certainly enjoyed reading
it.
Eldon R. Smith, MD, FRCSC
Professor o f Medicine and Medical
Physiology.
University o f Calgary,
Foothills Hospital.
Calgary, Alta.
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BOOKS RECEIVED
continued from page 121

s 0Mefoxin*n
(sterile cefoxitin sodium, MSD Std.)
A N T IB IO T IC

The Surgical Examination of Children.
J.M. Hutson and S.W. Beasley. 271 pp.
Illust. Butterworths, Stoneham, Mass.
1988. $95 (US). ISBN 0-433-00051-1

ACTION

Thoracic Surgery. Edited by H. Pichlmaier and F.W. Schildberg, 460 pp.
Illust. Springer-Verlag New York, Inc.,
Secaucus, NJ. 1989. $375 (US). ISBN
0-387-18464-3

INDICATIONS AND CLINICAL USES

Trauma. Pathogenesis and Treatment.
Edited by Stephen Westaby. 414 pp.
Illust. Heinemann Medical Books, Ox
ford; Butterworths, Stoneham, Mass.
1989. $125 (US). ISBN 0-433-355026

In vitro studies demonstrate that the bactericidal
action of cefoxitin, a cephamycin derived from
cephamycin C, results from the inhibition of
bacterial cell wall synthesis. Evidence suggests
that the methoxy group in the 7ar position is
responsible for the resistance of cefoxitin to
degradation by bacterial beta-lactamases.

TREATMENT

The treatment of the following infections when
due to susceptible organisms:
1 - Intra-abdominal infections such as peritonitis
and intra-abdominal abscess
2 - Gynecological infections such as endo
metritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and Serratia
spp.)

Urologic Pathology With Clinical and
Radiologic Correlations. Edited by
Ayten Someren. 753 pp. Illust. Macmil
lan Publishing Company, New York.
1989. $125 (US). ISBN 0-02-413750-

5 - Lower respiratory tract infections
6 - Bone and jo in t in fe ctio n s caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies
should be performed to determine the susceptib ilit y of the ca u sa tive o rg a n ism (s) to
MEFOXIN®. Therapy may be started while
awaiting the results of these tests, however,
modification of the treatment may be required
once these results become available.
Organisms particularly appropriate for therapy
with MEFOXIN® are:

2

Gram positive

Staphylococci, penicillinase producing and
non-producing
Streptococci excluding enterococci

Vascular Disorders of the Upper Ex
tremity. 2nd edition. Revised and en
larged. Edited by Herbert 1. Machleder.
409 pp. Future Publishing Company,
Inc., Mount Kisco, NY. 1989. $55 (US).
ISBN 0-87993-347-X

Vascular Surgery, Third Edition. Vol
ume 1. Edited by Robert B. Rutherford.
905 pp. Illust. W.B. Saunders Compa
ny, Philadelphia. 1989. $279.95 (US)
(set). ISBN 0-7216-2065-5

Gram negative (beta-lactamase producing and
non-producing strains)

Escherichia coli
Klebsiella species (including K. pneumoniae)
Proteus, indole positive and negative
Haemophilus influenzae
Providencia species
Anaerobes

Bacteroides fragilis
MEFOXIN® may also be appropriate for the
treatment of infections involving susceptible
strains of both aerobic and anaerobic bacteria.
MEFOXIN® is not active against Pseudomonas
spp., most strains of enterococci, many strains
of Enterobacter cloacae,
and m ethicillinr e s is ta n t s ta p h y lo c o c c i and L is te ria
monocytogenes.
Clinical experience has demonstrated that
MEFOXIN® can be administered to patients who
are also receiving carbenicillin, gentamicin,
tobramycin, or amikacin (see PRECAUTIONS
and ADMINISTRATION).
PROPHYLACTIC USE

Vascular Surgery, Third Edition. Vol
ume 2. Edited by Robert B. Rutherford.
862 pp. Illust. W.B. Saunders Compa
ny, Philadelphia. 1989. $279.95 (US)
(set). ISBN 0-7216-2065-5

Wound Healing. Problems in Genera!
Surgery, Volume 6, April-June 1989.
Edited by Harold Ellis and Peter M.
Lamont. 167 pp. Illust. J.B. Lippincott
Company, Philadelphia. 1989. Price not
stated. ISSN 0739-8328
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MEFOXIN® may be administered perioperatively (preoperatively, intraoperatively and postoperatively) to patients undergoing vaginal or
abdominal hysterectomy and abdominal surgery
when there is a significant risk of postoperative
infection or where the occurrence of post
operative infection is considered to be especially
serious.
In patients undergoing cesarean section, intra
operative (after clamping the umbilical cord)
and postoperative use of MEFOXIN® may
reduce the incidence of surgery related post
operative infections.

®Trademark Merck & Co., Inc./
Merck Frosst Canada Inc., R.U.

Effective prophylactic use depends on the time
of administration. MEFOXIN® usually should be
given one-half to one hour before the operation.
Prophylactic administration should usually be
stopped within 12 hours. It has been generally
reported that continuing administration of any
antibiotic beyond 24 hours following surgery
increases the possibility of adverse reactions
but, in the majority of surgical procedures, does
not reduce the incidence o f subsequent
infection.
If signs of postsurgical infection should appear,
specimens for culture should be obtained for
identification of the causative organism(s) so
that appropriate treatment may be instituted.

CONTRAINDICATIONS
MEFOXIN® is contraindicated in persons who
have shown hypersensitivity to cefoxitin or to
the cephalosporin group of antibiotics.

WARNINGS
Before therapy with MEFOXIN® is instituted,
careful inquiry should be made to determine
whether the patient has had previous hyper
sensitivity reactions to MEFOXIN®, cepha
losporins, penicillins or otherdrugs. MEFOXIN®
should be given with caution to penicillinsensitive patients.
There is some clinical and laboratory evidence
of partial cross-allergenicity between cephamycins and the other beta-lactam antibiotics,
penicillins and cephalosporins. Severe reactions
(including anaphylaxis) have been reported
with most beta-lactam antibiotics.
Pseudomembranous colitis has been reported
w ith v ir tu a lly all a n tib io tic s in c lu d in g
MEFOXIN®. This colitis can range from mild to
life threatening in severity. Antibiotics should
therefore be prescribed with caution in indi
viduals with a history of gastrointestinal disease,
particularly colitis. It is important to consider a
diagnosis of pseudomembranous colitis in
patients who develop diarrhea in association
with antibiotic use. While studies indicate that a
toxin produced by Clostridium difficile is one
primary cause of antibiotic-associated colitis,
other causes should also be considered.
Any patient who has demonstrated some form of
allergy, particularly to drugs, should receive
antibiotics including MEFOXIN® with caution.
If an allergic reaction to MEFOXIN® occurs,
adm inistration of the drug should be dis
continued. Serious hypersensitivity reactions
may require treatment with epinephrine and
other emergency measures.

PRECAUTIONS
The total daily dosage should be reduced when
MEFOXIN® is administered to patients with
transient or persistent reduction of urinary
output due to renal insufficiency (see DOSAGE
AND ADMINISTRATION) because high and
prolonged serum antibiotic concentrations can
occur from usual doses.
In patients treated with MEFOXIN® a false
positive reaction to glucose in the urine may
occur with Benedict’s or Fehling's solutions but
not with the use of specific glucose oxidase
methods.
Using the Jaffe Method, falsely high creatinine
values in serum may occur if serum concen
trations of cefoxitin exceed 100 pg/mL. Serum
samples from patients treated with MEFOXIN®
should not be analyzed for creatinine if with
drawn within two hours of drug administration.
High concentrations of cefoxitin in the urine
may interfere with measurement of urinary 17hydroxy-corticosteroids by the Porter-Silber
reaction, and produce false increases of modest
degree in the levels reported.
Increased nephrotoxicity has been reported
fo llo w in g co n co m ita n t a d m in is tra tio n of
cephalosporins and aminoglycoside antibiotics.
Prolonged use of MEFOXIN® may result in the
overgrowth of non-susceptible organisms.
Repeated evaluation of the patient's condition is
essential and if super-infection occurs during
therapy, appropriate measures should be taken.
Should an organism become resistant during
antibiotic therapy, another antibiotic should be
substituted.

Use in Pregnancy
The safety of MEFOXIN® in the treatment of
infections during pregnancy has not been
established. If the administration of MEFOXIN®
to pregnant patients is considered necessary, its
use requires that the anticipated benefits be
weighed against possible hazards to the fetus.
Reproductiveand teratogenic studies have been
performed in mice and rats and have revealed no
evidence of impaired fertility or harm to the fetus
due to MEFOXIN®.
Nursing Mothers
Cefoxitin is excreted in human milk.
Children
In children 3 months of age or older, higher
doses of MEFOXIN® (100 m g /kg /d a y and
above) have been associated with an increased
incidence of eosinophilia and elevated SGOT.

ADVERSE REACTIONS
MEFOXIN® is generally well tolerated. Adverse
reactions rarely required cessation of treatment
and usually have been mild and transient.
Local Reactions
Throm bophlebitis has occurred w ith intra
venous administration. Some degree of pain and
tenderness is usually experienced after intra
muscular injections using water. Induration has
occasionally been reported.
Allergic
M a cu lo p a p u la r rash, u rtic a ria , p ru ritu s,
eosinophilia, fever and other allergic reactions
have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can
appear during or after antibiotic treatment.
Nausea and vom iting have been reported rarely.
Blood
Eosinophilia, leukopenia, neutropenia, hemo
lytic anemia, and thrombocytopenia and bone
marrow depression have been reported. Some
individuals, particularly those with azotemia,
may develop positive direct Coombs tests
during therapy with MEFOXIN®.
Liver Function
Transient elevations in SGOT, SGPT, serum
LDFI, and serum alkaline phosphatase and
jaundice have been reported.
Cardiovascular Function
Fiypotension.
Renal Function
Elevations in serum creatinine and/or blood
urea nitrogen levels have been observed. As
with the cephalosporins, acute renal failure has
been reported rarely. The role of MEFOXIN® in
changes in renal function tests is difficult to
assess, since factors predisposing to prerenal
azotemia or to impaired renal function have
often been present.

TREATMENT OF OVERDOSE
Other than general supportive treatment, no
specific antidote is known. MEFOXIN® can be
eliminated by dialysis in patients with renal
insufficiency.

DOSAGE AND ADMINISTRATION
MEFOXIN® may be administered intravenously
or intramuscularly as required. (See complete
m on o g ra ph on A D M IN IS T R A T IO N and
RECONSTITUTION.)
Intravenous Administration
The intravenous route is preferable for patients
with bacteremia, bacterial septicemia, or other
severe or life-threatening infections, or for
patients who may be poor risks because of
lowered resistance resulting from such debili
tating conditions as m alnu tritio n , trauma,
surgery, diabetes, heart failure, or malignancy,
particularly if shock is present or impending.
TREATMENT DOSAGE
Adults
The usual a d u lt dosage is 1 g or 2 g of
MEFOXIN® every 6 to 8 hours. Dosage and
route of administration should be determined by
severity of infection, s u s c e p tib ility of the
causative organisms, and co n dition of the
patient. The usual adult dosages are shown in
the Table below.

Usual Adult Dosage
Type of
infection

Daily
Dosage

Frequency
and Route

1 g every 6-8 h

Uncomplicated
forms* of infections such as
pneumonia,
urinary tract
infection, soft
tissue infection

3-4 g

Moderately
severe or severe
infections

6-8 g

1 g every 4 h
or
2 g every 6-8 h I.V.

Infections
commonly
needing antibiotics in higher
dosage (e.g. gas
gangrene)

12 g

2 g every 4 h
or
3 g every 6 h I.V.

I.V. or I.M.

’ Including patients in whom bacteremia is absent or
unlikely

Therapy may be started while awaiting the
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic
streptococcal infections should be maintained
for at least 10 days to guard against the risk of
rheum atic fever or g lo m e ru lo n ep h ritis. In
staphylococcal and other infections involving a
collection of pus, surgical drainage should be
carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN® may be used in patients with
reduced renal function but a reduced dosage
should be employed and it is advisable to
monitor serum levels in patients with severe
impairment.
In adults with renal insufficiency, an initial
loading dose of 1 g to 2 g should be given. After
a loading dose, the following recommendations
for maintenance dosage may be used as a guide:
MAINTENANCE DOSAGE OF
MEFOXIN® IN ADULTS
WITH REDUCED RENAL FUNCTION
RENAL
FUNCTION

CREATININE
CLEARANCE
mL/min

DOSE

AVAILABILITY
MEFOXIN® is supplied as sterile powder in
boxes of 10 vials:
3356 Ca - 1 g cefoxitin as sodium salt
3357 Ca - 2 g cefoxitin as sodium salt
Storage
MEFOXIN® in the dry state should be stored
below 30°C . The d ry m aterial as w e ll as
solutions tends to darken, depending on storage
conditions; product potency, however, is not
adversely affected.

PRODUCT MONOGRAPH AVAILABLE
ON REQUEST

(332-a,4,89)

MERCK
SH A R ft
DOHME
C A N A D A

| PAAB | |
50-30

Moderate
impairment

29-10

1-2 g

every 12-24 h

9-5

0.5-1 g

every 12-24 h

<5

0.5-1 g

every 24-48 h

1-2 g

MSD

3386

FREQUENCY

Mild
impairment

Severe
impairment
Essentially
no function

A t p re s e n t th e re is in s u ffic ie n t d a ta to
recommend a specific dosage for children with
impaired renal function. However, if the adminis
tration of MEFOXIN® is deemed to be essential
the dosage should be modified consistent with
the recom m endations for adults (see Table
above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of
MEFOXIN® is recommended as follows:
Vaginal or abdom inal hysterectom y and
abdominal surgery
2 g adm inistered in tra m u scu la rly o r in tra 
venously just prior to surgery (approximately
one-half to one hour before initial incision).
The second and th ird 2 g doses should be
adm inistered at 2-6 hour intervals after the
initial dose.
Cesarean Section
The first dose of 2 g should be administered
intravenously as soon as the umbilical cord has
been clamped. The second and third 2 g doses
should be given intravenously or intram us
cularly four hours and eight hours after the first
dose.

every 8-12 h

l

P.O. BOX 1005, POINTE-CLAIRE
DORVAL, QUEBEC H9R 4P8

In patients u n d ergoing hem odialysis, the
loading dose of 1 - 2 g should be given after each
hemodialysis, and the maintenance dose should
be given as indicated in the Table above.
Neonates (Including Premature Infants), Infants
and Children (See WARNINGS for Neonates
under ADM INISTRATIO N in the complete
monograph.)
Premature Infants
with Body Weights
Above 1500 g

20-40 mg/kg every 12 h I.V.

Neonates

0-1 week of age
1-4 weeks of age

20-40 mg/kg every 12 h I.V.
20-40 mg/kg every 8 h I.V.

Infants

1 month to 2 years
of age

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

Children

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

In severe infections, the total daily dosage in
infants and children may be increased to
200 mg/kg, but not to exceed 12 g per day.
MEFOXIN® is not recommended for the therapy
of meningitis. If meningitis is suspected, an
appropriate antibiotic should be used.
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CLASSIFIED ADVERTISING

As a further service to its readers the Canadian Journal of Surgery is pleased to accept suitable classified advertisements. The deadline is 1
month before issue date. Regular classified rates (for each insertion): $50.00 for the first 40 words or less, additional words 65<f each (additional
$20.00 for frame). Special Display under 100 words, 2'/» in. X 2 in., $120.00. $15.00 charge (first insertion only) for CJS box numbers. Display
rates available on request.
Copy should be mailed to the Canadian Journal o f Surgery, PO Box 8650, Ottawa, Ontario K1G 0G8.

GENERAL SURGICAL ONCOLOGY FEL
LOWSHIP: ON - The Division of General
Surgery at the Toronto General Branch of the
Toronto Hospital is offering a 1 year clinical
fellowship available beginning July 1, 1990.
This fellowship provides excellent exposure
to complex general surgical oncological prob
lems including reoperative Gl cancer surgery,
endocrine malignancies, and head and neck
cancers. The fellow will also have the oppor
tunity to be involved in ongoing clinical trials
in adjuvant therapy of breast and colorectal
cancers and will be encouraged to initiate at
least one new prospective or retrospective
study with appropriate resources provided.
Block rotations of 6-8 weeks in the Depart
ments of Radiotherapy and Chemotherapy are
also an integral component of this program.
The fellow is also expected to take a minor
part in the training of residents in general
surgery. This fellowship is intended for indi

viduals who have completed a general sur
gery residency and are eligible for certifica
tion. Send enquiries and curriculum vitae to:
Dr. J. Ali, Director, Postgraduate Educa
tion, Department of Surgery, Banting Insti
tute, Room 311, 100 College St., Toronto,
ON M5G 1 L5.
-S90-03

HEAD OF ORTHOPEDIC DIVISION: ON Applications are invited for the above posi
tion. The Orthopaedic Services at The Toron
to General Hospital and Toronto Western
Hospital are being amalgamated, creating a
single division sited at The Toronto Western
Hospital. Applicants must show evidence of
proven ability in the organization of patient
care, research, teaching, and other aspects of
academic surgery. The candidate should have
the capacity to lead a large, multi-facetted
program. This joint hospital-university ap

HANTS COMMUNITY HOSPITAL
WINDSOR, NOVA SCOTIA

GENERAL SURGEON
Required for a 120-bed community hospital located in the beautiful
ANNAPOLIS VALLEY
The Hants Community is located in
WINDSOR
THE GATEWAY TO THE ANNAPOLIS VALLEY
Excellent recreational facilities, including skiing and golfing. It is
approximately 45 minutes from Halifax and serves a population of 25 000.
Applicants must be Canadian certified or eligible. Additional training in
minor orthopedics and gynecology a definite asset.
Reply to:
W.E. Skerry, Administrator
Hants Community Hospital
Windsor, Nova Scotia
BON 2T0
_____________________ Tel: (902) 798-8351
_________ S-90-7

CLASSIFIED ADVERTISING
Unlike a tabloid or newspaper that is read today and discarded
tomorrow, an advertisement in the Classified Advertising section
of CJS is read today and reread tomorrow.
CJS is the only Canadian publication exclusively for surgeons.
No other Canadian surgical publication reaches over 9000
subscribers every 2 months, giving wide coverage for your
advertising dollar.
Average issue readership of CJS (81 %) is among the highest of
any medical journal in Canada, and the latest readership
studies confirm the best and most cost efficient way to reach
Canadian surgeons is through the pages of CJS.
LET CJS CLASSIFIED ADS WORK FOR YOU
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pointment represents an exciting opportunity
for program development in orthopedic sur
gery. In accordance with Canadian immigra
tion requirements, this advertisement is di
rected to Canadian citizens and permanent
residents. Applications, with accompanying
curriculum vitae, should be addressed to: Dr.
Alan R. Hudson, Surgeon-in-Chief, The To
ronto Hospital, 585 University Ave., Bell
Wing 1-636, Toronto, ON Canada M5G
2C4.
-S 9 0 -1 1
GENERAL/THORACIC AND GENERAL/
VASCULAR SURGEON: SK —To join group
of three general surgeons and one general
vascular surgeon to service the respiratory
medical and vascular units at the Regina
General Hospital. For further information
please contact: Dr. D.A. Dunn, 550, 1809
Rose St., Regina, SK. Tel: (306)
7 5 7 -0484.
-S90-12

The Calgary
General Hospital

m

A

Bow Valley Centre
Peter Lougheed Centre

General Surgeon

The Calgary General Hospital invites
applications for a position in General
Surgery. The successful applicant will be
expected to have specialized training and
interest in thoracic or peripheral vascular
surgery and to participate in undergraduate
and post-graduate teaching and research.
The candidate should be a Fellow of the
Royal College of Physicians and Surgeons
of Canada and be eligible for licensure by
the College of Physicians and Surgeons of
Alberta.
The Calgary General Hospital is a 940-bed
teaching hospital affiliated with the
University of Calgary.
In a c c o r d a n c e w it h i m m i g r a t i o n
requirements, preference will be given to
Canadi an citi zens and p er m an en t
residents.
Reply, including curriculum vitae and the
names of three referees, to:
Director, Department o f Surgery
The Calgary General Hospital - Bow Valley Centre
841 Centre Avenue E. Calgary, Alberta T2E 0A1

—S-90-10

HEAD
DIVISION OF CARDIOVASCULAR SURGERY
VICTORIA HOSPITAL
CHILDREN’S HOSPITAL OF WESTERN ONTARIO
London, Ontario
Victoria Hospital, an 841-bed tertiary care teaching
hospital affiliated with the Faculty of Medicine,
University of Western Ontario, invites applications for
the position of Head of the Division of Cardiovascular
Surgery. The centre currently provides both adult and
pediatric surgery for southwestern Ontario and is
undergoing immediate expansion to meet regional
cardiovascular surgery needs.
The successful candidate will have an FRCSC, be
eligible to practise in Ontario, be recognized as a
skilled surgeon and teacher, have demonstrated
superior leadership and planning abilities, and maintain
active interest in clinical and laboratory research.
Deadline for receipt of applications is April 30, 1990.
Interested candidates should forward their curriculum
vitae in confidence to:
Glenn S. Bartlett
Chief Operating Officer
Victoria Hospital
375 South Street
London, Ontario
N6A 4G5

Requires An

ORTHOPAEDIC
SURGEON
The Nanaimo Regional General Hospital is
searching for an orthopaedic surgeon to join four
others on the medical staff. Our 436-bed regional
referral hospital provides community hospital
services for an immediate population of 85,000
and secondary referral services for a population
of 250,000.
Nanaimo is a scenic harbour city with exceptional
recreational opportunities on the east coast of
Vancouver Island. We are looking for a surgeon
who is interested in establishing a busy, general
orthopaedic practice in this very desirable location.
Interested othopaedic surgeons should forward
a curriculum vitae and the names of three references
to: Dr. B. Johnstone, Medical Coordinator,
Nanaimo Regional General Hospital, 1200
Dufferin Crescent, Nanaimo, B.C. V9S 2B7, at
their earliest convenience.
—S-90-9

s-90-8

ORDER FORM_________________ BOX NO.: YES □ NO □
ADVERTISEMENT:
NO. OF INSERTIONS:

INVOICE:

ALL ADVERTISEMENTS FROM OUTSIDE CANADA MUST BE PREPAID.
ADDRESS ORDERS TO: Classified Advertising,
Canadian Journal of Surgery,
PO Box 8650, Ottawa, ON K1G 0G8
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HEAD, DIVISION OF THORACIC SURGERY
MOUNT SINAI HOSPITAL, TORONTO, ONTARIO
Mount Sinai Hospital, a 526-bed acute care, general teaching hospital, fully affiliated with Canada’s largest
Faculty of Medicine at the University of Toronto, requires a Division Head of Thoracic Surgery. The Division
of Thoracic Surgery is a university-based program under the overall direction of Dr. Martin McKneally,
Professor of Thoracic Surgery.
The Division of Thoracic Surgery has a complement of 3 full-time staff surgeons and 20 beds, including 4 fully
equipped step-down beds. The Division’s major clinical and research thrust is in oncology and it also
participates in the University’s Lung Transplantation Program. The planned relocation of the Ontario Cancer
Institute/Princess Margaret Hospital, Canada’s premier oncology centre, next door to the Mount Sinai
Hospital will further stimulate development in oncology. Both institutions are renowned for their research
endeavours and the successful integration of these endeavours with patient care programs. The Division is
also committed to a very active undergraduate and postgraduate teaching program.
The successful candidate will have an FRCSC or equivalent; be eligible to practise medicine in Ontario; will
be recognized as a skilled thoracic surgeon and an outstanding teacher; will have a background in research
and be interested in and capable of furthering existing and planned research programs; will have effective
leadership abilities, with previous experience in an administrative position.
The successful candidate would be eligible for a senior academic appointment.
In accordance with Canadian immigration regulations, this advertisement is directed to Canadian citizens and
permanent residents of Canada.
Applications for this position will close May 11, 1990.
Interested candidates should forward their curriculum vitae to:
CHAIRMAN
SEARCH COMMITTEE FOR A HEAD, DIVISION OF THORACIC SURGERY
MOUNT SINAI HOSPITAL
600 UNIVERSITY AVENUE, ROOM 346
TORONTO, ONTARIO CANADA M5G 1X5
— S90-13
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The Department of Neurologic Surgery of the Scott
and White Institutions and Texas A&M University
College of Medicine is seeking applications for
senior staff physician faculty in the Sections of
Pain/Stcreotaxic Surgery or Neurosurgical Oncology.
Residency or post residency experience and a
defined interest in either subspecialty area together
with a broad capability and interest in general
neurosurgical disorders is desired. Basic and clinical
research opportunities are available commensurate
with previous experience. Medical student and
resident teaching/daily responsibilities are required.
The main campus is located in central Texas, north
o f Austin in the approximate center of the Dallas/ Ft.
Worth, San Antonio, Houston triangle and benefits
from easy access to other surrounding universities
(Southwestern University, Georgetown; University of
Mary Hardin-Baylor, Belton; Baylor University,
Waco.)
For further information, please send curriculum
vitae and references to:
Mitchell Smigicl, M.D.
Chairman, Neurologic Surgery
Scott and White, Texas A&M University
College o f Medicine
2401 South 31st Street
Temple, TX 76508
— S90-06

